

## Curriculum Vitae

**1. Date of Preparation:** September 14, 2024

### **2. Personal Data**

**2.1 Name:** Deborah Hasin, PhD

### **2.2 Contact Information**

[dsh2@cumc.columbia.edu](mailto:dsh2@cumc.columbia.edu)

[Deborah.hasin@nyspi.columbia.edu](mailto:Deborah.hasin@nyspi.columbia.edu)

[Deborah.hasin@gmail.com](mailto:Deborah.hasin@gmail.com)

Office Landline: 646-774-7909

Cellphone: 917-371-0303

### **3. Academic Appointments, Hospital Appointments, and Other Work Experiences**

<p><u>Professor of Epidemiology at Columbia University Irving Medical Center</u>            Department of Psychiatry            Columbia University College of Physicians and Surgeons &amp; Mailman School of Public Health</p>	<p>05/2007 – present</p>
<p><u>Professor of Clinical Public Health</u>            Departments of Psychiatry &amp; Epidemiology            Columbia University College of Physicians and Surgeons &amp; Mailman School of Public Health</p>	<p>05/1999 – 04/2007</p>
<p><u>Visiting Professor, Hebrew University, Jerusalem, Israel</u>            School of Public Health</p>	<p>05/1999 – 04/2000</p>
<p><u>Associate Professor of Clinical Public Health</u>            Departments of Psychiatry &amp; Epidemiology            Columbia University College of Physicians and Surgeons &amp; School of Public Health</p>	<p>05/1992 – 04/1999</p>
<p><u>Assistant Professor of Clinical Public Health</u>            Departments of Psychiatry &amp; Epidemiology            Columbia University College of Physicians and Surgeons &amp; School of Public Health</p>	<p>05/1988 – 04/1992</p>
<p><u>Adjunct Assistant Professor of Clinical Public Health</u>            Department of Epidemiology            Columbia University School of Public Health</p>	<p>07/1986 – 04/1988</p>
<p><u>Research Scientist II – VII, New York State Psychiatric Institute</u></p>	<p>08/1979 – present</p>
<p><u>Research Diagnostic Interviewer, Yale University Dept of Psychiatry</u></p>	<p>06/1978 – 08/1979</p>
<p><u>Psychiatric Aide, Connecticut Mental Health Center, New Haven, CT</u></p>	<p>05/1976 – 08/1977</p>

Deborah Hasin, PhD 2

Employment Counselor, Bailey Employment Services, New Haven, CT

12/1974 – 12/1975

Substitute Teacher, Madison Metropolitan School District, Madison, WI

08/1972 – 06/1973

#### **4. Education**

**Columbia University, Ph.D., Epidemiology**

09/1981 – 05/1986

**Dissertation title:** Evaluation Methods in Psychiatric Epidemiology: a comparison of contrasting approaches; Advisor: Elmer Streuning, Ph.D.

**Dissertation publication citations:**

Hasin DS, Grant BF: Diagnosing psychiatric disorders in patients with substance use problems: a comparison of two diagnostic procedures, the SADS-L and the DIS. Alcoholism, drug abuse/dependence, anxiety disorders, and antisocial personality disorder. J Psychiatric Research 21:7-22, 1987.

Hasin DS, Grant BF: Diagnosing depressive disorders in patients with alcohol and drug problems: the SADS-L and the DIS. J Psychiatric Research 21:301-311, 1987.

Hasin DS, Grant BF: Assessing drug disorders in a sample of substance abuse patients: a comparison of the DIS and SADS-L procedures. Drug Alch Dep 19:165-176, 1987.

09/1981 – 05/1985

**Columbia University, M.S. Epidemiology**

**Columbia University, M.S.W.**

09/1977 – 05/1980

**University of Connecticut, part-time graduate social work courses**

09/1975 – 06/1977

**University of California, Los Angeles, B.A., music**

09/1967 – 06/1972

#### **5. Training**

**Pre-doctoral fellowship**, Psychiatric Epidemiology Training (PET) Program, Columbia University

08/1981 – 05/1986

#### **8. Honors and Awards**

Research.com, **Among the top 1,000 Women Scientists In The World**. Based on contributions made, awards, recognition

2024

College on Problems of Drug Dependence, **President**

06/2023 – 06/2024

College on Problems of Drug Dependence, **President-elect**

06/2022 – 06/2023

College on Problems of Drug Dependence, **Board of Directors**

06/2018 – 2022

American Psychiatric Association, **Substance Disorders Section Text Editor**, DSM-5-TR (“Text Revision”)

04/2019 – 03/2022

American Psychopathological Association, <b>Hamilton President's Award</b>	03/2020
American College on Neuropsychopharmacology, <b>NEAR award for year's best literature review</b>	12/2019
American Psychopathological Association, <b>President</b>	3/2019 – 3/2020
<b>h-index, Scopus: 112</b>	
American Psychiatric Association, <b>DSM-5 Substance Disorders Workgroup</b>	06/2007 – 05/2013
Research Society on Alcoholism, <b>Jellinek Award</b> for lifetime achievement in Alcohol Epidemiology	06/2011
National Institute on Alcohol Abuse and Alcoholism, <b>National Advisory Council</b>	02/2008 – 09/2011
National Human Genome Research Institute, <b>Chair, Alcohol, Tobacco and Other Substance Workgroup</b> , PhenX measures for genetics studies	2008 – 2009
NIAAA, <b>K05 Senior Scientist and Mentoring Award</b> , Epidemiologic Studies of Alcohol Use Disorders	2003 – 2013
American Psychiatric Association, <b>DSM-V Substance Disorders Core Workgroup</b>	2004 – 2007
National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD), <b>Young Investigator Award</b> , "Comorbid Affective Disorders and Alcoholism"	06/1989 – 05/1991

## **9. Administrative Leadership and Academic Service**

### **9.1 Academic Service**

<b>NIDA K-DET Review Panel</b> , Chairperson	2022 - 2024
<b>NIDA ZDA1 SKM-D (03)</b>	06/2021
<b>NIDA ZAA1 GG 32</b> , F31 Review panel	02/2021
<b>NIDA ZAA1 GG (35)</b> , Co-Chairperson, T32 Review panel	11/2020
<b>NIDA SXM-M (09)</b>	07/2020
<b>NIDA ZDA1 SXM-M (24)</b>	03/2020
<b>Addiction Risks and Mechanisms (ARM)</b> , Ad Hoc reviewer	2/2019
<b>ZRG1 PSE-H (70)</b> NIH Director's Early Independence Awards (DP5)	12/2018
<b>NIDA ZRG1 RPHB-V (02)</b>	2/2018
<b>NIDA ZRG1 RPHB-V (02)</b>	10/2017

<b>Addiction Risks and Mechanisms Study Section (ARM), Ad Hoc reviewer</b>	2/2016
<b>Addiction Risks and Mechanisms Study Section (ARM), Ad Hoc reviewer</b>	10/2015
<b>Founding Director, Substance Abuse Epidemiology Training Program (SAETP)</b> <i>Pre- and post-doctoral fellows at Columbia University. This NIDA-funded program provides fellowships to 4 pre-doctoral fellows and 4 post-doctoral fellows. Most recent renewal application (5/2021) was scored 10; program funded until 6/2027</i>	08/2012 – present
<b>Steering Committee, Psychiatric Epidemiology Training Program, Division of Epidemiology, School of Public Health, Columbia University</b>	1990 – present
<b>Faculty member, Psychiatric Epidemiology Training Program, Division of Epidemiology, School of Public Health, Columbia University</b>	1987 – present
<b>Grand Rounds Committee, Department of Psychiatry, Columbia University</b>	2010 – 2020
<b>Council of the Faculty of Medicine</b>	2013 – 2017
<b>Committee on Appointments and Promotions, Mailman School of Public Health</b>	2001 – 2006
<b>Public Health Academic Coordinator, Joint MSW/MPH program, School of Public Health, Columbia University</b>	1992 – 1997
<b>Doctoral Committee, Epidemiology, Mailman School of Public Health</b>	1991 – 1994, 2009 – 2015
<b>Doctoral Examination Committee, Epidemiology, Mailman</b>	2008 – 2010
<b>MPH Committee, School of Public Health, Columbia University</b>	1987 – 1994

## **10. Professional Organizations and Societies**

### **10.1 Memberships and Positions**

#### **College on Problems of Drug Dependence**

Member, 06/2005 – present  
 Past president, June 2024-June 2025  
 Chair, Long-Range Planning Committee June 2024-June 2025  
 President, June 2023 – June, 2024  
 President-Elect, June, 2022 – June, 2023  
 Board of Directors, 2018 – 2022  
 Awards Committee, 2017 – 2019  
 Program Committee, 2012 – 2015  
 Publications Committee, 2008 – 2010  
 International Committee, 2007 – 2008

#### **Alcohol Clinical Trials Initiative (ACTIVE) affiliated with the American College on Neuropsychopharmacology**

Member, 10/2015 – 2024  
 Steering Committee, 4/2016 – 2024

#### **Research Society on Alcoholism**

Member, 06/1993 – 2023  
 Program Committee, 2009 – 2011  
 Scientific Priorities Committee, 2007 – 2009  
 Education Committee, 2005 – 2007

#### **American Psychopathological Association**

Member, 03/1988 – present  
 Past President, 2020 – 2021  
 President, 2019 – 2020  
 Vice-president, 2018 – 2019  
 Councilor, 2017 – 2018

### **10.2 Consultative**

<b>Panel Member, NIDA Institute Director Leadership Review</b>	10/2022
<b>Interagency Work Group on Drinking and Drug Use in Women and Girls, member</b>	06/2017 – 01/2023
<b>Technical Expert Panel, SAMHSA/HHS review of harms/risks of marijuana</b>	09/2019 – 10/2019
<b>Technical Expert Panel, SAMHSA review of substance use disorders modules for the National Surveys on Drug Use and Health (NSDUH) annual surveys</b>	05/2017
<b>Panel member, Measures of Outcome for Stimulant Trials (MOST) at FDA</b>	10/2016

<b>Review Panel</b> , Science Faculty Hiring Strategic Plan, University of Connecticut School of Medicine	10/2016 – 11/2016
<b>Expert Advisory Group</b> on Cannabis, Canadian Centre on Substance Abuse	2014 – 2016
<b>Scientific Advisory Committee</b> , World Trade Center Health Registry	2011 – 2015
<b>Member</b> , Board of Directors, Research Foundation for Mental Hygiene	1995 –1999, 2008 – 2010
<b>Israel-American Research Committee</b> , Israel Anti-Drug Authority	2005 – 2008
<b>Conference Expert Group</b> , WHO/APIRE Conference on Public Health Aspects of Diagnosis and Classification	2006
<b>Expert Panel</b> , SSA–SAMHSA Disability Determination, Bethesda, MD	09/2006
<b>Expert Panel</b> , WHO/APIRE Conference on Prevention of Mental Disorders	05/2006
<b>Advisory Panel</b> , NIAAA/NIDA/NIMH, Methodology of conducting clinical trials in patients with alcohol/drug dependence and psychiatric comorbidity	02/2006
<b>Chair</b> , NIDA Clinical Trials Network Common Assessment Battery Committee	2003 – 2005
<b>Member</b> , NIAAA Committee, Social Work Education for the Prevention and Treatment of Alcohol Use Disorders	2000 – 2005
<b>Advisory Panel</b> , NIAAA, Risk for alcohol use disorders: genetic and environmental influences, Bethesda, Maryland, Invited expert	08/2004
<b>Task Force Member</b> , World Health Organization assessment of disability study	1999 – 2001
<b>Advisor</b> , DSM-IV text revisions, American Psychiatric Association	1999 – 2001
<b>Advisor</b> , DSM-IV Substance Use Workgroup, American Psychiatric Association	1988 – 1994
<b>Advisor</b> , DSM-IV Eating Disorders Workgroup, American Psychiatric Association	1988 – 1994
<b>Advisor</b> , World Health Organization Joint WHO/NIH 11-country project on reliability and validity of alcohol and drug disorders for international research	09/1990 – 09/2000
<b>Panel Member</b> , NIDA Technical Review, Measurement of HIV risk behaviors	1997
<b>Reviewer</b> , American Psychiatric Association Practice Guidelines	1995

### **10.3 Journal Reviewer**

JAMA Psychiatry, JAMA Open Network, American Journal of Psychiatry, Addiction, Drug and Alcohol Dependence, American Journal of Preventive Medicine, Addictive Behaviors, Pediatrics, The Lancet Public Health, The Lancet Psychiatry, The Lancet Healthy Longevity, AIDS Care, Psychological Medicine, International Journal of Drug Policy

**10.4 Editorial Board**

<b>Editorial Advisory Board</b> , Lancet Psychiatry	03/2023 - present
<b>Editorial Board</b> , Drug and Alcohol Dependence	06/2015 – 2024
<b>Associate Editor</b> , Drug and Alcohol Dependence	06/2007 – 05/2015
<b>Assistant Editor</b> , Addiction	2004 – 2007
<b>Editor in Chief</b> , Journal of Substance Abuse	09/1997 – 08/2001

## **11. Fellowship and Grant Support**

### **11.1 Active Research Funding**

#### **Role: Principal Investigator**

**Title:** “Impact of Medical and Recreational Marijuana Laws on Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024”

**Dates:** 7/1/2019 – 4/30/2025 **Funder:** National Institute on Drug Abuse (R01DA048860)

**Direct support:** \$3,225,547

**Purpose:** *To utilize the vast electronic medical records (EMR) data of the Veterans Administration (VA) to determine the health effects of changing marijuana laws on a population with substantial pain and psychiatric comorbidity. The research team combines epidemiologic and clinical experts from the VA and academia.*

**Title:** “Impact of Medical and Recreational Marijuana Laws on Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 – 2024: Competing Revision (2020-2021)”

**Dates:** 5/1/2020 – 4/30/2025 **Funder:** National Institute on Drug Abuse (R01DA048860-S1)

**Direct support:** \$197,015

**Purpose:** *To investigate the relationship of substance use and substance use disorders to the risk for COVID-19 infection in 2020 among VA patients seen in 2019, and among those infected, the risk for poor prognosis.*

**Title:** “COVID-19, heavy drinking and alcohol use disorders: a national study of Veterans Administration patients”

**Dates:** 3/23/2023 – 2/28/2025 **Funder:** National Institute on Alcohol Abuse and Alcoholism (R21AA029153-01A1)

**Direct support:** \$275,000

**Purpose:** *To investigate the relationship of alcohol use and alcohol use disorder to the risk for COVID-19 infection in 2020 among VA patients seen in 2019, and among those infected, the risk for poor prognosis.*

**Title:** “Epidemiology of Substance Use Disorders Training Program at Columbia University”

**Dates:** 7/1/2012 – 4/30/2027 **Funder:** National Institute on Drug Abuse (T32DA031099)

**Direct support:** \$2,759,670

**Purpose:** *To provide training in the epidemiology of substance use and substance use disorders and for career development of 4 pre-doctoral and 4 post-doctoral fellows. Impact score of 10 on this and previous submission.*

**Title:** “Leveraging Social Media to Develop the Cannabis Exposure Index (CEI), A Standardized Measure of Cannabis Use”

**Role:** Multiple Principal Investigator/Director (with Alan Budney, Dartmouth)

**Dates:** 9/30/2020 – 7/31/2025 **Funder:** National Institute on Drug Abuse (1R01DA050032)

**Direct support:** \$1,148,601

**Purpose:** *To develop and validate a standardized self-administered measure of cannabis consumption*

**Title:** “PRISM-5-OP in PMR Study 1A on Prospective Risk of Addiction to Prescription Opioid Medication”

**Dates:** 1/2016 – 12/31/2025 **Funder:** Syneos Health **Direct support:** \$1,291,421

**Purpose:** *To provide training, supervision and quality assurance on a large-scale, FDA-mandated longitudinal study of the likelihood of addiction to opioid medication in chronic pain patients. The PRISM-5-OP measure of addiction for this population was developed in Dr. Hasin’s lab. To provide consultation on use of the PRISM-5-OP addiction diagnoses in large-scale studies of prescription opioid use among patients with chronic pain.*

**Title:** “Neurocognitive mechanisms underlying smartphone-assisted prevention of relapse in opioid use disorder”

**Funder:** Sub-contract from University of Arkansas for Medical Sciences (for study funded by National Institute on Drug Abuse).

**Dates of funding:** 2021-2026

**Direct support:** \$48,660

**PI of sub-contract:** Deborah Hasin, Ph.D. (PI: Andrew James, PhD, University of Arkansas)

**Purpose:** *To use a smartphone-assisted treatment enhancement to improve treatment outcome in patients with opioid use disorder (OUD), and then use neuroimaging to evaluate neurocognitive mechanisms associated with remission from OUD).*

**Role: Co-Investigator and/or Mentor**

**Title:** “Examining the Synergistic Effects of Cannabis and Prescription Opioid Policies on Chronic Pain, Opioid Prescribing, and Opioid Overdose”

**Role:** Co-investigator (Multiple Principal Investigators: Silvia Martins, MD, PhD and Magdalena Cerda, PhD)

**Dates:** 2019 – 2024

**Funder:** National Institute on Drug Abuse (R01DA045872)

**Direct support:** \$1,035,598

**Title:** “As Adolescent Substance Use Declines, Internalizing Symptoms Increase: Identifying High-Risk Substance Using Groups And The Role Of Social Media, Parental Supervision, And Unsupervised Time”

**Role:** Co-investigator (Principal Investigator: Katherine Keyes, PhD)

**Dates:** 2019 – 2024

**Funder:** National Institute on Drug Abuse

**Direct support:** \$1,245,000

**Title:** “Social-environmental drivers of stimulant use and its impact on HIV prevention and treatment in Black men who have sex with men”

**Role:** Sponsor (Principal Investigator: Justin Knox, PhD)

**Dates:** 2020 – 2025

**Funder:** NIAAA (K01AA028199)

**Direct support:** \$847,039

**Title:** “COVID-19 Pandemic: Natural Experiment in Telehealth on Buprenorphine Treatment in a Large Integrated Healthcare System”

**Role:** Sponsor (Principal Investigator: David Fink, PhD)

**Dates:** 2023 – 2028

**Funder:** National Institute on Drug Abuse (K99DA055724)

**Direct support:** \$174,257

**Title:** “Cannabis use patterns and associations with cognitive impairment in older adults”

**Role:** Sponsor (Principal Investigator: Ofir Livne, MD, MPH)

**Dates:** 2023 – 2028

**Funder:** National Institute on Drug Abuse (K23 DA057417)

**Direct support:** \$977,395

**Title:** “Barriers to and Health Consequences of Non- Pharmacological Chronic Pain Treatment among Patients Tapering Prescription Opioids in a Large Integrated Healthcare System”  
**Role:** Sponsor (Principal Investigator: Zachary Mannes, PhD)  
**Dates:** 2023 – 2028  
**Funder:** National Center for Complementary and Integrative Health (K01AT012205)  
**Direct support:** \$610,000

## **11.2 Past Support**

### **Role: Principal Investigator**

**Title:** “Drinking Levels (Binge, Volume) And Alcohol Consequences: Using National Data To Identify Clinical Trial Endpoints.”  
**Dates:** 3/10/2016 – 2/28/2022 **Funder:** NIAAA (1R01AA025309) **Direct support:** \$561,135

**Purpose:** *To examine whether non-abstinent reductions in drinking as defined by World Health Organization (WHO) drinking risk levels confer medical and psychiatric benefits.*

**Title:** “Substance Use, Substance Use Disorders - Annual Meeting of the American Psychopathological Association (APPA)”  
**Dates of funding:** 3/1/2020 – 2/28/2021 **Funder:** NIDA & NIAAA (R13DA051099) **Direct support:** \$30,000  
**Purpose:** *To support speaker expenses and travel awards for early-career and diversity investigators at the 2020 APPA annual meeting.*

**Title:** “HealthCall: Enhancing Brief Intervention For HIV Primary Care Alcohol Dependence”  
**Role:** Principal Investigator  
**Dates:** 9/25/2014 – 7/31/2020  
**Funder:** NIAAA (R01AA023163)  
**Direct support:** \$2,911,646  
**Purpose:** *To determine whether daily use of a smartphone app that integrates video clips of a bi-lingual counselor with self-monitoring questions improves the efficacy of standard, evidence-based brief interventions to reduce drinking in primary care patients.*

**Title:** “DSM–IV Dependence and DSM–5 SUD: Reliability And Validity In Patient Samples”  
**Role:** Principal Investigator  
**Dates:** 7/1/2014 – 6/30/2020  
**Funder:** NIDA (R01DA018652)  
**Direct support:** \$1,403,121, Years 01-05; \$2,438,627 Years 06-10  
**Purpose:** *To determine whether the substantial changes in the criteria for DSM-5 Substance Use Disorders offer benefit in terms of reliability and validity over prior definitions of substance dependence.*

**Title:** “Validation of PRISM-5-OP, Measure of Addiction to Prescription Opioid Medication (PMR Study 2B)”  
**Role:** Principal Investigator  
**Dates:** 2014 – 2019  
**Funder:** Campbell Alliance (for nine ER/LA opioid prescription drug sponsors) NCT02660619  
**Direct support:** \$2,680,362  
**Purpose:** *To develop and conduct reliability and validity testing of the Psychiatric Research Interview for Substance and Mental Disorders for DSM-5, Prescription Opioid version (PRISM-5-OP), a clinician-administered measure of addiction for prescription opioid users with chronic pain, per FDA mandate for a post-marketing research (PMR) study.*

**Title:** “State medical marijuana laws and MTF teen marijuana use and attitudes since 1991”

**Role:** Principal Investigator

**Dates:** 2012 – 2018

**Funder:** NIDA (R01DA034244)

**Direct support:** \$2,122,584

**Purpose:** *To determine whether state medical marijuana laws were increasing the rates of adolescent marijuana use.*

**Title:** “State medical marijuana laws and MTF teen marijuana use and attitudes since 1991 – supplement”

**Role:** Principal Investigator

**Dates:** 2013 – 2015

**Funder:** NIDA (R01DA034244)

**Direct support:** \$187,091

**Title:** “Adverse childhood experiences, personality psychopathology, and alcohol disorders”

**Role:** Principal Investigator

**Dates:** 2009 – 2015

**Funder:** NIAAA (U01AA018111-01)

**Direct support:** \$2,356,062

**Purpose:** *To determine the relationship between childhood abuse or neglect with adult personality disorders and their relationships to alcohol and drug use disorders using nationally representative data.*

**Title:** “National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III) Test–Retest Validity Study”

**Role:** Principal Investigator

**Dates:** 2009 – 2014

**Funder:** NIH (HHSN275200900007C)

**Direct support:** \$1,892,277

**Purpose:** *To determine whether the diagnostic measure used in the NESARC-III was validated by comparing its results to diagnoses from the clinician-administered Psychiatric Research Interview for Substance and Mental Disorders for DSM-5, developed and tested in Dr. Hasin’s group.*

**Title:** “Senior Scientist and Mentoring Award; Epidemiologic Studies of Alcohol Use Disorders”

**Role:** Principal Investigator

**Dates:** 2003 – 2013 (2003-2008; 2008-2013)

**Funder:** NIAAA (K05AA014223)

**Direct support:** \$734,695

**Purpose:** *Senior-level career support.*

**Title:** “Reducing Unsafe Drinking in HIV Primary Care”

**Role:** Principal Investigator

**Dates:** 2005 – 2011

**Funder:** NIAAA (R01AA014323)

**Direct support:** \$2,230,973

**Purpose:** *To determine whether daily use of a interactive voice response system designed to self-monitor drinking improved the efficacy of standard, evidence-based brief interventions to reduce drinking in primary care patients.*

**Title:** “Phenotypes for Drug Abuse: Epidemiologic– Genetic Approach” (renamed for Years 06-10; see “DSM–IV Dependence and DSM–5 SUD: Reliability and validity in patient samples” under current funding)

**Role:** Principal Investigator

**Dates:** 2004 – 2010

**Funder:** NIDA (R01DA018652)

**Direct support:** \$1,403,121

**Purpose:** *To determine valid and updated definitions of Substance Use Disorders*

**Title:** “Alcohol in Israel: Genetic and Environmental Effects”

**Role:** Principal Investigator

**Dates:** 2003 – 2009

**Funder:** NIAAA (R01AA013654), NIDA co–funding.

**Direct support:** \$3,268,874

**Purpose:** *To investigate the interplay between genetic and environmental influences on heavy drinking by comparing Russian immigrants to Israel with other Israelis.*

**Title:** Alcohol Dependence: General Population Validity”

**Role:** Principal Investigator

**Dates:** 1990 – 2004; 1990-1995, 1999-2005

**Funder:** NIAAA (R01AA08159)

**Direct support:** \$3,454,951

**Purpose:** *To determine whether new definitions of alcohol and drug use disorders that had been developed in clinical samples were valid in nationally representative samples.*

**Title:** “PRISM – Comorbidity Diagnosis for Drug Abuse Treatment”

**Role:** Principal Investigator

**Dates:** 1998 – 2003

**Funder:** NIDA (R01DA10919)

**Direct support:** \$1,608,095

**Purpose:** *To develop and test a clinician-administered diagnostic interview for assessing psychiatric comorbidity among patients in treatment for drug use disorders.*

**Title:** “Epidemiologic Studies of Alcohol Disorders; Independent Investigator Award”

**Role:** Principal Investigator

**Dates:** 1993 – 2003; 1993-1998; 1998-2003

**Funder:** NIAAA (K02AA0016)

**Direct support:** \$848,024

**Purpose:** *Mid-career support.*

**Title:** “Course of Drug Use Disorders–Effects of Comorbidity”

**Role:** Principal Investigator

**Dates:** 1994 – 2000.

**Funder:** NIDA (R01DA08409)

**Direct support:** \$3,150,872

**Purpose:** *To determine whether the course of drug use disorders had poor outcome in patients with psychiatric comorbidity.*

**Title:** “Validating Epidemiologic Measures of Alcohol Dependence”

**Role:** Principal Investigator

**Dates:** 1992 – 1995

**Funder:** NIAAA (R01AA08910)

**Direct support:** \$1,075,442

**Purpose:** *To determine the comparative validity of different measures of alcohol use disorders.*

**Title:** “Alcohol Dependence: General Population Validity”

**Role:** Principal Investigator

**Dates:** 1990 – 2005

**Funder:** NIAAA (R01AA08159) 1990-1995, 1999-2005

**Direct support:** \$3,454,951

**Purpose:** *During the first funding period, to determine the validity of measures of alcohol use disorders in a suburban community-based samples of heavier-than-average drinkers. During the second funding period, to investigate the stability of diagnoses of alcohol use disorders in this sample 10 years later, and to investigate the impact of proximity to the World Trade Center on 9/11/01 on subsequent drinking.*

**Title:** “Effects of Alcoholism and Depression When Comorbid” (Young Investigator Award)

**Role:** Principal Investigator

**Dates:** 1988 – 1990 Two years of award.

**Funder:** National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD, now Brain and Behavior Research Institute)

**Direct support:** \$60,000

**Purpose:** *To determine whether the course of major depressive disorder differed by whether patients also had alcohol use disorders.*

**Title:** “Alcohol Dependence in the General Population”

**Role:** Principal Investigator

**Dates:** 1987 – 1988 One year of award.

**Funder:** New York State Psychiatric Institute Pilot Studies Grant Program

**Direct support:** \$3,000

**Purpose:** *To investigate the validity and structure of new definitions of alcohol use disorders in nationally representative data.*

**Role: Co-Investigator and/or Mentor**

**Title:** “Survey of self-reported cognitive and other functioning in subjects on Buprenorphine or XR-Naltrexone treatment for Opioid use disorder”

**Role:** Co-investigator (Principal Investigator: Efrat Aharanovich, PhD)

**Dates:** 2018 – 2021

**Funder:** Alkermes, Inc. (ALKS 21-029N)

**Direct Support:** \$70,000

**Title:** “Understanding and intervening with heavy drinking among patients with HIV and HCV”

**Role:** Sponsor (Principal Investigator: Jennifer Elliott, PhD)

**Dates:** 2015 – 2020

**Funder:** NIAAA (K23 AA023753)

**Direct support:** \$899,800

**Title:** “State medical marijuana laws and NSDUH marijuana use and consequences since 2004”

**Role:** Co– investigator (Principal Investigator: Silvia Martins, MD, PhD)

**Dates:** 2014 – 2019

**Funder:** NIDA (R01DA 037866)

**Direct support:** \$1,413,724

**Title:** “Race, alcohol consumption, and vehicle crashes: epidemiologic paradox”

**Role:** Mentor (Principal Investigator: Katherine Keyes, PhD)

**Dates:** 2013 – 2019

**Funder:** NIAAA (K01 AA021511)

**Direct support:** \$837,388

**Title:** “Role of depression and anxiety in the tobacco epidemic”

**Role:** Co– investigator (Principal Investigator: Renee Goodwin, PhD)

**Dates:** 2014 – 2019

**Funder:** NIDA (R01 DA020892)

**Direct support:** \$1,510,751

**Title:** “Substance Use And Sexual Risk Behavior Among MSM In South African Townships”

**Role:** Sponsor (Principal Investigator: Justin Knox, PhD)

**Dates:** 2015 – 2018

**Funder:** NIDA (F31DA037128)

**Direct support:** \$114,486

**Title:** “Brief drug and HIV interventions for homeless young adults”

**Role:** Sponsor (Principal Investigator: Ronald G. Thompson, Jr., PhD)

**Dates:** 2011 – 2016

**Funder:** NIDA (K23DA032323) Five years of award.

**Direct support:** \$843,486

**Title:** “HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care: Administrative supplement to investigate drug abusers who also binge drink”

**Role:** Co–principal investigator (Principal Investigator: Efrat Aharonovich, PhD)

**Dates:** 2014 – 2016

**Funder:** NIDA (R01DA024606)

**Direct support:** \$98,641

**Title:** “Conflict, substance use and HIV and related diseases”

**Role:** Mentor (Principal Investigator: Bradley Kerridge, PhD)

**Dates:** 2013 – 2016

**Funder:** NIDA (F32DA036431)

**Direct support:** \$152,443

**Title:** “Prenatal Smoke Exposure and Offspring Substance Use: An Imaging– Genetics Approach”

**Role:** Co– mentor (Principal Investigator: Ardesheer Talati, PhD)

**Dates:** 2010 – 2016

**Funder:** NIDA (K01DA029598)

**Direct support:** \$838,640

**Title: “HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care”**

**Role:** Co–principal investigator (Principal Investigator: Efrat Aharonovich, PhD)

**Dates:** 2010 – 2016

**Funder:** NIDA (R01DA024606)

**Direct support:** \$2,662,434

**Title: “Social stress and substance abuse disparities in sexual minority youth”**

**Role:** Sponsor (Principal Investigator: Mark Hatzenbuehler, PhD)

**Dates:** 2012 – 2017 (actively involved as sponsor, 2012 – 2014)

**Funder:** NIDA (K01 DA032558)

**Direct support:** \$813,619

**Title: “Modified Behavioral Treatment for Cocaine Patients with Cognitive Deficits”**

**Role:** Co–Investigator and Mentor (Principal Investigator: Efrat Aharonovich, PhD)

**Dates:** 2007 – 2013

**Funder:** NIDA (R01DA020647)

**Direct support:** \$1,093,965

**Title: “Brief Alcohol and HIV Prevention for Homeless Adolescents Who Exited Foster Care”**

**Role:** Co–investigator and mentor (Principal Investigator: Ronald Thompson, PhD)

**Dates:** 2008 – 2011

**Funder:** NIAAA (R21AA017862)

**Direct support:** \$259,825

**Title: “Age–period–cohort effects on substance use in adolescence, 1976– 2006”**

**Role:** Mentor (Principal Investigator: Katherine Keyes, PhD)

**Dates:** 2009 – 2010

**Funder:** NIDA (F31DA026689)

**Direct support:** \$23,449

**Title: “Imaging dopamine transmission in comorbid schizophrenia and cannabis dependence”**

**Role:** Co–investigator (Principal Investigator, Anissa Abi–Dargham, MD)

**Dates:** 2007 – 2010

**Funder:** NIDA (R21 DA023039)

**Direct support:** \$1,045,451

**Title: “Columbia Center for Homelessness Prevention Studies”**

**Role:** Co–investigator (Principal Investigator: Carol Caton, PhD)

**Dates:** 2005 – 2011

**Funder:** NIMH (P30 MH071430)

**Direct support:** \$3,168,487

**Title: “Role of depression and anxiety in the tobacco epidemic”**

**Role:** Co–Investigator and mentor (Principal Investigator: Renee Goodwin, PhD)

**Dates:** 2005 – 2011

**Funder:** NIDA (R01 DA020892).

**Direct support:** \$1,510,752

**Title:** “<sup>3</sup>PET imaging of serotonin transmission in MDMA users”  
**Role:** Co– investigator (Principal Investigator, Anissa Abi–Dargham, MD)  
**Dates:** 2003 – 2009  
**Funder:** NIDA (R01DA015806)  
**Direct support:** \$516,694

**Title:** “Cognition in Cocaine Dependence: Assessment and Therapy”  
**Role:** Preceptor (Principal Investigator: Efrat Aharonovich, PhD)  
**Dates:** 2003 – 2009  
**Funder:** NIDA (K23 DA 016743)  
**Direct support:** \$742,776

**Title:** “Cognitive Deficits: Treatment Outcome in Cocaine Abusers”  
**Role:** Co–Investigator and Mentor (Principal Investigator: Efrat Aharonovich, PhD)  
**Dates:** 2002 – 2005  
**Funder:** NIDA (R21DA14091)  
**Direct support:** \$276,856

**Title:** “Alcohol Use Disorder in Patients Treated for Depression”  
**Role:** Co–Investigator (Principal Investigator: Patrick McGrath, MD)  
**Dates:** 2001 – 2006  
**Funder:** NIAAA (R01AA13303)  
**Direct support:** \$1,262,943

**Title:** “Effect of maternal– fetal attachment in heavy drinkers”  
**Role:** Mentor (Principal Investigator: Marilyn Lewis, PhD)  
**Dates:** 2001 – 2002  
**Funder:** NIH (F31AA005560)  
**Direct support:** \$49,961

**Title:** “Service Needs in Early Psychosis and Drug Use”  
**Role:** Co–Investigator (Principal Investigator: Carol Caton, PhD)  
**Dates:** 1997 – 2004  
**Funder:** NIDA (R01DA10539)  
**Direct support:** \$2,694,006

**Title:** “Drug Use and Homelessness Among Indigent Urban Adults”  
**Role:** Co–Investigator (Principal Investigator: Carol Caton, PhD)  
**Dates:** 1995 – 1998  
**Funder:** NIDA (R01DA09152)  
**Direct support:** \$562,486

## **12. Educational Contributions**

### **12.1 Direct Teaching/Precepting/Supervising**

<b>Lecturer</b> , 4-session series, <i>Epidemiology of Alcohol and Drug Use and Disorders</i> . Brief non-credit course for pre- and post-doctoral fellows in Substance Abuse Epidemiology Training Program	2023-present
<b>Professor</b> , EPID P8470: <i>Epidemiology of Alcohol and Drug Use and Disorders</i> , Mailman School of Public Health Core course for Substance Abuse Epidemiology Training Program at Columbia University. Fall semester, 2 hours/week, lecture + student debate each week. My role: course designer, yearly updates to lectures and reading lists.	2010 – 2022
<b>Lecturer</b> , Reliability and Validity in Research Studies. Psychiatric Institute Post-Doctoral Research Fellows Seminar Series	2010 – 2018
<b>Occasional seminar and mock review leader</b> , K Series Seminar, NYS Psychiatric Institute	2007 – present
<b>Co-director</b> , F31 workshop series, Mailman School of Public Health	2011 – 2012
<b>Professor</b> , EPID P8470: Epidemiology of Alcohol and Drug use and Disorders, Mailman School of Public Health, earlier version of course	2000 – 2003
<b>Lecturer</b> , Assessment of Adult Psychopathology. Course for psychiatrists, pre- and post- doctoral researchers, Mailman School of Public Health	1987 – 1993
<b>Leader</b> , Group Tutorial in Public Health: Assessment issues in clinical and epidemiological studies that involve psychiatric and substance use disorders, Mailman School of Public Health	1986 – 1994

## 12.2 Advising and Mentorship

**Zachary Mannes, PhD**, 2020-present

Post-doctoral fellow, Substance Abuse Epidemiology Training Program

Nature of mentoring I mentor him on publications, on his K01 and career development.

Areas Substance use issues in athletes, veterans and other populations heavily exposed to injury and pain.

Accomplishments. 38 publications (18 first-authored), several additional papers now under review, currently a tenure-track Assistant Professor in Emergency Medicine at Columbia University and Mailman School of Public Health.

**Ofir Livne, M.D.**, 2017-2018, 2020-present

Former post-doctoral fellow, Substance Abuse Epidemiology Training Program

Nature of mentoring I mentored him on publications and career development while he was a visiting scholar in my lab in 2017-2018. Since then, he finished his psychiatric residency at Lev-Hasharon Medical Center in Israel and at Montefiore Medical Center, Albert Einstein College of Medicine in New York, and he became a post-doctoral fellow in the training program. I now mentor him on papers and on his NIDA-funded K23 grant.

Areas Cannabis use disorders, substance and psychiatric comorbidity.

Accomplishments. 40 publications (15 first-authored). Co-founder of Lev-Hasharon Epidemiology Substance Use Research Unit. Currently Assistant Professor in Psychiatry at Columbia University

**Sarah Gutkind, MPH, 2019-present**

Pre-doctoral fellow, Substance Abuse Epidemiology Training Program

Nature of mentoring I mentor her on publication and presentation preparation, on progression through the fellowship and doctoral program, sponsor of her doctoral dissertation and her NIDA-funded R36 grant

Areas: Drug use epidemiology, including relative harms of using cannabis, alcohol and opioids.

Accomplishments: 27 publications (6 first-authored), several papers in preparation, 2020 CPDD NIDA Directors Travel Awardee. Currently a post-doctoral fellow at Weill-Cornell Medical School.

**David S. Fink, PhD, 2017 – present**

Former pre-doctoral fellow, Substance Abuse Epidemiology Training Program. He is now Technical Specialist, New York State Psychiatric Institute.

Nature of mentoring I was his dissertation sponsor, now mentor him on publications, career development, and on his NIDA-funded K99/R00 grant

Areas Opioid prescription supply and economic conditions as factors in overdose fatalities, substance and psychiatric problems in veterans.

Accomplishments 79 publications (24 first-authored). Awards: American Journal of Epidemiology (2017), Haddon award (2018), O'Neal Addiction Science award (2018), American Psychopathological Association Student Service (APPA) award (2020), Anna C. Gelman Award for Excellence in Epidemiology, Columbia University, New York, NY (2021)

**Lauren Gorfinkel, MPH, MD Master's thesis, 2019-2020**

Area: Comorbidity of cannabis and opioid use; comorbidity of cannabis use with depression, prescriptions for opioid and non-opioid pain medications

Winner: Anna Gelman Award for Excellence in Epidemiology, Columbia University Department of Epidemiology, Mailman School of Public Health (2020).

Accomplishments: 19 publications, 9 first-authored. Completed medical school at University of British Columbia, Canada. Currently a psychiatric research resident at Columbia University Department of Psychiatry.

**Justin Knox, PhD, 2014 – present**

Former post-doctoral fellow, Substance Abuse Epidemiology Training Program. He is now Assistant Professor, Columbia University Department of Psychiatry

Nature of mentoring I was sponsor of his F31DA037128 and am mentor of his K01 award

Areas Alcohol, drugs and sexual behavior in South Africa and the US, relationship of reduction in harmful drinking to reduction in risk for other adverse health outcomes in US adults

Accomplishments 73 publications (28 first-authored). Awards: NIDA Director's travel award (2017), early-career investigator travel awards from APPA, College on Problems of Drug Dependence (CPDD), Research Society on Alcoholism (RSA) and Society for Prevention Research (2019) and Conference on Retroviruses and Opportunistic Infections (2020); he has also received an R21 grant from NIAAA and is MPI on an R01 grant from NIDA. Currently Assistant Professor, Columbia University Department of Psychiatry and Mailman School of Public Health.

**Greta Bushnell, PhD, 2022-2026**

Former Post-Doctoral Fellow, Psychiatric Epidemiology Training Program.

Nature of mentoring I mentor her NIDA-funded K01 grant on issues related to psychiatric and substance disorder diagnoses, and on study design.

Area: Pharmacoepidemiology

Accomplishments: 11 publications, 7 first-authored. She is now Assistant Professor, Rutgers University.

**Drew Westmoreland, Ph.D., 2021-2024**

Nature of mentoring. I mentored her NIAAA-funded K01 grant on epidemiologic and measurement issues in her research at Florida University

Areas. HIV and substance abuse

Accomplishments. 47 publications, 6 first-authored. Currently Assistant Professor in the Department of Epidemiology at the University of Florida

**Jennifer Elliott, PhD, 2012 – 2020**

Former Post-Doctoral fellow, Substance Abuse Epidemiology Training Program.

Nature of mentoring I mentored her on publications and career development while a SAETP post-doctoral fellow, was a sponsor of her NIAAA-funded K23AA023753 and career development.

Areas HIV, HCV, stress, motives for drinking

Accomplishments 56 publications (35 first-authored). She received K23 AA023753 with a score of 20 on its first submission. She is currently a tenured Associate Professor of Psychology at Molloy College, New York.

Awards: She received the NIDA Director's Travel Award and the RSA junior investigator award (2014). She is currently Assistant Professor, Molloy University, New York.

**Dvora Shmulewitz, PhD, 2009 – 2024**

Former Post-doctoral fellow, Statistical Genetics.

Nature of mentoring I have mentored her on publications and career development as she has worked in my lab as a data analyst and balanced work-life issues given her seven children.

Areas Phenotypes of alcohol and substance use disorders, time trends in drug and alcohol use.

Accomplishments 75 publications (12 first-authored). She is was Assistant Professor, Columbia University Department of Psychiatry for many years, and is **now**

**Jacquelyn Meyers, PhD, 2011 – 2020**

Former Post-Doctoral fellow, Psychiatric Epidemiology Training Program.

Nature of mentoring I mentored her on publications and career development while a post-doctoral fellow in the NIMH T32 Psychiatric Epidemiology Training (PET) program and was sponsor of her K01DA037914.

Areas Genetic and environmental etiology of substance disorders

Accomplishments 122 publications (15 first-authored). Now Associate Professor, SUNY Downstate. Awards: Junior Investigator awards from CPDD, RSA and the World Congress of Psychiatric Genetics (2011-2012), Women and Gender Differences Junior Investigator Award, CPDD (2016), the prestigious Early Career Investigator award, RSA (2019), now PI and MPI on several funded R01 grants from NIAAA and NIMH. She is now Associate Professor, SUNY Downstate.

**Hillary Samples, PhD, 2017-2020**

Former Post-Doctoral fellow, Substance Abuse Epidemiology Training Program.

Nature of mentoring I was co-mentor of her fellowship while she was a post-doctoral fellow in the Substance Abuse Epidemiology Training Program and mentored her on her NIDA-funded K01 grant and on career development issues.

Areas Use of large-scale medical claims data to understand health phenomena including opioid overdoses.

Accomplishments 40 publications (10 first authored). She is now Assistant Professor, Rutgers University School of Public Health.

**Ronald Thompson, PhD, 2007 – 2018**

Nature of mentoring I mentored him on publications and career development, I was sponsor of his NIAAA-funded R21 and K23 grants

Areas Childhood adverse experiences and substance problems; drinking and drug use reduction in homeless and other high-risk populations.

Accomplishments 37 publications (18 first authored). Now Assistant Professor and research investigator, Psychiatric Research Institute, University of Arkansas.

**Katherine Keyes, PhD, 2005 – 2019**

Former pre-doctoral fellow, Psychiatric Epidemiology Training Program

Nature of mentoring I mentored her on scientific and career development from the time she was a volunteer in my lab, through her NIMH pre-doctoral fellowship, her NIDA-funded F31DA026689, her post-doctoral merit fellowship and her NIAAA-funded K01 grant, which ended in 2018.

Areas Group- and individual-level influences on trends in psychiatric, substance abuse and other health outcomes.

Accomplishments: 484 publications (89 first-authored). She is now Professor, Department of Epidemiology, Mailman School of Public Health, Columbia University.

Awards: Dr. Keyes now has 3 R01 grants and is Director of the NIMH-funded T32 Psychiatric Epidemiology Training program at Columbia University. She received many prestigious awards for her research throughout her career. She is now Professor and Vice Chair for Research, Department of Epidemiology, Mailman School of Public Health, Columbia University

**Aaron Sarvet, MPH, PhD 2015 – 2017**

Nature of mentoring I mentored him on publications and career development while he was a data analyst in my lab.

Areas Psychiatric and substance epidemiology, causal inference

Accomplishments 41 publications (7 first-authored). He completed his doctorate in Epidemiology at Harvard University in 2021, and a post-doctoral fellowship at the EPFL (École Polytechnique Fédérale de Lausanne). He is now assistant professor in the Department of Biostatistics and Epidemiology, University of Amherst, Massachusetts

**Qiana Brown, PhD, 2014 – 2019**

Former post-doctoral fellow, Substance Abuse Epidemiology Training Program. She is now Assistant Professor of Social Work and Public Health, Rutgers University.

Nature of mentoring I mentored her on publications and career development while a SAETP post-doctoral fellow.

Areas: Substance abuse, maternal and child health; race/ethnic disparities

Accomplishments 28 publications (9 first-authored), including a first-authored paper in JAMA and a commentary in Addiction. Awards: Junior Investigator Travel Award, RSA (2015), APPA and NIDA (2016), NIDA Diversity Grantsmanship, CPDD, International Women's and Children's Health (2017). She is Assistant Professor, Rutgers University School of Social Work and is on the Board of Directors for CPDD.

**Hannah Carliner, ScD, 2015 – 2017**

Former post-doctoral fellow, Substance Abuse Epidemiology Training Program, now Director of Research and Evaluation, Health Resources in Action, Boston MA

Nature of mentoring I mentored her on publications and career development while a SAETP post-doctoral fellow.

Areas: Stress, social disparities, discrimination

Accomplishments 16 publications (8 first-authored), including a recent commentary in Am J Public Health. She is currently Director of Research and Evaluation, Health Resources in Action, Boston MA

**Bradley Kerridge, PhD, 2012 – 2017**

Nature of mentoring I mentored his publications and career development and was sponsor of his NIDA-funded F32 grant.

Areas: U.S. alcohol and drug epidemiology, international HIV issues

Accomplishments 39 publications (20 first-authored). Awards: NIDA Director's Travel Award (2012), CPDD Early Investigator Travel Award (2016). He is now Research Scientist, National Institute on Alcohol Abuse and Alcoholism, Laboratory of Epidemiology and Biometry.

**Ardesheer Talati, PhD, 2010 – 2016**

Nature of mentoring I was a co-mentor for his NIDA-funded K01 grant, with a focus specifically on the epidemiology of smoking and psychiatric disorders.

Accomplishments: 91 publications (18 first-authored). He is now Associate Professor of Clinical Neurobiology, Columbia University

**Kate Walsh, 2012 – 2016**

Former post-doctoral fellow, Substance Abuse Epidemiology Training Program.

Nature of mentoring I mentored her publications and career development while a SAETP post-doctoral fellow.

Areas: Trauma exposure, PTSD, substance abuse

Accomplishments 89 publications (39 first-authored). Awards: Junior Investigators awards from CPDD and the American Psychological Association (2013). She is now Professor & Chair of the Psychology Clinical Area Group, Department of Psychology, University of Wisconsin, Madison WI.

**Miriam Fenton, PhD, 2009 – 2015**

Nature of mentoring I mentored her on publications while a doctoral student and was chair of her dissertation committee.

Area: Pharmacoepidemiology, alcohol/drug epidemiology

Accomplishments 21 publications (7 first-authored).

Awards: RSA travel award (2010), RSA Student Merit award (2011). Now Director, Real World Investigations (evidence on efficacy from sources other than randomized trials), Syneos Health.

**Mark Hatzenbuehler, PhD, 2007 – 2014**

Nature of mentoring I mentored him on publications and career development from the time he was a predoctoral research technician in my lab through to 2014, and was the initial sponsor of his NIDA-funded K01 grant.

Areas Stigma and discrimination, treatment disparities, mental disorders

Accomplishments 153 publications (57 first-authored).

He has had multiple NIH grants, and is currently MPI of two NIMH-funded R01 grants. Awards: He has received numerous awards throughout his career, including the William T. Grant Award (2018); Janet Taylor Spence Award from the Association for Psychological Science (2016); and the 2015 Kidder Early Career Award (2015). He is now Professor, Department of Psychology, Harvard University.

**Cheryl Beseler, PhD, 2006 – 2012**

Nature of mentoring I mentored her on publications and career development when she was a post-doctoral fellow in the Department of Psychiatry, Columbia University

Areas Substance use, environmental toxins

Accomplishments 72 publications, 25 first-authored. She is now Associate Professor, Department of Environmental, Agricultural and Occupational Health, College of Public Health, at the University of Nebraska Medical Center.

**Lynn Boschloo, PhD, 2011 – 2012**

Nature of mentoring I mentored her research on the structure of psychiatric and substance use disorders as a visiting pre-doctoral scholar from the University of Groningen, Netherlands (Netherlands Study of Depression and Anxiety (NESDA)).

Accomplishments 49 publications, 23 first-authored. She is now Assistant Professor of Clinical Psychology at Utrecht University.

**Daniel Pilowsky, MD, 2005 – 2012**

Nature of mentoring I mentored him on publications from the NESARC studies.

Area Early childhood experiences and risk for alcohol and drug disorders

Accomplishments 81 publications (24 first-authored). Until 2016, he was Assistant Professor, Department of Psychiatry, Columbia University. He is now in private practice in New York.

**Suzette Glasner, PhD, 2007-2011**

Nature of mentoring I mentored her on her K23 from NIDA. Now Associate Professor, Department of Psychiatry, University of California at Los Angeles (UCLA), Principal Investigator on numerous NIDA- and NIAAA-funded grants.

Area Substance use and psychiatric comorbidity

Accomplishments 38 publications (19 first-authored)

**Stephanie Gamble, PhD, 2008-2012**

Nature of mentoring I mentored her on her K23 from NIAAA. Now Associate Professor, Department of Psychiatry, University of Rochester; Deputy Director, Center of Excellence for Suicide Prevention, Veterans Health Administration VISN 2,

Area Treatment of women with alcohol and depressive disorders

Accomplishments 32 publications (7 first-authored)

**Sharon Samet, PhD, 2003 – 2010**

Nature of mentoring I mentored her on publications and career development while she was a project director in my lab and on her doctoral dissertation using data from my studies. Now visiting Professor, Touro Graduate School of Social Work

Areas comorbidity of alcohol and drug use with psychiatric disorders

Accomplishments 19 publications (4 first-authored)

**Miriam Schiff, PhD, 2001 – 2009**

Nature of mentoring I mentored her on publications and grant proposals. Now Professor of Social Work, Hebrew University, Jerusalem, Israel. She has received several grants from the Israeli equivalent of NIAAA/NIDA.

Areas Alcohol/substance use, terrorism exposure, stressful early childhood experiences

Accomplishments 88 publications (42 first-authored).

**Efrat Aharonovich, PhD, 1999 – 2009**

Nature of mentoring I mentored her on publications, grant writing and career development.

Areas cognitive functioning, substance abuse treatment development and testing

Accomplishments 100 publications (19 first-authored). She had several NIDA-funded grants, including K23, R21 and 2 R01 grants. She is now Associate Professor of Medical Psychology, Department of Psychiatry, Columbia University

**Dana Lizardi Alonzo, PhD, 2007– 2008**

Nature of mentoring I mentored her on early-career publications using NESARC data in her areas of interest.  
Areas Childhood parental divorce, suicidality, comorbidity with alcohol, drug and psychiatric problems  
Accomplishments 44 publications (19 first-authored). She is now Professor, Fordham University and founder of the Suicide Prevention Research Program in the Graduate School of Social Service.

**Carlos Blanco, PhD, MD, 2004 – 2008**

Nature of mentoring While he was at Columbia University, I mentored him on substance and psychiatric epidemiology, and on use of the NESARC datasets. He had several NIDA-funded R01 grants while there. He is now Director, Division of Epidemiology, Services and Prevention (DESPR), NIDA Areas Substance and psychiatric disorders in the general population.  
Accomplishments 525 publications (112 first-authored).

**Renee Goodwin, PhD, 2002 – 2007**

Former post-doctoral fellow, Psychiatric Epidemiology Training program  
Nature of mentoring I mentored her while she was a post-doctoral fellow on publications and career development, and on her first NIDA-funded R01, to study depression and anxiety in the tobacco epidemic.  
Areas smoking, nicotine dependence, psychiatric comorbidity.  
Accomplishments 272 publications (147 first-authored). Now Professor, Department of Psychology, City University of New York (CUNY). Her R01 was renewed and she now has a new R21 grant to explore cannabis legalization and respiratory health.

**Jakob Meydan, PsyD, 2001 – 2005**

Nature of mentoring I mentored him on data analysis and issues in psychopathology while he worked in my lab, and was a member of his dissertation committee while he was at Adelphi University.  
Areas Alcohol and drug use in schizophrenic patients  
Accomplishments 5 publications (1 first-authored). Now Director of Clinical Training, Jacobi Hospital Department of Psychology, Bronx

**Claire Henderson, MD, 2002 – 2004**

Nature of mentoring During a visiting Columbia University Public Psychiatry fellowship, I mentored her on analyses of income inequality, alcohol policy and rates of alcohol disorders in NESARC data.  
Areas Stigma and services for mental disorders  
Accomplishments 238 publications (49 first-authored), now Director, Community Mental Health, Institute of Psychiatry, King's College, London

**Marilyn Lewis, PhD, 2001 – 2002**

Nature of mentoring I sponsored her NIAAA-funded F31 grant  
Areas maternal–fetal attachment and drinking  
Accomplishments 30 publications (24 first-authored), now Professor of Social Work, Norfolk State University, VA

**Kenneth Carpenter, PhD, 1996 – 2001**

Former post-doctoral fellow, Psychiatric Epidemiology Training program  
Nature of mentoring I mentored him on measurement and substance abuse issues during his post-doctoral fellowship in the Psychiatric Epidemiology Training program.  
Areas substance abuse treatment and measurement  
Accomplishments 69 publications (23 first-authored), now Associate Professor of Medical Psychology, Department of Psychiatry, Columbia University. He has now received NIDA-funded K23 and R01 grants

**Gloria Miele, PhD, 1997 – 2000**

Nature of mentoring I mentored her on measurement of substance use disorders in a post-doctoral position in my lab.

Areas Measures of substance disorder severity, treatment

Accomplishments 34 publications (6 first-authored). Author of Substance Dependence Severity Scale. Now Instructor in Clinical Psychology, Columbia University and in private practice.

### **Other Mentorship Activities**

**Chui Ying Vivian Chiu, MPH student, 2022-2023.** Queensland University, Australia. Outside thesis reader.

Area: Cannabis use and changing cannabis laws, US and Australia

**Claire Walsh, MA student (psychology), 2022-2023.** Master's thesis, New School, New York, NY, now pre-doctoral fellow, University of Southern California Department of Psychology.

Areas: National time trends in hallucinogen use, adolescent use of cannabis and alcohol

**Isabel Zhang, MPH student, Master's thesis, 2019-2020**

Area: Cannabis use and comorbidity

**Giuliana Graziosi, rising senior, North Shore High School Summer Mentoring Program.**

Area: Survey on drinking and drug use in New York during the COVID-19 pandemic

**Gautam Kumar, MPH student, Yale University, Master's thesis, 2019-2020**

Area: Alcohol use among different Asian-American subgroups in the United States

**Victor Puac-Polanco, PhD, Faculty reader, Doctoral Dissertation, 2019-2020**

Area: Anti-Drink Special Laws and Fatal Crashes in the United States

**Sarah McKetta, MPH, PhD. Chair, Doctoral Committee, 2020-2021**

Area: Structural sexism and drinking in middle-aged women.

Now in medical school, Columbia University. Accomplishments: 23 publications, 8 first-authored.

**Cheri Raffo, PhD, Member, Dissertation Committee, 2016 – 2018**

Area: Biostatistics, measurement models for substance use disorders

**P. Nina Bannerji, DrPH, Chair, Dissertation Committee, 2010 – 2018**

Area: Maternal factors (depression/alcohol), birth weight, and infant cognitive ability

**Adina Lemeshow, PhD, Chair, Dissertation Committee, 2012 – 2016**

Area: Food addiction

**Reanne Rahim, MS, Faculty Reader, Master's thesis, Teacher's College (psychology), 2015**

Area: Racial discrimination and PTSD

**Matt McEnany, MPH, Faculty Reader, Master's thesis, 2014 – 2015**

Area: Longitudinal study of opioid-addicted patients in Shanghai

**Niki Palmetto, PhD, Chair, Dissertation Committee, 2012-2014**

Area: Suicidality

**Christine Chan, MPH**, Faculty Reader, Master's thesis, 2013 – 2014  
Area: Personal and partner alcohol and HIV in the general population

**Rachel Rhoades, MPH**, Faculty Reader, Master's thesis, 2013 – 2014  
Area: Mental disorders, childhood maltreatment and nicotine dependence in the general population

**Bari Kilcoyne, DO**, Faculty Reader, Master's Thesis, 2012 – 2013  
Area: Genetic and environmental influences on substance abuse

**Gordon Shott, MPH**, Faculty Reader, Master's Thesis, 2012 – 2013  
Area: Early adverse experiences and adult substance abuse

## **15. Publications**

### **15.1 Peer-Reviewed Research Publications in Print or other Media**

- 2024**
1. \* **Hasin DS**, Mannes ZL, Livne O, Fink DS, Martins SS, Stohl M, Olfson M, Cerdá M, Keyes KM, Keyhani S, Wisell CG, Bujno JM, Saxon, A. Cannabis Use and Cannabis Use Disorder among US Adults with Psychiatric Disorders: 2001-2002 and 2012-2013. medRxiv. [Preprint] 2024 Feb 29:2024.02.29.24303158. doi: <https://doi.org/10.1101/2024.02.29.24303158>
  2. Bushnell GA, Rynn MA, Gerhard T, Keyes KM, **Hasin DS**, Cerdá M, Nyandegé A, Olfson M. Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals. *Addiction*. 2024 Feb;119(2):356-368. doi: 10.1111/add.16359. Epub 2023 Oct 10. PMID: 37816665; PMCID: PMC10838605.
  3. Cerdá M, Wheeler-Martin K, Bruzelius E, Mauro CM, Crystal S, Davis CS, Adhikari S, Santaella-Tenorio J, Keyes KM, Rudolph KE, **Hasin D**, Martins SS. The role of prescription opioid and cannabis supply policies on opioid overdose deaths. *Am J Epidemiol*. 2024 Jul 18:kwa210. Epub ahead of print. PMID: 39030721.
  4. \* Elliott JC, Ali M, Radecka O, Lérias D, Shalev N, Stohl M, Aharonovich E, **Hasin DS**. An Intervention to Reduce Drinking Among Individuals With HIV and Hepatitis C: A Pilot Randomized Controlled Trial. *J Stud Alcohol Drugs*. 2024 Mar;85(2):227-233. doi: 10.15288/jsad.23-00010. Epub 2023 Nov 2. PMID: 37947429; PMCID: PMC10941824.
  5. \* Fink DS, Schleimer JP, Keyes KM, Branas CC, Cerdá M, Gruenwald P, **Hasin D**. Social and economic determinants of drug overdose deaths: a systematic review of spatial relationships. *Soc Psychiatry Psychiatr Epidemiol*. 2024 Feb 14. doi: 10.1007/s00127-024-02622-4. Epub ahead of print. PMID: 38356082.
  6. \* Gorfinkel L, Stohl M, Shmulewitz D, **Hasin D**. Self-Reported Substance Use With Clinician Interviewers Versus Self-Administered Surveys. *J Stud Alcohol Drugs*. 2024 Jan;85(1):92-99. doi: 10.15288/jsad.23-00004. Epub 2023 Oct 3. PMID: 37796626; PMCID: PMC10846601.
  7. Hammond CJ, Hyer JM, Boustead AE, Fristad MA, Steelesmith DL, Brock GN, **Hasin DS**, Fontanella CA. Association Between Marijuana Laws and Suicide Among 12- to 25-Year-Olds in the United States From 2000 to 2019. *J Am Acad Child Adolesc Psychiatry*. 2024 Mar;63(3):345-354. doi: 10.1016/j.jaac.2023.06.014. Epub 2023 Jun 27. PMID: 37385585.

8. \* Knox J, Aharonovich E, Zingman BS, Stohl M, Walsh C, Elliott JC, Fink DS, Durant S, Menchaca R, Sharma A, Denning M, **Hasin D**. HealthCall: Smartphone Enhancement of Brief Interventions to Improve HIV Medication Adherence Among Patients in HIV Care. *AIDS Behav*. 2024 Mar 13. Epub ahead of print. PMID: 38478322.
9. \* Livne O, Budney A, Borodovsky J, Shmulewitz D, Walsh C, Struble CA, Habib M, Aharonovich E, **Hasin DS**. Age differences in patterns of cannabis use among an online US sample of adults who consume cannabis frequently. *Am J Drug Alcohol Abuse*. 2024 Mar 3;50(2):242-25. Epub 2024 Apr 19. PMID: 38640463.
10. \* Livne O, Malte CA, Olfson M, Wall MM, Keyes KM, Maynard C, Gradus JL, Saxon AJ, Martins SS, Keyhani S, McDowell Y, Fink DS, Mannes ZL, Gutkind S, **Hasin DS**. Trends in Prevalence of Cannabis Use Disorder Among U.S. Veterans With and Without Psychiatric Disorders Between 2005 and 2019. *Am J Psychiatry*. 2024 Feb 1;181(2):144-152. doi: 10.1176/appi.ajp.20230168. Epub 2023 Nov 29. PMID: 38018141; PMCID: PMC10843609.
11. Mauro PM, Gutkind S, Askari MS, **Hasin DS**, Samples H, Mauro CM, Annunziato EM, Boustead AE, Martins SS. Associations between cannabis policies and state-level specialty cannabis use disorder treatment in the United States, 2004-2019. *Drug Alcohol Depend*. 2024 Feb 2;257:111113. doi: 10.1016/j.drugalcdep.2024.111113. Epub ahead of print. PMID: 38382162.
12. Struble CA, Borodovsky JT, Habib MI, Livne O, Walsh CA, Aharonovich E, **Hasin DS**, Budney AJ. Evaluating age-related disparities in cannabis-related problems among LGBT+ versus non-LGBT+ adults. *Addict Behav*. 2024 Jan;148:107861. doi: 10.1016/j.addbeh.2023.107861. Epub 2023 Sep 14. PMID: 37748224; PMCID: PMC10713017.
13. Turi E, McMenamin AL, Courtwright S, Martsof G, Liu J, **Hasin D**, Poghosyan L. Nurse Practitioner Work Environment and Rural Primary Care for Substance Use. *J Nurse Pract*. 2024 Oct;20(9):105152. Epub 2024 Jul 20. PMID: 39131540; PMCID: PMC11308990.
14. Turi E, McMenamin AL, Martsof G, **Hasin D**, Han BH, Liu J, Poghosyan L. Primary care nurse practitioner work environments and emergency department utilization among older adults with substance use disorders in rural areas. *J Subst Use Addict Treat*. 2024 Feb;157:209285. doi: 10.1016/j.josat.2023.209285. Epub 2023 Dec 28. PMID: 38159910; PMCID: PMC10922346.
15. \* Walsh CA, Gorfinkel L, Shmulewitz D, Stohl M, **Hasin DS**. Use of Lysergic Acid Diethylamide by Major Depression Status. *JAMA Psychiatry*. 2024 Jan 1;81(1):89-96. doi: 10.1001/jamapsychiatry.2023.3867. PMID: 37819655; PMCID: PMC10568444.
16. Zaman T, Bravata DM, Byers A, Krebs E, Leonard S, Austin C, Sandbrink F, **Hasin DS**, Keyhani S. A national study of clinical discussions about cannabis use among Veteran patients prescribed opioids. *J Cannabis Res*. 2024 Mar 16;6(1):12. doi: 10.1186/s42238-024-00221-3. PMID: 38493111; PMCID: PMC10943860.
- 2023** 17. \* **Hasin DS**, Wall MM, Choi CJ, Alschuler DM, Malte C, Olfson M, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, Mannes Z, Sherman S, Saxon AJ. State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019. *JAMA Psychiatry*. 2023 Apr 1;80(4):380-388. doi: 10.1001/jamapsychiatry.2023.0019. PMID: 36857036; PMCID: PMC9979011.

18. \* **Hasin DS**, Borodovsky J, Shmulewitz D, Walsh C, Struble CA, Livne O, Habib MI, Fink DS, Aharonovich E, Budney A. Adult use of highly-potent  $\Delta$ 9-THC cannabis concentrate products by U.S. state cannabis legalization status, 2021. *Addict Behav.* 2023 May;140:107617. doi: 10.1016/j.addbeh.2023.107617. Epub 2023 Jan 10. PMID: 36736229; PMCID: PMC9930475.
19. \* **Hasin DS**, Wall MM, Alschuler DM, Mannes Z, Malte C, Olfson M, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, McDowell Y, Sherman S, Saxon AJ. Chronic pain, cannabis legalization and cannabis use disorder in the US Veterans Health Administration, 2005 to 2019, a repeated, cross-sectional study. *Lancet Psychiatry.* 2023 Nov;10(11):877-886. Epub 2023 Oct 11. Erratum in: *Lancet Psychiatry.* 2023 Oct 18;: PMID: 37837985.
20. Borodovsky JT, Struble CA, Habib MI, **Hasin DS**, Shmulewitz D, Walsh C, Livne O, Aharonovich E, Budney AJ. Exploring survey methods for measuring consumption quantities of cannabis flower and concentrate products. *Am J Drug Alcohol Abuse.* 2023 Nov 2;49(6):733-745. doi: 10.1080/00952990.2023.2246635. Epub 2023 Dec 11. PMID: 37774316; PMCID: PMC10795727.
21. \* Brown QL, Shmulewitz D, Sarvet AL, Young-Wolff KC, Howard T, **Hasin DS**. Cannabis use, cannabis use disorder and mental health disorders among pregnant and postpartum women in the US: A nationally representative study. *Drug Alcohol Depend.* 2023 Jul 1;248:109940. doi: 10.1016/j.drugalcdep.2023.109940. Epub 2023 May 22. PMID: 37267745; PMCID: PMC10518192.
22. Bruzelius E, Cerdá M, Davis CS, Jent V, Wheeler-Martin K, Mauro CM, Crystal S, Keyes KM, Samples H, **Hasin DS**, Martins SS. Naloxone expansion is not associated with increases in adolescent heroin use and injection drug use: Evidence from 44 US states. *Int J Drug Policy.* 2023 Apr;114:103980. doi: 10.1016/j.drugpo.2023.103980. Epub 2023 Feb 28. PMID: 36863285.
23. Chambers J, Keyhani S, Ling PM, Hoggatt KJ, **Hasin D**, Nguyen N, Woods A, Ryder A, Cohen BE. Perceptions of Safety of Daily Cannabis vs Tobacco Smoking and Secondhand Smoke Exposure, 2017-2021. *JAMA Netw Open.* 2023 Aug 1;6(8):e2328691. PMID: 37566411; PMCID: PMC10422186.
24. Chapron SA, Kervran C, Da Rosa M, Fournet L, Shmulewitz D, **Hasin D**, Denis C, Collombat J, Monsaingeon M, Fatseas M, Gatta-Cherifi B, Serre F, Auriacombe M. Does food use disorder exist? Item response theory analyses of a food use disorder adapted from the DSM-5 substance use disorder criteria in a treatment seeking clinical sample. *Drug Alcohol Depend.* 2023 Oct 1;251:110937. doi: 10.1016/j.drugalcdep.2023.110937. Epub 2023 Aug 23. PMID: 37666092.
25. \* Fink DS, Keyes KM, Branas C, Cerdá M, Gruenwald P, **Hasin D**. Understanding the differential effect of local socio-economic conditions on the relation between prescription opioid supply and drug overdose deaths in US counties. *Addiction.* 2023 Jun;118(6):1072-1082. Epub 2023 Jan 26. PMID: 36606567; PMCID: PMC10175115.
26. \* Fink DS, Malte C, Cerdá M, Mannes ZL, Livne O, Martins SS, Keyhani S, Olfson M, McDowell Y, Gradus JL, Wall MM, Sherman S, Maynard CC, Saxon AJ, **Hasin DS**. Trends in Cannabis-positive Urine Toxicology Test Results: US Veterans Health Administration Emergency Department Patients, 2008 to 2019. *J Addict Med.* 2023 Nov-Dec 01;17(6):646-653. doi: 10.1097/ADM.0000000000001197. Epub 2023 Jul 7. PMID: 37934524; PMCID: PMC10766071.

27. \* Fink DS, Samples H, Malte CA, Olfson M, Wall MM, Alschuler DM, Saxon AJ, **Hasin DS**. Association of Cannabis Legalization with Cannabis Positive Drug Screening in US Veterans. medRxiv [Preprint]. 2023 Dec 9;2023.12.08.23299731. doi: 10.1101/2023.12.08.23299731. PMID: 38105937; PMCID: PMC10723559.
28. Gonçalves PD, Bruzelius E, Levy NS, Segura LE, Livne O, Gutkind S, Boustead AE, **Hasin DS**, Mauro PM, Silver D, Macinko J, Martins SS. Recreational cannabis legislation and binge drinking in U.S. adolescents and adults. *Int J Drug Policy*. 2023 Aug; 118:104085. Epub 2023 Jun 15. PMID: 37329666. PMCID: PMC10527765.
29. \* Gutkind S, Shmulewitz D, **Hasin D**. Sex differences in Cannabis use disorder and associated psychosocial problems among US adults, 2012-2013. *Prev Med*. 2023 Mar;168:107422. doi: 10.1016/j.ypmed.2023.107422. Epub 2023 Jan 11. PMID: 36641126; PMCID: PMC9974921.
30. Keyes KM, Joseph V, Kaur N, Kreski NT, Chen Q, Martins SS, **Hasin D**, Olfson M, Mauro PM. Adolescent simultaneous use of alcohol and marijuana by trends in cigarette and nicotine vaping from 2000 to 2020. *Drug Alcohol Depend*. 2023 Aug 1;249:109948. doi: 10.1016/j.drugalcdep.2023.109948. Epub 2023 May 27. PMID: 37270934; PMCID: PMC10348405.
31. Kreski NT, Riehm KE, Cerdá M, Chen Q, **Hasin DS**, Martins SS, Mauro PM, Olfson M, Keyes KM. Parenting Practices and Adolescent Internalizing Symptoms in the United States, 1991-2019. *J Adolesc Health*. 2023 Feb;72(2):189-196. doi: 10.1016/j.jadohealth.2022.09.014. Epub 2022 Nov 21. PMID: 36424334.
32. Kreski NT, Ankrum H, Cerdá M, Chen Q, **Hasin D**, Martins SS, Olfson M, Keyes KM. Nicotine Vaping and Co-occurring Substance Use Among Adolescents in the United States from 2017-2019. *Subst Use Misuse*. 2023;58(9):1075-1079. doi: 10.1080/10826084.2023.2188462. Epub 2023 May 17. PMID: 37198725; PMCID: PMC10277150.
33. Kreski NT, Askari MS, Cerdá M, Chen Q, **Hasin DS**, Martins SS, Mauro PM, Olfson M, Keyes KM. Changing adolescent activity patterns and the correlation of self-esteem and externalizing mental health symptoms across time: results from the USA from 1991 through 2020. *Psychol Med*. 2023 May 15:1-9. Epub ahead of print. PMID: 37183659.
34. Knox JR, Dolotina B, Moline T, Matthews I, Durrell M, Hanson H, Almirol E, Hotton A, Pagkas-Bather J, Chen YT, English D, Manuzak J, Rower JE, Miles C, Millar B, Jean-Louis G, Rendina HJ, Martins SS, Grov C, **Hasin DS**, Carrico AW, Shoptaw S, Schneider JA, Duncan DT. HIV Prevention and Care Among Black Cisgender Sexual Minority Men and Transgender Women: Protocol for an HIV Status-Neutral Cohort Study Using an Observational-Implementation Hybrid Approach. *JMIR Res Protoc*. 2023 Dec 1;12:e48548. doi: 10.2196/48548. PMID: 38039075; PMCID: PMC10724817.
35. \* Livne O, Mannes ZL, McDowell YE, Shmulewitz D, Malte CA, Saxon AJ, **Hasin DS**. Mental and Physical Health Conditions Among U.S. Veterans with Cannabis Use and Cannabis Use Disorders. *Curr Addict Rep*. 2023 Sep;10(3):441-457. doi: 10.1007/s40429-023-00490-7. Epub 2023 Jun 2. PMID: 38149223; PMCID: PMC10751043.

36. \* Mannes ZL, Malte CA, Olfson M, Wall MM, Keyes KM, Martins SS, Cerdá M, Gradus JL, Saxon AJ, Keyhani S, Maynard C, Livne O, Fink DS, Gutkind S, **Hasin DS**. Increasing risk of cannabis use disorder among U.S. veterans with chronic pain: 2005-2019. *Pain*. 2023 Sep 1;164(9):2093-2103. doi: 10.1097/j.pain.0000000000002920. Epub 2023 May 8. PMID: 37159542; PMCID: PMC10524371.
37. Mannes ZL, Livne O, Knox J, **Hasin DS**, Kranzler HR. Prevalence and correlates of DSM-5 opioid withdrawal syndrome in U.S. adults with non-medical use of prescription opioids: results from a national sample. *Am J Drug Alcohol Abuse*. 2023 Nov 2;49(6):799-808. doi: 10.1080/00952990.2023.2248646. Epub 2023 Dec 11. PMID: 37948571; PMCID: PMC10867630.
38. Mannes ZL, Wheeler-Martin K, Terlizzi K, **Hasin DS**, Perry A, Pamplin JR 2nd, Crystal S, Cerdá M, Martins SS. Risks of opioid overdose among New York State Medicaid recipients with chronic pain before and during the COVID-19 pandemic. *Prev Med*. 2023 Dec;177:107789. doi: 10.1016/j.ypmed.2023.107789. Epub 2023 Nov 26. PMID: 38016582; PMCID: PMC10842754.
39. McKetta S, Prins SJ, **Hasin D**, Patrick ME, Keyes KM. Structural sexism moderates work and occupational risks for alcohol consumption and binge drinking among US women, 1989-2016. *Soc Sci Med*. 2023 May;324:115878. Epub 2023 Mar 29. PMID: 37003025; PMCID: PMC10121897.
40. Mintz CM, Knox J, Hartz SM, **Hasin DS**, Martins SS, Kranzler HR, Greene E, Geng EH, Gruzca RA, Bierut LJ. Demographic differences in the cascade of care for unhealthy alcohol use: A cross-sectional analysis of data from the 2015-2019 National Survey on Drug Use and Health. *Alcohol Clin Exp Res (Hoboken)*. 2023 Oct;47(10):1890-1903. Epub 2023 Sep 10. PMID: 37864538; PMCID: PMC10590988.
41. Perry A, Wheeler-Martin K, Terlizzi K, Krawczyk N, Jent V, **Hasin DS**, Neighbors C, Mannes ZL, Doan LV, Pamplin JR, Townsend TN, Crystal S, Martins SS, Cerdá M. Evaluating chronic pain as a risk factor for COVID-19 complications among New York State Medicaid beneficiaries: a retrospective claims analysis. *Pain Med*. 2023 Dec 1;24(12):1296-1305. doi: 10.1093/pm/pnad121. PMID: 37651585; PMCID: PMC10690846.
42. Perry A, Wheeler-Martin K, **Hasin DS**, Terlizzi K, Mannes ZL, Jent V, Townsend TN, Pamplin JR 2nd, Crystal S, Martins SS, Cerdá M, Krawczyk N. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic. *Drug Alcohol Depend*. 2023 Dec 1;253:111023. doi: 10.1016/j.drugalcdep.2023.111023. Epub 2023 Nov 11. PMID: 37984034; PMCID: PMC10841620.
43. \* Shmulewitz D, Budney AJ, Borodovsky JT, Bujno JM, Walsh CA, Struble CA, Livne O, Habib MI, Aharonovich E, **Hasin DS**. Dimensionality and differential functioning of DSM-5 cannabis use disorder criteria in an online sample of adults with frequent cannabis use. *J Psychiatr Res*. 2023 Jul;163:211-221. doi: 10.1016/j.jpsychires.2023.05.048. Epub 2023 May 16. PMID: 37224773; PMCID: PMC10330577.
44. Starbird LE, Gutkind S, Teixeira P, Murphy S, Aharonovich E, Zingman BS, **Hasin D**, Schackman BR. Economic Cost of the HealthCall Smartphone Intervention to Reduce Heavy Alcohol Drinking in Adults With HIV. *J Stud Alcohol Drugs*. 2023 Nov;84(6):814-822. doi: 10.15288/jsad.22-00377. Epub 2023 Jul 11. PMID: 37449954; PMCID: PMC10765982.

45. Struble CA, Borodovsky JT, Habib MI, **Hasin DS**, Shmulewitz D, Livne O, Walsh C, Aharonovich E, Budney AJ. Extending Gender- and Sex-Based Analyses in Cannabis Research: Findings from an Online Sample of Gender Diverse Young Adult Consumers. *Cannabis Cannabinoid Res.* 2023 Aug 18. doi: 10.1089/can.2023.0069. Epub ahead of print. PMID: 37594777.
46. Thompson RG Jr, Bollinger M, Mancino MJ, **Hasin D**, Han X, Bush KA, Kilts CD, James GA. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial. *Trials.* 2023 Apr 4;24(1):255. doi: 10.1186/s13063-023-07213-3. PMID: 37016394; PMCID: PMC10071730.
47. Turi E, McMenamin AL, Martsof G, **Hasin D**, Han BH, Liu J, Poghosyan L. Primary care nurse practitioner work environments and emergency department utilization among older adults with substance use disorders in rural areas. *J Subst Use Addict Treat.* 2023 Dec 28;157:209285. doi: 10.1016/j.josat.2023.209285. Epub ahead of print. PMID: 38159910.
48. \* Walsh CA, Struble CA, Aharonovich E, Shmulewitz D, Borodovsky J, Habib MI, Budney A, Livne O, **Hasin DS**. Evaluating cannabis exposure in survey items: Insights, strategies, and remaining challenges identified from cognitive interviewing. *Drug Alcohol Depend Rep.* 2023 Apr 19;7:100161. PMID: 37179574; PMCID: PMC10173391.
- 2022** 49. \* **Hasin DS**, Aharonovich E, Zingman BS, Stohl M, Walsh C, Elliott JC, Fink DS, Knox J, Durant S, Menchaca R, Sharma A. HealthCall: A randomized trial assessing a smartphone enhancement of brief interventions to reduce heavy drinking in HIV care. *J Subst Abuse Treat.* 2022 Jul;138:108733. Epub 2022 Jan 31. PMID: 35131124; PMCID: PMC9167215.
50. \* **Hasin DS**, Fink DS, Olfson M, Saxon AJ, Malte C, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Livne O, Mannes ZL, Sherman SE, Wall MM. Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records. *Drug Alcohol Depend.* 2022 May 1;234:109383. Epub 2022 Mar 3. PMID: 35279457; PMCID: PMC8891118.
51. \* **Hasin DS**, Saxon AJ, Malte C, Olfson M, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, Mannes Z, Wall MM. Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005-2019. *Am J Psychiatry.* 2022 Jul 28;appiajp22010034. Epub ahead of print. PMID: 35899381.
- Commentary on this article: Lake S, Cooper ZD. Understanding Cannabis Use Disorders in the U.S. Veterans Health Administration in the Era of Legalization. *Am J Psychiatry.* 2022 179(10):702-704. PMID 36181332.
52. \* **Hasin DS**, Shmulewitz D, Stohl M, Greenstein E, Aharonovich E, Petronis KR, Von Korff M, Datta S, Sonty N, Ross S, Inturrisi C, Weinberger ML, Scodes J, Wall MM. Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain. *Am J Psychiatry.* 2022 Jun 15;appiajp21070721. Epub ahead of print. PMID: 35702830.
- Commentary on this article: Sullivan MD, Ballantyne J. Understanding the Risks of Long-Term Opioid Therapy for Chronic Pain. *Am J Psychiatry* 2022 Oct;179(10):696-698. doi: 10.1176/appi.ajp.20220592. PMID: 36181333

53. Ankrum H, Kreski NT, Cerdá M, Chen Q, **Hasin DS**, Martins SS, Miech R, Olfson M, Keyes KM. Co-substance use of nicotine vaping and non-cigarette tobacco products among U.S. grade 12 students from 2017-2019. *Drug Alcohol Depend Rep.* 2022 Dec;5:100112. doi: 10.1016/j.dadr.2022.100112. Epub 2022 Nov 1. PMID: 36644225; PMCID: PMC9838102.
54. Borodovsky JT, **Hasin DS**, Shmulewitz D, Walsh C, Livne O, Aharonovich E, Struble CA, Habib MI, Budney AJ. Typical Hits, Grams, or Joints: Evaluating Cannabis Survey Measurement Strategies for Quantifying Consumption. *Cannabis Cannabinoid Res.* 2022 Dec 26. doi: 10.1089/can.2022.0237. Epub ahead of print. PMID: 36577020.
55. Boudard M, Alexandre JM, Kervran C, Jakubiec L, Shmulewitz D, **Hasin D**, Fournet L, Rassis C, Claverie P, Serre F, Auriacombe M. Item Response Theory Analyses of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Criteria Adapted to Screen Use Disorder: Exploratory Survey. *J Med Internet Res.* 2022 Jul 27;24(7):e31803. PMID: 35896018; PMCID: PMC9377463.
56. Budney AJ, Borodovsky JT, Struble CA, Habib MI, Shmulewitz D, Livne O, Aharonovich E, Walsh C, Cuttler C, **Hasin DS**. Estimating THC Consumption from Smoked and Vaped Cannabis Products in an Online Survey of Adults Who Use Cannabis. *Cannabis Cannabinoid Res.* 2022 Dec 15. doi: 10.1089/can.2022.0238. Epub ahead of print. PMID: 36521175.
57. Bushnell GA, Gerhard T, Keyes K, **Hasin D**, Cerdá M, Olfson M. Association of Benzodiazepine Treatment for Sleep Disorders With Drug Overdose Risk Among Young People. *JAMA Netw Open.* 2022 Nov 1;5(11):e2243215. doi: 10.1001/jamanetworkopen.2022.43215. PMID: 36413369; PMCID: PMC9682430.
58. \* Fink DS, Shmulewitz D, Mannes ZL, Stohl M, Livne O, Wall M, **Hasin DS**. Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use. *J Psychiatr Res.* 2022 Nov;155:387-394. doi: 10.1016/j.jpsychires.2022.09.016. Epub 2022 Sep 21. PMID: 36182768; PMCID: PMC9590423.
59. \* Fink DS, Stohl M, Mannes ZL, Shmulewitz D, Wall M, Gutkind S, Olfson M, Gradus J, Keyhani S, Maynard C, Keyes KM, Sherman S, Martins S, Saxon AJ, **Hasin DS**. Comparing mental and physical health of U.S. veterans by VA healthcare use: implications for generalizability of research in the VA electronic health records. *BMC Health Serv Res.* 2022 Dec 9;22(1):1500. doi: 10.1186/s12913-022-08899-y. PMID: 36494829; PMCID: PMC9733218.
60. Gonçalves PD, Levy NS, Segura LE, Bruzelius E, Boustead AE, **Hasin DS**, Mauro PM, Martins SS. Cannabis Recreational Legalization and Prevalence of Simultaneous Cannabis and Alcohol Use in the United States. *J Gen Intern Med.* 2022 Nov 30. doi: 10.1007/s11606-022-07948-w. Epub ahead of print. PMID: 36451010.
61. Gorfinkel LR, **Hasin D**, Saxon AJ, Wall M, Martins SS, Cerdá M, Keyes K, Fink DS, Keyhani S, Maynard CC, Olfson M. Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018. *J Pain.* 2022 Jul;23(7):1187-1195. Epub 2022 Feb 8. PMID: 35143969; PMCID: PMC9271556.

62. Kaur N, Hamilton AD, Chen Q, **Hasin D**, Cerda M, Martins SS, Keyes KM. Age, Period, and Cohort Effects of Internalizing Symptoms Among US Students and the Influence of Self-Reported Frequency of Attaining 7 or More Hours of Sleep: Results From the Monitoring the Future Survey 1991-2019. *Am J Epidemiol*. 2022 May 20;191(6):1081-1091. PMID: 35048117; PMCID: PMC9393068.
63. Keyes KM, Kaur N, Kreski NT, Chen Q, Martins SS, **Hasin D**, Olfson M, Mauro PM. Temporal trends in alcohol, cannabis, and simultaneous use among 12th-grade U.S. adolescents from 2000 to 2020: Differences by sex, parental education, and race and ethnicity. *Alcohol Clin Exp Res*. 2022 Sep;46(9):1677-1686. doi: 10.1111/acer.14914. Epub 2022 Sep 20. PMID: 36125706; PMCID: PMC9635013.
64. Keyes KM, Kreski NT, Ankrum H, Cerdá M, Chen Q, **Hasin DS**, Martins SS, Olfson M, Miech R. Frequency of adolescent cannabis smoking and vaping in the United States: Trends, disparities and concurrent substance use, 2017-19. *Addiction*. 2022 Aug;117(8):2316-2324. Epub 2022 May 19. PMID: 35588004.
65. Keyhani S, Cohen BE, Vali M, Hoggatt KJ, Bravata DM, Austin PC, Lum E, **Hasin DS**, Grunfeld C, Shlipak MG. The Heart and Cannabis (THC) Cohort: Differences in Baseline Health and Behaviors by Cannabis Use. *J Gen Intern Med*. 2022 Jan 10. Epub ahead of print. PMID: 35013928.
66. Kreski NT, Cerdá M, Chen Q, **Hasin DS**, Martins SS, Mauro PM, Olfson M, Keyes KM. Adolescents' Use of Free Time and Associations with Substance Use from 1991 to 2019. *Subst Use Misuse*. 2022;57(13):1893-1903. doi: 10.1080/10826084.2022.2115849. Epub 2022 Sep 20. PMID: 36127772; PMCID: PMC9746067.
67. Kreski NT, Chen Q, Olfson M, Cerdá M, **Hasin DS**, Martins SS, Mauro PM, Keyes KM. Time use and associations with internalizing symptoms from 1991 to 2019 among US adolescents. *SSM Popul Health*. 2022 Aug 3;19:101181. PMID: 35968043; PMCID: PMC9365953.
68. Kreski NT, Chen Q, Olfson M, Cerdá M, Martins SS, Mauro PM, **Hasin DS**, Keyes KM. National Trends and Disparities in Bullying and Suicidal Behavior Across Demographic Subgroups of US Adolescents. *J Am Acad Child Adolesc Psychiatry*. 2022 Apr 27:S0890-8567(22)00210-6. Epub ahead of print. PMID: 35489630.
69. \* Livne O, Budney A, Borodovsky J, Walsh C, Shmulewitz D, Fink DS, Struble CA, Habib M, Aharonovich E, **Hasin DS**. Delta-8 THC use in US adults: Sociodemographic characteristics and correlates. *Addict Behav*. 2022 Oct;133:107374. Epub 2022 May 23. PMID: 35644057; PMCID: PMC9245337.
70. \* Livne O, Shmulewitz D, Walsh C, **Hasin DS**. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP. *Addiction*. 2022 Aug 17. Epub ahead of print. PMID: 35978453.
71. Livne O, Feinn R, Knox J, Hartwell EE, Gelernter J, **Hasin DS**, Kranzler HR. Alcohol withdrawal in past-year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey. *Alcohol Clin Exp Res*. 2022 Mar;46(3):422-433. PMID: 35275407; PMCID: PMC8928097.

72. \* Mannes ZL, Stohl M, Fink DS, Olfson M, Keyes KM, Martins SS, Gradus JL, Saxon AJ, Maynard C, Livne O, Gutkind S, **Hasin DS**. Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems. *J Gen Intern Med*. 2022 Jan 19;1–10. Epub ahead of print. PMID: 35048300; PMCID: PMC8769678.
73. Mannes ZL, **Hasin DS**, Ben Abdallah A, Cottler LB. Co-Use of Opioids and Sedatives Among Retired National Football League Athletes. *Clin J Sport Med*. 2022 May 1;32(3):322-328. Epub 2021 Dec 27. PMID: 35470340; PMCID: PMC9043466.
74. Mannes ZL, **Hasin DS**, Martins SS, Gonçalves PD, Livne O, de Oliveira LG, de Andrade AG, McReynolds LS, McDuff D, Hainline B, Castaldelli-Maia JM. Do varsity college athletes have a greater likelihood of risky alcohol and cannabis use than non-athletes? Results from a National Survey in Brazil. *Braz J Psychiatry*. 2022 May-Jun;44(3):289-297. PMID: 35293519; PMCID: PMC9169487.
75. McKetta S, Prins SJ, **Hasin D**, Patrick ME, Keyes KM. Structural sexism and Women's alcohol use in the United States, 1988-2016. *Soc Sci Med*. 2022 May;301:114976. Epub 2022 Apr 14. PMID: 35461082.
76. Nguyen N, Keyhani S, Ling PM, Hoggatt KJ, **Hasin D**, Cohen BE. Self-reported Changes in Cannabis Use Due to the COVID-19 Pandemic among US Adults. *J Psychoactive Drugs*. 2022 Mar 31:1-5. Epub ahead of print. PMID: 35356866.
77. \* Shmulewitz D, Greenstein E, Stohl M, Fink DS, Roncone S, Walsh C, Aharonovich E, **Hasin DS**. Validity of the DSM-5 tobacco use disorder diagnostics in adults with problematic substance use. *Drug Alcohol Depend*. 2022 May 1;234:109411. Epub 2022 Mar 17. PMID: 35338898; PMCID: PMC9035622.
78. Struble CA, Borodovsky JT, Habib MI, **Hasin DS**, Shmulewitz D, Livne O, Walsh C, Aharonovich E, Budney AJ. Cannabis Practices Among a Gender-Diverse Sample of Young Adults. *Drug Alcohol Depend Rep*. 2022 Dec;5:100113. doi: 10.1016/j.dadr.2022.100113. Epub 2022 Nov 2. PMID: 36741544; PMCID: PMC9894216.
79. \* Walsh CA, Livne O, Shmulewitz D, Stohl M, **Hasin DS**. Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019. *Addict Behav Rep*. 2022 Sep 6;16:100454. doi: 10.1016/j.abrep.2022.100454. PMID: 36119808; PMCID: PMC9471967.
- 2021** 80. \* **Hasin DS**, Borodovsky J, Shmulewitz D, Walsh C, Livne O, Struble CA, Aharonovich E, Fink DS, Budney A. Use of highly-potent cannabis concentrate products: More common in U.S. states with recreational or medical cannabis laws. *Drug Alcohol Depend*. 2021 Dec 1;229(Pt B):109159. Epub 2021 Oct 29. PMID: 34844095; PMCID: PMC8667084.
81. \* Aharonovich E, Scodes J, Wall MM, **Hasin DS**. The relationship of frequency of cocaine use to substance and psychiatric disorders in the U.S. general population. *Drug Alcohol Depend*. 2021 Oct 1;227:108933. Epub 2021 Jul 27. PMID: 34358768; PMCID: PMC8464522.

82. \* Browne KC, Stohl M, Bohnert KM, Saxon AJ, Fink DS, Olfson M, Cerda M, Sherman S, Gradus JL, Martins SS, **Hasin DS**. Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III). *Am J Psychiatry*. 2022 Jan;179(1):26-35. Epub 2021 Aug 19. PMID: 34407625; PMCID: PMC8724447.
83. \* Elliott JC, Greene AL, Thompson RG Jr, Eaton NR, **Hasin DS**. Substance use in a sexual context: The association of sex-related substance use motives with substance choice and use behaviors. *J Subst Use*. 2021;26(2):212-217. PMID: 33732094
84. \* Gutkind S, Fink DS, Shmulewitz D, Stohl M, **Hasin D**. Psychosocial and health problems associated with alcohol use disorder and cannabis use disorder in U.S. adults. *Drug Alcohol Depend*. 2021 Dec 1;229(Pt B):109137. Epub 2021 Oct 28. PMID: 34763137; PMCID: PMC8665071.
85. \* Enkema MC, **Hasin DS**, Browne KC, Stohl M, Shmulewitz D, Fink DS, Olfson M, Martins SS, Bohnert KM, Sherman SE, Cerda M, Wall M, Aharonovich E, Keyhani S, Saxon AJ. Pain, cannabis use, and physical and mental health indicators among veterans and nonveterans: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Pain*. 2022 Feb 1;163(2):267-273. PMID: 34108436; PMCID: PMC8985055.
86. Aldridge AP, Zarkin GA, Dowd WN, Witkiewitz K, **Hasin DS**, O'Malley SS, Isenberg K, Anton RF. The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup. *J Addict Med*. 2022 Jul-Aug 01;16(4):425-432. Epub 2021 Dec 3. PMID: 34864785; PMCID: PMC9163210.
87. Cerdá M, Wheeler-Martin K, Bruzelius E, Ponicki W, Gruenewald P, Mauro C, Crystal S, Davis CS, Keyes K, **Hasin D**, Rudolph KE, Martins SS. Spatiotemporal Analysis of the Association Between Pain Management Clinic Laws and Opioid Prescribing and Overdose Deaths. *Am J Epidemiol*. 2021 Dec 1;190(12):2592-2603. PMID: 34216209; PMCID: PMC8796812.
88. Gorfinkel L, **Hasin D**, Miech R, Keyes KM. The Link Between Depressive Symptoms and Vaping Nicotine in U.S. Adolescents, 2017-2019. *J Adolesc Health*. 2022 Jan;70(1):133-139. Epub 2021 Aug 9. PMID: 34384705.
89. \* Gutkind S, Gorfinkel L, **Hasin DS**. Prospective Effects of Loneliness on Frequency of Alcohol and Marijuana Use. *Addict Behav*. 2022 Jan;124:107115. Epub 2021 Sep 17. PMID: 34543868; PMCID: PMC8511227.
90. \* Livne O, Shmulewitz D, Sarvet AL, Wall MM, **Hasin DS**. Association of Cannabis Use-Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001-2002 and 2012-2013. *Am J Psychiatry*. 2022 Jan;179(1):36-45. Epub 2021 Oct 14. PMID: 34645275; PMCID: PMC8945254.
91. \* Livne O, Shmulewitz D, Stohl M, Mannes Z, Aharonovich E, **Hasin D**. Agreement between DSM-5 and DSM-IV measures of substance use disorders in a sample of adult substance users. *Drug Alcohol Depend*. 2021 Oct 1;227:108958. Epub 2021 Aug 12. PMID: 34450471.
92. Livne O, Wengrower T, Feingold D, Shmulewitz D, **Hasin D**, Lev-Ran S. Religiosity and Substance Use in US Adults: Findings from a Large-Scale National Survey. *Drug Alch Dep*. 2021 Aug 1;225:108796. PMID: 34119881

93. Kervran C, Shmulewitz D, Serre F, Denis C, Roux P, Jauffret-Roustide M, Lalanne L, **Hasin D**, Auriacombe M. Do DSM-5 substance use disorder criteria differ by user care settings? An item response theory analysis approach. *Addict Behav.* 2021 May;116:106797. PMID: 33450665
94. \* Kim JH, Martins SS, Shmulewitz D, **Hasin D**. Association between fatal opioid overdose and state medical cannabis laws in US national survey data, 2000-2011. *Int J Drug Policy.* 2022 Jan;99:103449. Epub 2021 Sep 26. PMID: 34587580; PMCID: PMC8755580.
95. King A, Vena A, **Hasin DS**, deWit H, O'Connor SJ, Cao D. Subjective Responses to Alcohol in the Development and Maintenance of Alcohol Use Disorder. *Am J Psychiatry.* 2021 Jun;178(6):560-571. Epub 2021 Jan 5. PMID: 33397141; PMCID: PMC8222099.
96. Kreski NT, Chen Q, Olfson M, Cerdá M, **Hasin D**, Martins SS, Keyes KM. Explaining US Adolescent Depressive Symptom Trends Through Declines in Religious Beliefs and Service Attendance. *J Relig Health.* 2022 Feb;61(1):300-326. Epub 2021 Aug 20. PMID: 34417680; PMCID: PMC8840960.
97. Kreski NT, Chen Q, Olfson M, Cerdá M, **Hasin D**, Martins SS, Mauro PM, Keyes KM. Trends in Adolescent Online and Offline Victimization and Suicide Risk Factors. *Pediatrics.* 2021 Sep;148(3):e2020049585. Epub 2021 Aug 2. PMID: 34341075.
98. Mannes ZL, Ferguson EG, Ennis N, **Hasin DS**, Cottler LB. Pain Acceptance Among Retired National Football League Athletes: Implications for Clinical Intervention. *J Clin Sport Psychol.* 2023 Mar;17(1):27-40. doi: 10.1123/jcsp.2020-0061. Epub 2021 Sep 25. PMID: 36919031; PMCID: PMC10010661.
99. \* Mannes ZL, Shmulewitz D, Livne O, Stohl M, **Hasin DS**. Correlates of mild, moderate, and severe Alcohol Use Disorder among adults with problem substance use: Validity implications for DSM-5. *Alcohol Clin Exp Res.* 2021 Oct;45(10):2118-2129. Epub 2021 Sep 28. PMID: 34581461; PMCID: PMC8602758.
100. Martins SS, Bruzelius E, Stingone JA, Wheeler-Martin K, Akbarnejad H, Mauro CM, Marziali ME, Samples H, Crystal S, Davis CS, Rudolph KE, Keyes KM, **Hasin DS**, Cerdá M. Prescription Opioid Laws and Opioid Dispensing in US Counties: Identifying Salient Law Provisions With Machine Learning. *Epidemiology.* 2021 Nov 1;32(6):868-876. PMID: 34310445; PMCID: PMC8556655.
101. \* Martins SS, Segura LE, Levy NS, Mauro PM, Mauro CM, Philbin MM, **Hasin DS**. Racial and Ethnic Differences in Cannabis Use Following Legalization in US States With Medical Cannabis Laws. *JAMA Netw Open.* 2021 Sep 1;4(9):e2127002. Erratum in: *JAMA Netw Open.* 2021 Oct 1;4(10):e2136454. PMID: 34570205; PMCID: PMC8477268.
102. \* Shmulewitz D, Aharonovich E, Witkiewitz K, Anton RF, Kranzler HR, Scodes J, Mann KF, Wall MM, **Hasin D**; Alcohol Clinical Trials Initiative (ACTIVE Group). The World Health Organization Risk Drinking Levels Measure of Alcohol Consumption: Prevalence and Health Correlates in Nationally Representative Surveys of U.S. Adults, 2001-2002 and 2012-2013. *Am J Psychiatry.* 2021 Jun;178(6):548-559. Epub 2021 Jan 21. PMID: 33472388; PMCID: PMC8222066.

103. \* Shmulewitz D, Stohl M, Greenstein E, Roncone S, Walsh C, Aharonovich E, Wall MM, **Hasin DS**. Validity of the DSM-5 craving criterion for alcohol, tobacco, cannabis, cocaine, heroin, and non-prescription use of prescription painkillers (opioids). *Psychol Med*. 2021 Nov 1:1-15. Epub ahead of print. PMID: 35506791; PMCID: PMC9096712.
104. Witkiewitz K, Kranzler HR, Hallgren KA, **Hasin DS**, Aldridge AP, Zarkin GA, Mann KF, O'Malley SS, Anton RF. Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. *J Gen Intern Med*. 2021 Feb;36(2):404-412. PMID: 33180306
- 2020** 105. \* **Hasin DS**, Shmulewitz D, Stohl M, Greenstein E, Roncone S, Aharonovich E, Wall MM. Test-retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview. *Drug Alcohol Depend*. 2020 Nov 1;216:108294. PMID: 33007702
106. \* **Hasin DS**, Shmulewitz D, Cerdá M, Keyes KM, Olfson M, Sarvet AL, Wall MM. US adults with pain, an increasingly vulnerable group for non-medical cannabis use and cannabis use disorder: 2001-2002 and 2012-2013. *Am J Psychiatry*. 2020 Jan 22 PMID: 31964162
- Commentary on this article: Brady KT. Medical Marijuana: Putting the Cart Before the Horse *Am J Psychiatry*. 2020 Jul 1;177(7):570-571. PMID: 32605450
107. Barrington-Trimis JL, Cho J, Ewusi Boisvert E, **Hasin D**, Unger JB, Miech RA, Leventhal AM. Risk of Persistence and Progression of Use of 5 Cannabis Products After Experimentation in Adolescence. *JAMA Network Open*. 2020 Jan 3;3(1):e1919792. PMID: 31977062
108. Borodovsky JT, Marsch LA, Scherer EA, Grucza RA, **Hasin DS**, Budney AJ. Perceived Safety of Cannabis Intoxication Predicts Frequency of Driving While Intoxicated. *Preventive Medicine*. 2020 Feb; 131:105956. PMID: 31863787
109. \* Fink DS, Stohl M, Sarvet AL, Cerda M, Keyes KM, **Hasin DS**. Medical Marijuana Laws and Driving Under the Influence of Marijuana and Alcohol. *Addiction*. 2020 Oct;115(10):1944-1953. PMID: 32141142
110. \* Gorfinkel LR, Stohl M, **Hasin D**. Association of Depression With Past-Month Cannabis Use Among US Adults Aged 20 to 59 Years, 2005 to 2016, *JAMA Netw Open*. 2020 Aug 18;3(8):e2013802. PMID: 32809032
111. \* Gorfinkel LR, Stohl M, Greenstein E, Aharonovich E, Olfson M, **Hasin D**. Is Cannabis being used as a substitute for non-medical opioids by adults with problem substance use in the United States? A within-person analysis. *Addiction*. 2021 May;116(5):1113-1121. Epub 2020 Oct 8. PMID: 33029914; PMCID: PMC8026758.
112. \* Howard R, **Hasin D**, Stohl M. Substance use disorders and criminal justice contact among those with co-occurring antisocial and borderline personality disorders: Findings from a nationally representative sample. *Personal Ment Health*. 2021 Feb;15(1):40-48. Epub 2020 Jun 26. PMID: 32588546.

113. Kervran C, Shmulewitz D, Serre F, Stohl M, Denis C, **Hasin D**, Auriacombe M. Item Response Theory analyses of DSM-5 substance use disorder criteria in French outpatient addiction clinic participants. How much is craving special? *Drug Alcohol Depend*. 2020 Jul 1;212:108036. Epub 2020 May 12. PMID: 32464467.
114. \* Knox JR, Wall MM, Witkiewitz K, Kranzler HR, Falk DE, Litten R, Mann K, O'Malley SS, Scodes J, Anton R, **Hasin DS**. Reduction in World Health Organization (WHO) risk drinking levels and cardiovascular disease. *Alch Clin Exp Research*. 2020 Aug;44(8):1625-1635. PMID: 32619058
115. Santaella-Tenorio J, Wheeler-Martin K, DiMaggio Cj, Castillo-Carniglia A, Keyes KM, **Hasin D**, Cerdá M. Recreational cannabis laws in Colorado and Washington State and changes in traffic fatalities 2005-2017. *JAMA Internal Medicine*. 2020 Aug 1;180(8):1061-1068. PMID: 32568378
116. Silverstein AR, Kee R, Gleeson CD, Sussell J, O'Sullivan AK, Goldman DP, **Hasin D**. Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015. *Alcohol*. 2020 Dec;89:19-25. Epub 2020 Aug 7. PMID: 32777472.
117. \* Thompson RG, Aivadyan C, Stohl M, Aharonovich E, **Hasin DS**. Smartphone application plus brief motivational intervention reduces substance use and sexual risk behaviors among homeless young adults: Results from a randomized controlled trial. *Psychol Addictive Beh*. 2020 Mar 16. 2020 Sep;34(6):641-649. PMID: 32175752
118. Weinberger AH, Chaiton M, Zhu J, Wall MM, **Hasin DS**, Goodwin RD. Trends in the prevalence of current, daily, and nondaily cigarette smoking and quit ratios by depression status in the United States, 2005-2017. *Am J Preventive Medicine*. 2020 May;58(5):691-658. PMID: 32156490
119. Witkiewitz K, Heather N, Falk DE, Litten RZ, **Hasin DS**, Kranzler HR, Mann KF, O'Malley SS, Anton RF. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. *Addiction*. 2020 Sep;115(9):1668-1680. Epub 2020 Mar 10. PMID: 32056311; PMCID: PMC7841874.
- 2019** 120. \* **Hasin DS**, Shmulewitz D, Sarvet AL. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. *Am J Drug Alcohol Abuse*. 2019;45(6):623-643. PMID: 30870044
121. \* **Hasin DS**, Shmulewitz D, Keyes KM. Alcohol use and binge drinking among U.S. men, pregnant and non-pregnant women ages 18-44: 2002 to 2017. *Drug Alch Dependence*. 2019 Dec 1;205:107590. PMID: 31600616
122. Cerdá M, Mauro C, Hamilton A, Levey NS, Santaella-Tenorio J, **Hasin D**, Wall MM, Keyes KM, Martins SS. Legalization of recreational marijuana and association with marijuana use and cannabis use disorder: United States, 2008 – 2016. *JAMA Psychiatry*. 2019 Nov 13;77(2):165-171. PMID: 31722000
123. \* Elliott JC, Shalev A, **Hasin DS**. Medical Reasons for Limiting Drinking: Data from a Sexual Health Clinic. *Substance Use and Misuse*. 2019 Jan 8;1-6. PMID: 30618338

124. Elliott JC, Critchley L, Feaser DJ, **Hasin DS**, Mandler RN, Osorio G, Rodriguez AE, del Rio, C, Metsch LR. The roles of heavy drinking and drug use in engagement in HIV care among hospitalized substance using individuals with poorly controlled HIV infection. *Drug Alch Dependence*, 2019 Aug 1;201:171-177. PMID: 31234013
125. Falk D, O'Malley SS, Witkiewitz K, Anton R, Litten R, Slater M, Kranzler HR, Mann K, **Hasin DS**, Johnson B, Meulien D. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: a secondary analysis of 3 randomized clinical trials. *JAMA Psychiatry*. 2019 Apr 1;76(4):374-381. PMID: 30865232
126. Kerridge BT, Chou SB, Pickering RP, Ruan WJ, Huanga B, Jung J, Zhang H, Fan AZ, Saha TD, Grant BF, **Hasin DS**. Changes in the prevalence and correlates of cocaine use and cocaine use disorder in the United States, 2001–2002 and 2012–2013. *Addictive Beh*. 2019 90:250-257. PMID: 30471553
127. King AC, Cao D, DeWit H, O'Connor SJ, **Hasin DS**. The role of alcohol response phenotypes in the risk for alcohol use disorder. *BJPsych Open*. 2019 Apr 22;5(3):e38. PMID: 31685074
128. Knox J, Schneider J, Greene E, Nicholson J, **Hasin D**, Sandfort T. Using social network analysis to examine alcohol use among adults: a systematic review. *Plos One*. 2019 Aug 22;14(8):e0221360. PMID: 31437257
129. \* Knox J, Scodes J, Wall M, Witkiewitz K, Kranzler HR, Falk D, Litten R, Mann K, O'Malley SS, Anton R, **Hasin DS**. Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. *Drug Alch Dependence*. 2019 Feb 14;197:228-235. PMID: 30852375
130. \* Knox J, Wall M, Witkiewitz K, Kranzler HR, Falk DE, Litten R, Mann K, O'Malley SS, Scodes J, Anton R, **Hasin DS**. Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. *Drug Alch Dependence*. 2019 Aug 1;201:16-22. PMID: 31174140
131. Knox J, Reddy V, Lane T, Lovasi GS, **Hasin D**, Sandfort T. Safer sex intentions modify the relationship between substance use and sexual risk behavior among black South African men who have sex with men. *Int J STD AIDS*. 2019 Jul;30(8):786-794. PMID: 31142222
132. \* Livne O, Shmulewitz D, Lev-Ran S, **Hasin DS**. DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. *Drug Alcohol Depend*. 2019 Feb 1;195:170-177 PMID:30361043
133. \* Shmulewitz D, **Hasin DS**. Risk factors for alcohol use among pregnant women, ages 15-44, in the United States, 2002 to 2017. *Preventive Medicine*. 2019 Jul;124:75-83. PMID: 31054285
134. Steigerwald S, Cohen BE, Vali M, **Hasin D**, Cerda M, Keyhani S. Differences in Opinions About Marijuana Use and Prevalence of Use by State Legalization Status. *J Addict Med*. 2020 Jul/Aug;14(4):337-344. PMID: 31821192; PMCID: PMC7269858.
135. Tagert TC, Rodriguez-Seijas C, Dyar C, Elliott JC, Thompson RG, **Hasin DS**, Eaton NR. Sexual Orientation and Sex-Related Substance Use: The Unexplored Role of Bisexuality. *Behaviour Research and Therapy*. 2019 Apr;115:55-63. PMID: 30594299

136. Wall M, Liu J, **Hasin D**, Blanco C, Olfson M. Use of marijuana exclusively for medical purposes. *Drug Alch Dependence*. 2019 Feb 1;195:13-15. PMID: 30557813
137. Witkiewitz K, Falk D, Litten R, **Hasin DS**, Kranzler HR, Mann K, O'Malley SS, Anton R. Maintenance of World Health Organization Risk Drinking Level Reductions and Post-Treatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. *Alcohol Clin Exp Res*. 2019 May;43(5):979-987 PMID: 30951210
- 2018** 138. \* **Hasin DS**, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, Grant BF. The Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers: United States, 2012-2013. *JAMA Psychiatry*. 2018 Apr 1;75(4):336-346. PMID: 29450462 PMCID: PMC5875313
139. Aharonovich E, Hasin DS, Nunes EV, Stohl M, Cannizzaro D, Sarvet A, Bolla K, Carroll KM, Genece KG. Modified cognitive behavioral therapy (M-CBT) for cocaine dependence: Development of treatment for cognitively impaired users and results from a Stage 1 trial. *Psychol Addict Behav*. 2018 Nov;32(7):800-811. PMID: 30346186
140. \* Algur Y, Elliott JC, Aharonovich E, **Hasin DS**. A Cross-Sectional Study of Depressive Symptoms and Risky Alcohol Use Behaviors Among HIV Primary Care Patients in New York City. *AIDS Behav*. 2018 May;22(5):1423-1429. PMID: 29214410
141. Blanco C, Flórez-Salamanca L, Secades-Villa R, Wang S, **Hasin DS**. Predictors of initiation of nicotine, alcohol, cannabis, and cocaine use: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Am J Addict*. 2018 Sep;27(6):477-484. PMID: 30088294
142. \* Cerdá M, Sarvet AL, Wall M, Feng T, Keyes KM, Galea S, **Hasin DS**. Medical marijuana laws and adolescent use of marijuana and other substances: Alcohol, cigarettes, prescription drugs, and other illicit drugs. *Drug Alch Dependence*. 2018 Feb 1;183:62-68. PMID: 29227839
143. Dyar C, Taggart TC, Rodriguez-Seijas C, Thompson RG, Elliott JC, **Hasin DS**, Eaton NR. Physical health disparities affecting sexual minority groups: Identifying unique health correlates of bisexuality. *Arch Sexual Beh*. 2018 Apr 9. PMID: 29633061
144. Elliott JC, Brincks AM, Feaster DJ, **Hasin DS**, Del Rio C, Lucas GM, Rodriguez AE, Nijhawan AE, Metsch LR. Psychosocial Factors Associated with Problem Drinking Among Substance Users with Poorly Controlled HIV Infection. *Alcohol Alcohol*. 2018 Sep 1;53(5):603-610. PMID: 29596589; PMCID: PMC6104623.
145. \* Elliott JC, Stohl M, **Hasin DS**. Heavy drinking among individuals with HIV: who drinks despite knowledge of the risk? *AIDS Care*. 2018 May;30(5):560-563. PMID: 28944687
146. Goodwin RD, Pacek LR, Copeland J, Moeller SJ, Dierker L, Weinberger AH, Gbedemah M, Zvolensky MJ, Wall MM, **Hasin DS**. Trends in daily cannabis use among cigarette smokers in the United States, 2002-2014. *Am J Public Health*. 2018 Jan;108(1):137-142. PMID: 29161058 PMCID: PMC5719676
147. Goodwin RD, Cheslack-Postava K, Santoscoy S, Bakoyiannis N, **Hasin DS**, Collins BN, Lepore SJ, Wall MM. Trends in Cannabis and Cigarette Use Among Parents With Children at Home: 2002 to 2015. *Pediatrics*. 2018 Jun;141(6). PMID: 29759986

148. Goodwin RD, Wall MM, Gbedemah M, Hu MC, Weinberger AH, Galea S, Zvolensky MJ, Hangle E, **Hasin DS**. Trends in cigarette consumption and time to first cigarette on awakening from 2002 to 2015 in the USA: new insights into the ongoing tobacco epidemic. *Tob Control*. 2018 Jul;27(4):379-384. PMID: 28801362
149. \* Kerridge BT, Pickering R, Chou P, Saha TD, **Hasin DS**. DSM-5 Cannabis Use Disorder in the National Epidemiologic Survey on Alcohol and Related Conditions – III: Gender specific profiles. *Addictive Behaviors*. 2018 Jul 14;76:52-60. PMID: 28755613
150. Keyhani S, Vali M, Cohen B, Woodbridge A, Arenson M, Eilkhani E, Aivadyan C, **Hasin D**. A search algorithm for identifying likely users and non-users of marijuana from the free text of the electronic medical record. *PLoS One*. 2018 Mar 6;13(3):e0193706. PMID: 29509775
151. Keyhani S, Steigerwald S, Ishida J, Vali M, Cerda M, **Hasin D**, Dollinger C, Yoo SR, Cohen BE. Risks and Benefits of Marijuana Use: A National Survey of US Adults. *Annals of Int Medicine*. 2018 Sep 4;169(5):282-290. PMID: 30039154
152. \* Knox J, Wall M, Witkiewitz K, Kranzler HR, Falk D, Litten R, Mann K, O'Malley SS, Scodes J, Anton R, **Hasin DS**. Reduction in non-abstinent WHO drinking risk levels and change in risk for liver disease and positive AUDIT-C scores: Prospective 3-year follow-up results in the US general population. *Alch Clin Exp Research* 2018 Nov;42(11):2256-2265. PMID: 30204248
153. Lemeshow AR, Rimm EB, **Hasin DS**, Gearhardt AN, Flint AJ, Field AE, Genkinger JM. Food and Beverage Consumption and Food Addiction Among Women in the Nurses' Health Studies. *Appetite*. 2018 Feb 1;121:186-197. PMID: 29102534
154. Livne O, Razon L, Rehm J, **Hasin DS**, Lev-Ran S. The association between lifetime cannabis use and dysthymia across six birth decades. *J Affective Disorders*. 2018 Jul;234:327-334. PMID: 29605793
155. \* Livne O, Shmulewitz D, Lev-Ran S, **Hasin DS**. Prevalence and Correlates of DSM-5 Cannabis Withdrawal Syndrome, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Drug Alch Dependence*. 2018 Oct 16. PMID: 30361043
156. Mauro PM, Santaella-Tenorio J, Perlmutter AS, **Hasin DS**, Mauro CM, Martins SS. Correct knowledge of medical cannabis legal status in one's own state: Differences between adolescents and adults in the United States, 2004-2013. *Addictive Behaviors* 2019 Jan;88:23-28. PMID: 30103098
157. Mauro PM, Carliner H, Brown QL, **Hasin DS**, Shmulewitz D, Rahim R, Sarvet AL, Wall MM, Martins SS. Age differences in daily and non-daily cannabis use in the United States, 2002-2014. *Journal of Studies on Alcohol and Drugs*. 2018 May;79(3):423-431. PMID: 29885150
158. \* Meyers JL, Sartor CE, Werner KB, Koenen KC, Grant BF, **Hasin D**. Childhood interpersonal violence and adult alcohol, cannabis, and tobacco use disorders: variation by race/ethnicity? *Psychol Med*. 2018 Jul;48(9):1540-1550. PMID: 29310741
159. Moeller SJ, Fink DS, Gbedemah M, **Hasin DS**, Galea S, Zvolensky MJ, Goodwin RD. Trends in Illicit Drug Use Among Smokers and Nonsmokers in the United States, 2002-2014. *J Clin Psychiatry*. 2018 May/Jun;79(3). PMID: 29894597

160. Raffo CD, **Hasin DS**, Appelbaum P, Wall MW. A data-driven method for identifying shorter symptom criteria sets: The case for DSM-5 alcohol use disorder. *Psychol Med*. 2018 Jun 27;1-9. PMID: 29947307
161. \* Sarvet AL, Wall MM, Keyes KM, Olfson M, Cerdá M, **Hasin DS**. Self-medication of mood and anxiety disorders with marijuana: Higher in states with medical marijuana laws. *Drug Alch Dependence*. 2018 Mar 2;186:10-15. PMID: 29525698
162. \* Sarvet AL, Wall MM, Keyes KM, Cerdá, Schulenberg JE, O'Malley PM, Johnston LD, **Hasin DS**. Recent rapid decrease in adolescents' perception that marijuana is harmful, but no concurrent increase in use. *Drug Alch Dependence*. 2018 May 1;186:68-74. PMID: 29550624
163. Weinberger AH, Gbedemah M, Wall MM, **Hasin DS**, Zvolensky MJ, Goodwin RD. Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002-14: emerging disparities in vulnerable populations. *Addiction*. 2018 Apr;113(4):719-728. PMID: 29265574
164. Weinberger AH, Pacek LR, Wall MM, Zvolensky MJ, Copeland J, Galea S, Nahvi S, Moeller SJ, **Hasin DS**, Goodwin RD. Trends in cannabis use disorder by cigarette smoking status in the United States, 2002-2016. *Drug Alch Dependence*. 2018 Oct 1;191:45-51. PMID: 30077055
165. Witkiewitz K, Kranzler HR, Hallgren KA, O'Malley SS, Falk DE, Litten RZ, **Hasin DS**, Mann KF, Anton RF. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. *Alch Clin Exp Research*. 2018 Nov 5. PMID: 30395350
166. Zvolensky MJ, Jardin C, Wall MM, Gbedemah M, **Hasin D**, Shankman SA, Gallagher MW, Bakhshaei J, Goodwin RD. Psychological Distress Among Smokers in the United States: 2008-2014. *Nicotine Tob Res*. 2018 May 3;20(6):707-713. PMID: 28482108
- 2017** 167. \* **Hasin DS**, Sarvet AL, Cerdá M, Keyes KM, Stohl M, Galea S, Wall MM. U.S. Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. *JAMA Psychiatry*. 2017 Jun 1;74(6):579-588. PMID: 28445557.
- Commentary on this article: Compton WM, Volkow ND, Lopez MF. Medical Marijuana Laws and Cannabis Use: Intersections of Health and Policy. *JAMA Psychiatry*. 2017 Jun 1;74(6):559-560.
168. \* **Hasin DS**, Wall MM, Witkiewitz K, Kranzler HR, Falk D, Litten R, Mann K, O'Malley SS, Scodes J, Robinson RL, Anton R. Change in Non-Abstinent WHO Risk Drinking Levels and Alcohol Dependence: A 3-Year Follow-Up Study in the United States General Population. *Lancet Psychiatry*. 2017 Jun;4(6):469-476. PMID: 28456501. PMCID: 5536861.
169. Aharonovich E, Shmulewitz D, Wall MM, Grant BF, **Hasin DS**. Self-reported Cognitive Scales in a U.S. National Survey: Reliability, Validity, and Preliminary Evidence for Associations with Alcohol and Drug Use. *Addiction*. 2017 Jun 17. PMID: 28623859
170. \* Aharonovich E, Stohl M, Canizzaro D, **Hasin D**. HealthCall delivered via smartphone to reduce co-occurring drug and alcohol use in HIV-infected adults: a randomized pilot trial. *J Subst Abuse Treat*. 2017 Dec;83:15-26. PMID: 29129192

171. \* Aharonovich E, Stohl M, Sarvet A, Des Jarlais D, Tross S, Hurst T, Urbino T, **Hasin D**. Reducing non-Injection drug use in HIV primary care: a randomized trial of brief motivational interviewing, with and without HealthCall, a technology-based enhancement. *Journal of Substance Abuse Treatment*. 2017 Mar;74:71-79. PMID: 28132704
172. \* Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, **Hasin DS**. Trends in marijuana use among pregnant and non-pregnant reproductive-aged women, 2002-2014. *JAMA*. 2017 Jan 10;317(2):207-209. PMID: 27992619.
173. \* Carliner H, Mauro PM, Brown QL, Shmulewitz D, Rahim R, Sarvet AL, Wall MM, Martins SS, Carliner G, **Hasin DS**. The Widening Gender Gap in Marijuana Use Prevalence in the U.S. during a Period of Economic Change, 2002-2014. *Drug Alch Dependence*. 2017 Jan 1;170:51-58. PMID: 27875801
174. \* Carliner H, Sarvet AL, Gordon AR, **Hasin D**. Gender discrimination, educational attainment, and illicit drug use among U.S. women. *Social Psychiatry and Psychiatric Epidemiology*. 2017 Mar;52(3):279-289. PMID: 28025690 PMCID: PMC5346046 [Available on 2018-03-01]
175. \* Cerdá M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, O'Malley PM, Pacula RL, Galea S, **Hasin DS**. State Recreational Marijuana Laws and Adolescent Marijuana Use. *JAMA Pediatrics*. 2017 Feb 1;171(2):142-149. PMID: 28027345.
176. Elliott JC, **Hasin DS**, Des Jarlais D. Perceived health and alcohol use in individuals with HIV and Hepatitis C who use drugs. *Addictive Behaviors*. 2017 Sep;72:21-26. PMID: 28342409
177. Elliott JC, Stohl M, **Hasin DS**. Drinking despite health problems among individuals with liver disease across the United States. *Drug Alch Dependence*. 2017 Jul 1;176:28-32. PMID: 28514693
178. \* Elliott JC, Stohl M, **Hasin DS**. Heavy drinking among individuals with HIV: Who drinks despite knowledge of the risk? *AIDS Care*. 2017 Sep 25:1-4. PMID: 28944687
179. Goodwin RD, Cheslack-Postava K, Nelson DB, Smith PH, Wall MM, **Hasin DS**, Nomura Y, Galea S. Smoking during pregnancy in the United States, 2005-2014: The role of depression. *Drug Alch Dependence*. 2017 Jul 18;179:159-166. PMID: 28783546
180. Goodwin RD, Cheslack-Postava K, Nelson DB, Smith PH, **Hasin DS**, Janevic T, Bakoyiannis N, Wall MM. Serious psychological distress and smoking during pregnancy in the United States: 2008-2014. *Nicotine and Tobacco Research*. 2017 May 1;19(5):605-614. PMID: 28403468
181. Goodwin RD, Wall MM, Garey L, Zvolensky MJ, Dierker L, Galea S, Gbedemah M, Weinberger AH, Williams JM, Hu MC, **Hasin DS**. Depression among current, former, and never smokers from 2005-2013: The hidden role of disparities in depression in the ongoing tobacco epidemic. *Drug Alch Dependence*. 2017 Apr 1;173:191-199. PMID: 28209289 PMCID: PMC5366262
182. Goodwin RD, Wall MM, Gbedemah M, Hu MC, Weinberger AH, Galea S, Zvolensky MJ, Hangle E, **Hasin DS**. Trends in cigarette consumption and time to first cigarette on awakening from 2002 to 2015 in the USA: new insights into the ongoing tobacco epidemic. *Tob Control*. 2017 Aug 10. PMID: 28801362

183. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, **Hasin DS**. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 2017 Sep 1;74(9):911-923. PMID: 28793133.
184. \* Kerridge BT, Mauro PM, Chou P, Saha TD, Pickering RP, Fan AZ, Grant BF, **Hasin DS**. Predictors of treatment utilization and barriers to treatment utilization among individuals with lifetime cannabis use disorder in the United States. *Drug Alch Dependence*. 2017 Dec 1;181:223-228. PMID: 29107786
185. \* Kerridge BT, Pickering RP, Saha TD, Ruan WJ, Chou SP, Zhang H, Jung J, **Hasin DS**. Prevalence, Sociodemographic Correlates and DSM-5 Substance Use Disorders and Other Psychiatric Disorders among Sexual Minorities in the United States. *Drug Alch Dependence*. 2017 Jan 1;170:82-92. PMID: 27883948
186. Keyes KM, Wall M, Feng T, Cerdá M, **Hasin DS**. Race/ethnicity and marijuana use in the United States: Diminishing differences in the prevalence of use, 2006-2015. *Drug Alch Dependence*. 2017 Oct 1;179:379-386. PMID: 28846954 PMCID: PMC5599376
187. Knox J, Reddy V, Lane V, Lovasi G, **Hasin D**, Sandfort T. Determinants of hazardous drinking among black South African men who have sex with men. *Drug Alch Dependence*. 2017 Nov 1;180:14-21. PMID: 28850902 PMCID: PMC5648600
188. Knox J, Reddy V, **Hasin D**, Sandfort T. Substance use and sexual risk behavior among black South African men who have sex with men: the moderating effects of reasons for drinking and safer sex intentions. *AIDS Behav*. 2017 Jul;21(7):2023-2032. PMID: 28025737
189. Kotov R, Krueger R F, Watson D, Achenbach TM, Althoff RR, Bagby M, Brown TA, Carpenter WT, Caspi A, Clark LA, Eaton NR, Forbes MK, Forbush KT, Goldberg D, **Hasin D**, Hyman SE, Ivanova MY, Lynam D, Markon K, Miller J, Moffitt TE, Morey LC, Ormel J, Patrick CJ, Regier DA, Rescorla L, Robinson E, Ruggero CJ, Samuel DB, Sellbom M, Simms LJ, Skodol AE, Slade T, South SC, Tackett JL, Waldman ID, Widiger TA, Wright AG, Zimmerman M. The Hierarchical Taxonomy Of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *Journal of Abnormal Psychology*. 2017 May;126(4):454-477. PMID: 28333488
190. Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerdá M, Keyes KM, Ghandour LA, Storr CL, **Hasin DS**. Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014. *Addictive Behaviors*. 2017 Feb;65:236-241. PMID: 27614657.
191. \* Martins SS, Sarvet AL, Santaella-Tenorio J, Saha T, Grant BF, **Hasin DS**. Changes in lifetime heroin use and heroin use disorder: United States 2001-2002 to 2012-2013. *JAMA Psychiatry*. 2017 May 1;74(5):445-455. PMID: 28355458. Viewed >3,000 times, Altmetric 671, 104 news stories
192. \* Meyers JL, Brown Q, Grant BF, **Hasin D**. Religiosity, race, and alcohol use disorders in the U.S. *Psychological Medicine*. *Psychol Med*. 2017 Jan;47(1):103-114. PMCID: PMC5319200

193. Rodriguez-Seijas C, Arger KB, Thompson RG, **Hasin DS**, Eaton NR. Sex-related Substance Use and the Externalizing Spectrum. *Drug Alch Dependence*. 2017 May 1;174:39-46. PMID: 28301821
194. Rodriguez-Seijas C, Eaton NR, Stohl M, Mauro P, **Hasin DS**. Mental Disorder Comorbidity and Treatment Utilization. *Comprehensive Psychiatry*. 2017 Feb 9. PMID: 28215792
195. Santaella J, Mauro CM, Wall MM, Kim JH, Cerda M, Keyes KM, **Hasin DS**, Galea S, Martins SM. U.S. traffic fatalities, 1985-2014, and their relationship to medical marijuana laws. *Am J Public Health*, 2017 Feb;107(2):336-342. PMID: 27997245
196. \* Thompson RG Jr., Alonzo D, Hu MC, **Hasin DS**. Substance use disorders and poverty as prospective predictors of first-time suicide ideation or attempt in the United States. *Community Mental Health Journal*. 2017 Apr;53(3):324-333. PMID: 27423659.
197. \* Thompson R, Alonzo D, Hu MC, **Hasin DS**. The influences of parental divorce and maternal-versus-paternal alcohol abuse on offspring lifetime suicide attempt. *Drug and Alcohol Review*. 2017 May;36(3):408-414. PMID: 27538533.
198. \* Thompson R, Elliott J, Hu M-C, Aivadyan C, Aharonovich E, **Hasin D**. Feasibility and preliminary effectiveness of a brief motivation-based intervention to reduce alcohol and HIV sexual risk behaviors among homeless young adults. *Addiction Research and Theory*. 2017;25(1):24-31. PMID: 28620272
199. Weinberger AH, Gbedemah M, Wall MM, **Hasin DS**, Zvolensky MJ, Chaiton M, Goodwin RD. Depression among non-daily smokers compared to daily smokers and never smokers in the United States: An emerging problem. *Nicotine and Tobacco Research*. 2017 Jan 25. PMID: 28339571
200. Weinberger AH, Gbedemah M, Wall MM, **Hasin DS**, Zvolensky MJ, & Goodwin RD. Cigarette use is increasing among persons with illicit substance use disorders in the United States, 2002-2014: Emerging disparities in vulnerable populations. *Addiction*. 2017 Dec 19. PMID: 29265574
201. Witkiewitz K, Hallgren KA, Kranzler HR, Mann, KF, **Hasin DS**, Falk DE, Litten RZ. Clinical Validation of Reduced Alcohol Consumption after Treatment for Alcohol Dependence using the World Health Organization Risk Drinking Levels. *Alch Clin and Exp Research* 2017 Jan;41(1):179-186. PMID: 28019652 PMCID: PMC5205540
202. Witkiewitz K, Wilson AD, Pearson MR, Hallgren KA, Falk DE, Kranzler HR, Mann KF, **Hasin DS**, O'Malley SS, Anton RF. Temporal Stability of Heavy Drinking Days and Drinking Reductions among Heavy Drinkers in the COMBINE Study. *Alch Clin Exp Rsch*. 2017 May;41(5):1054-1062. PMID: 28295414 PMCID: PMC5404970
- 2016** 203. \* **Hasin DS**, Grant B. NESARC Findings on Increased Prevalence of Marijuana Use Disorders-Consistent with Other Sources of Information. *JAMA Psychiatry*. 2016 May 1;73(5):532. PMID: 27008098

204. \* **Hasin DS**, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF. Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III. *Am J Psychiatry*. 2016 Jun 1;173(6):588-99. PMID: 26940807.
- Commentary on this article: Compton WM, Baler R. The Epidemiology of DSM-5 Cannabis Use Disorders Among U.S. Adults: Science to Inform Clinicians Working in a Shifting Social Landscape. *Am J Psychiatry*. 2016 Jun 1;173(6):551-3.
205. Blanco C, **Hasin DS**, Wall MM, Flórez-Salamanca L., Hoertel N, Wang S, Kerridge BT, Olfson M. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence from a US National Longitudinal Study. *JAMA Psychiatry*. 2016 Apr;73(4):388-395. PMID: 26886046.
206. Brave Heart MY, Lewis-Fernández R, Beals J, **Hasin DS**, Sugaya L, Wang S, Grant BF, Blanco C. Psychiatric disorders and mental health treatment in American Indians and Alaska Natives: results of the National Epidemiologic Survey on Alcohol and Related Conditions. *Soc Psychiatry Psychiatr Epidemiol*. 2016 Jul;51(7):1033-46. PMID: 27138948
207. \* Brown QL, **Hasin DS**, Keyes KM, Fink DS, Ravenell O, Martins SS. Health insurance, alcohol and tobacco use among pregnant and non-pregnant women of reproductive age. *Drug Alch Dependence*. 2016 Sep 1;166:116-24. PMID: 27422762
208. \* Carliner H, Delker E, Fink DS, Keyes KM, **Hasin DS**. Racial discrimination, socioeconomic position, and illicit drug use among US Blacks. *Social Psychiatry and Psychiatric Epidemiology*. 2016 Apr;51(4):551-60. PMID: 26810670.
209. \* Delker E, Aharonovich E, **Hasin DS**. Interviewer-administered TLFB vs. self-administered computerized (A-CASI) drug use frequency questions: a comparison in HIV-infected drug users. *Drug Alch Dependence*. 2016 Apr 1;161:29-35. PMID: 26880593.
210. Eaton NR, Rodriguez-Seijas C, Krueger RF, Campbell WK, Grant BF, **Hasin DS**. Narcissistic personality disorder and the structure of common mental disorders. *Journal of Personality Disorders*. 2016 Sep 12:1-13. PMID: 27617650.
211. \* Elliott JC, Delker E, Wall MM, Feng T, Aharonovich E, Tracy M, Galea S, Ahern J, **Hasin DS**. The importance of context: Neighborhood drinking norms and heavy drinking among HIV patients. *J Acquir Immune Defic Syndr*. 2016 Jun 1;72(2):e55-7. PMID: 26959191. PMCID: PMC4867137.
212. \* Elliott JC, Delker E, Wall MM, Feng T, Aharonovich E, Tracy M, Galea S, Ahern J, Sarvet AL, **Hasin DS**. Neighborhood-level drinking norms and alcohol intervention outcomes in HIV patients who are heavy drinkers. *Alch Clin Exp Rsearch*. 2016 Oct;40(10):2240-2246. PMID: 27543208.
213. Elliott JC, **Hasin DS**, DesJarlais DC. HIV, Hepatitis C, and abstinence from alcohol among injection and non-injection drug users. *AIDS and Behavior*. 2016 Mar;20(3):548-54. PMID: 26080690.
214. \* Elliott JC, **Hasin DS**, Des Jarlais DC. Perceived risk for severe outcomes and drinking status among drug users with HIV and Hepatitis C Virus (HCV). *Addict Behav*. 2016 Dec;63:57-62. PMID: 27423099

215. \* Elliott JC, Stohl M, Aharonovich E, **Hasin DS**. Reasons for drinking as predictors of alcohol involvement one year later among HIV-infected individuals with and without hepatitis C. *Annals of Medicine*. 2016 Dec;48(8):634-640. PMID: 27460482.
216. \* Elliott JC, Stohl M, Wall MM, Keyes KM, Skodol AE, Eaton NR, Shmulewitz D, Goodwin RD, Grant BF, **Hasin DS**. Childhood maltreatment, personality disorders, and 3-year persistence of adult alcohol and nicotine dependence in a national sample. *Addiction*. 2016 May;111(5):913-23. PMID: 26714255. PMCID: PMC4826838.
217. Gause NK, Elliott JC, Delker E, Stohl M, **Hasin D**, Aharonovich E. Association between change in self-efficacy to resist drinking and drinking behaviors among an HIV-infected sample: Results from a large randomized controlled trial. *Journal of Health Psychology*. 2016 May;23(6):829-839. PMID: 27577039.
218. \* Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, **Hasin DS**. Epidemiology of DSM-5 Drug Use Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions—III. *JAMA Psychiatry*. 2016 Jan 1;73(1):39-47. PMID: 26580136.
219. Kerridge BT, Saha TD, **Hasin DS**. Armed Conflict, Substance Use and HIV: A Global Analysis. *AIDS Behav*. 2016 Mar;20(3):473-83. PMID: 26286341
220. \* Keyes KM, Wall MM, Cerda M, Schulenberg J, O'Malley PM, Galea S, Feng T, **Hasin DS**. How does state marijuana policy affect U.S. youth? Medical marijuana laws, marijuana use and perceived harmfulness: 1991-2014. *Addiction*. 2016 Dec;111(12):2187-2195. PMID: 27393902.
221. Kim JH, Santaella-Tenorio J, Mauro C, Cerdá M, Wrobel J, Keyes KM, **Hasin D**, Martins SS, Li G. State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers. *Am J Public Health*. 2016 Nov;106(11):2032-2037. PMID: 27631755.
222. King AC, **Hasin D**, O'Conner SJ, McNemara SJ, Cao D. A Prospective 5-Year Re-Examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder (AUD). *Biological Psychiatry*. 2016 Mar 15;79(6):489-98. PMID: 26117308. PMCID: PMC4644521.
223. Lipsky S, Kernic MA, Qiu Q, **Hasin DS**. Traumatic Events Associated with Posttraumatic Stress Disorder: The Role of Race/Ethnicity and Depression. *Violence Against Women*. 2016 Aug;22(9):1055-74. PMID: 26620827. PMCID: PMC4884659.
224. Lipsky S, Kernic MA, Qiu Q, **Hasin DS**. Posttraumatic stress disorder and alcohol misuse among women: Effects of ethnic minority stressors. *Social Psychiatry and Psychiatric Epidemiology*. 2016 Mar;51(3):407-19. PMID: 26266627. PMCID: PMC4752921.
225. Lipsky S, Kernic MA, Qiu Q, **Hasin DS**. Traumatic Events Associated With Posttraumatic Stress Disorder: The Role of Race/Ethnicity and Depression. *Violence Against Women*. 2016 Aug;22(9):1055-74. PMID: 26620827
226. Martins SS, Mauro CM, Santaella-Tenorio J, Kim JH, Cerda M, Keyes KM, **Hasin DS**, Galea S, Wall M. State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S. population. *Drug Alch Dependence*. 2016 Oct 11;169:26-32. PMID: 27755989

227. Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, **Hasin DS**, Grant BF. Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States. *J Clinical Psychiatry*. 2016 Jun;77(6):772-780. PMID: 27337416.
228. \* Shmulewitz D, Meyers JL, Wall MM, Aharonovich E, Frisch A, Spivak B, Weizman A, Edenberg HJ, Gelernter J, **Hasin D**. CHRNA5/A3/B4 variant rs3743078 and nicotine-related phenotypes: indirect effects through nicotine craving. *J Stud Alch Drug*. 2016 Mar;77(2):227-37. PMID: 26997181. PMCID: PMC4803655.
229. \* Shmulewitz D, Stohl M, Keyes KM, Brown Q, Saha TD, **Hasin D**. Effects of State-Level Tobacco Environment on Cigarette Smoking are Stronger Among Those With Individual-Level Risk Factors. *Nicotine Tob Res*. 2016 Oct;18(10):2020-30. PMID: 27130948
230. Talati A, Keyes KM, **Hasin DS**. Changing relationships between smoking and psychiatric comorbidity across 20th century birth cohorts: Clinical and Research Implications. *Molecular Psychiatry*. 2016 Apr;21(4):464-71. PMID: 26809837. PMCID: PMC4801658.
231. Wall MM, Mauro C, **Hasin DS**, Keyes KM, Cerda M, Martins SS, Feng T. Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: Commentary on and reanalysis of US National Survey on Drug Use in Households data 2002-2011. *Int J Drug Policy*. 2016 Mar;29:9-13. PMID: 26895950
232. Walsh K, **Hasin D**, Keyes KM, Koenen KC. Associations between gender-based violence and personality disorders in US women. *Personality Disorders: Theory, Research, & Treatment*. 2016 Apr;7(2):205-10. PMID: 26569577. PMCID: PMC4816663.
- 2015** 233. \* **Hasin DS**, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF. Prevalence of Marijuana Use Disorders in the United States between 2001-2002 and 2012-2013. *JAMA Psychiatry*. 2015 Dec 1;72(12):1235-42. PMID: 26502112.
234. \* **Hasin DS**, Wall M, Keyes KM, Cerdá M, Schulenberg J, O'Malley PM, Galea S, Pacula RL, Feng T. State Medical Marijuana Laws and Adolescent Marijuana Use in The United States: 1991 – 2014. *Lancet Psychiatry*. 2015 Jul; 2(7):601-8. PMID: 26303557. PMCID: PMC4630811.
235. \* **Hasin DS**, Greenstein E, Aivadyan C, Stohl M, Aharonovich E, Saha T, Goldstein R, Nunes EV, Jung J, Zhang H, Grant BF. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample. *Drug Alch Dependence*. 2015 Mar 1; 148:40-6. PMID: 25604321.
236. \* **Hasin DS**, Shmulewitz D, Stohl M, Greenstein E, Aivadyan C, Morita K, Saha T, Aharonovich E, Jung Jeesun, Zhang H, Nunes EV, Grant BF. Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: substance abusers and others in the general population. *Drug Alch Dependence*. 2015 Jul 1; 152:246-56. PMID: 25939727.
237. \* Eaton NR, Thompson RG, Hu M-C, Goldstein RB, Saha TD, **Hasin DS**. Regularly Drinking Alcohol Before Sexual Activity in a Nationally Representative Sample: Prevalence, Sociodemographics, and Associations With Psychiatric and Substance Use Disorders. *Am J Public Health*. 2015 Jul;105(7):1387-93. PMID: 25973812.

238. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, **Hasin DS**. Epidemiology of DSM-5 Alcohol Use Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 2015 Aug 1; 72(8):757-66. PMID: 26039070.
239. Grant BF, Goldstein RB, Smith SM, Jung J, Zhang H, Chou SP, Pickering RP, Ruan WJ, Huang B, Saha TD, Aivadyan C, Greenstein E, **Hasin DS**. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample. *Drug Alch Dependence*. 2015 Mar 1; 148:27-33. PMID: 25595052. PMCID: PMC4330104.
240. \* Kerridge BT, Saha TD, Chou SP, Zhang H, Jung J, Ruan WJ, Smith SM, Huang B, **Hasin DS**. Gender and Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions – III. *Drug Alch Dependence*. 2015 Nov 1;156:47-56. PMID: 26374990. PMCID: PMC4633313.
241. \* Kerridge BT, Tran P, **Hasin DS**. Intoxication at Last Sexual Intercourse and Unprotected Sex among HIV– Positive and HIV– Negative Individuals in Uganda: An Event– Level Analysis. *AIDS and Behavior*. 2015 Mar; 19(3):412-21. PMID: 25074735. PMCID: PMC4485440.
242. Keyes KM, Vo T, Wall MM, Caetano R, Suglia SF, Martins SS, Galea S, **Hasin D**. Racial/ethnic differences in use of alcohol, tobacco, and marijuana: Is there a cross-over from adolescence to adulthood? *Soc Sci Med*. 2015 Jan; 124:132-41. PMID: 25461870. PMCID: PMC4391514.
243. Latack JA, Rodriguez-Seijas C, Stohl M, Blanco C, **Hasin DS**, Eaton NR. Transdiagnostic Psychopathology Mediates the Relationship Between Childhood Sexual Abuse and HIV/AIDS and other Sexually Transmitted Infections in Adulthood. *Comprehensive Psychiatry*. 2015 Oct; 62:71-9. PMID: 26343469.
244. \* Meyers JL, Shmulewitz D, Wall MM, Keyes KM, Aharonovich E, Spivak B, Weizman A, Frisch A, Edenberg HJ, Gelernter J, Grant BF, **Hasin D**. Childhood adversity moderates the effect of ADH1B on risk for alcohol–related phenotypes in Jewish Israeli drinkers. *Addiction Biology*. *Addict Biol*. 2015 Jan; 20(1):205-14. PMID: 24164917. PMCID: PMC3999313.
245. \* Meyers JL, Lowe SR, Eaton NR, Krueger R, Grant BF, **Hasin D**. Childhood maltreatment, 9/11 exposure, and latent dimensions of psychopathology: A test of stress sensitization. *J Psychiatr Res*. 2015 Sep;68:337-45. PMID: 26037889. PMCID: PMC4677391.
246. Okuda M, Picazo J, Olfson M, **Hasin DS**, Liu SM, Bernardi S, Blanco C. Prevalence and correlates of anger in the community: results from a national survey. *CNS Spectr*. 2015 Apr; 20(2):130-9. PMID: 25831968. PMCID: PMC4384185.
247. Rodriguez-Seijas C, Stohl, MS, **Hasin DS**, Eaton NR. Transdiagnostic Factors and Mediation of the Relationship Between Perceived Racial Discrimination and Mental Disorders. *JAMA Psychiatry*. 2015 Jul; 72(7):706-13. PMID: 25901783.
248. \* Walsh K, Keyes KM, Koenen KC, **Hasin D**. Lifetime Prevalence of Gender-Based Violence in US Women: Associations with Mental and Substance Use Disorders. *J Psychiatric Research*. 2015 Mar; 62:7-13. PMID: 25648384. PMCID: PMC4386280.

- 2014 249. \***Hasin D**, Aharonovich E, Greenstein E. HealthCall for the Smartphone: Technology Enhancement of Brief Intervention in HIV Alcohol Dependent Patients. *Addiction Science & Clinical Practice*. 2014 Feb 17; 9(1):5. PMID: 24533631. PMCID: PMC3943503.
250. \* Aharonovich E, Stohl M, Ellis J, Amerheim P, **Hasin DS**. Commitment Strength, Alcohol Dependence and HealthCall Participation: Effects on Drinking Reduction in HIV Patients. *Drug Alch Dependence*. 2014 Feb 1; 135:112-8. PMID: 24332577. PMCID: PMC3918435
251. \* Alonzo D, Thompson R, Hu MC, Stohl M, **Hasin DS**. The influence of parental divorce and alcohol abuse on the risk for adult offspring lifetime suicide attempt in the United States. *American Journal of Orthopsychiatry*. 2014 May; 84(3):316-20. PMID: 24827026.
252. Cannizzaro DL, Elliott JC, Stohl M, **Hasin DS**, Aharonovich E. Neuropsychological Assessment Battery– Screening Module (S– NAB): Performance in Treatment Seeking Cocaine Users. *Am J Drug Alcohol Abuse*. 2014 Nov; 40(6):476-83, PMID: 24949996. PMCID: PMC4309379.
253. \* Elliott JC, Aharonovich EA, **Hasin DS**. Reasons for limiting drinking in an HIV primary care sample. *Alcoholism Clinical and Experimental Research*. 2014 Jun; 38(6):1720-7. PMID: 24796381. PMCID: PMC4565134.
254. \* Elliott JC, Aharonovich E, O’Leary A, Wainberg M, **Hasin DS**. Drinking motives as prospective predictors of outcome in an intervention trial among heavily drinking HIV patients. *Drug Alch Dependence*. 2014 Jan 1; 134:290-5. PMID: 24286967. PMCID: PMC3908664.
255. \* Elliott JC, Aharonovich E, O’Leary A, Johnston B, **Hasin DS**. Perceived medical risks of drinking, alcohol consumption, and hepatitis C status among heavily drinking HIV primary care patients. *Alch Clin Exp Res*. 2014 Dec; 38(12):3052-9. PMID: 25581660. PMCID: PMC4845641.
256. \* Elliott JC, Aharonovich E, O’Leary A, Wainberg M, **Hasin DS**. Drinking motives among HIV primary care patients. *AIDS and Behavior*. 2014 Jul; 18(7):1315-23. PMID: 24165984. PMCID: PMC4004709.
257. \* Elliott J, Stohl M, Wall M, Keyes K, Goodwin R, Skodol A, Krueger R, Grant B, **Hasin D**. The risk for persistent adult alcohol and nicotine dependence: the role of childhood maltreatment. *Addiction*. 2014 May; 109(5):842-50. PMID: 24401044. PMCID: PMC3984602.
258. Goodwin RD, Wall MM, Choo T, Galea S, Horowitz J, Nomura Y, Zvolensky I, **Hasin DS**. Changes in the prevalence of mood and anxiety disorders among male and female current smokers in the United States: 1990 to 2001. *Ann Epidemiology*. 2014 Jul; 24(7):493-7. PMID: 24935462. PMCID: PMC4393820.
259. Hatzenbuehler ML, Keyes KM, Hamilton A, **Hasin DS**. State-level tobacco environments and sexual orientation disparities in tobacco use and dependence in the USA. *Tobacco Control*. 2014 Nov; 23(e2):e127-32. PMID: 24570099. PMCID: PMC4386615.
260. \* Kerridge BT, Saha TD, **Hasin DS**. DSM– IV Antisocial Personality Disorder and Conduct Disorder: Evidence for Taxonic Structures among Individuals with and Without Substance Use Disorders in the General Population. *J Stud Alcohol Drugs*. 2014 May; 75(3):496-509. PMID: 24766762. PMCID: PMC4002863.

261. \* Kerridge BT, Saha T, **Hasin DS**. DSM– IV Schizotypal Personality Disorder: A Taxometric Analysis Among Individuals With and Without Substance Use Disorders in the General Population. *Mental Health and Substance Use*. 2014; 7(4):446-460. PMID: 26322122. PMCID: PMC4549000.
262. \* Keyes KM, Shmulewitz D, Greenstein E, McLaughlin KA, Wall M, Aharonovich E, Weizman A, Frisch A, Spivak B, Grant BF, **Hasin D**. Exposure to the Lebanon War of 2006 and effects on alcohol use disorders: The moderating role of childhood maltreatment. *Drug Alch Dependence*. 2014 Jan; 134:296-303. PMID: 24262650. PMCID: PMC3884580.
263. \* Kilcoyne B, Shmulewitz D, Meyers JL Aharonovich E, Frisch A, Weizman A, Spivak B, Edenberg HJ, Gelernter J, **Hasin D**. Alcohol consumption mediates the relationship between ADH1B and DSM–IV alcohol use disorder and criteria. *J Stud Alch Drugs*. 2014 Jul; 75(4):635-42. PMID: 24988262. PMCID: PMC4108604.
264. \* Kim J, Martins SS, Shmulewitz D, Santaella J, Wall MM, Keyes KM, Eaton NR, Krueger R, Grant BF, **Hasin DS**. Childhood maltreatment, stressful life events, and alcohol craving in adult drinkers. *Alch Clin Exp Rsch*. 2014 Jul; 38(7):2048-55. PMID: 24961735. PMCID: PMC4107183.
265. Lypsky S, Kernic M, Qiu Q, Wright C, **Hasin D**. A Two– Way Street for Alcohol Use and Partner Violence: Who’s Driving It? *J Fam Violence*. 2014 Nov, 29(8):815-828.
266. \* Meyers JL, Shmulewitz D, Elliott J, Thompson RG, Aharonovich E, Spivak B, Weizman A, Frisch A, Grant BF, **Hasin D**. Parental Alcohol History Differentially Predicts Offspring Disorders in Distinct Subgroups in Israel. *J Stud Alch Drugs*. 2014 Sep; 75(5):859-69. PMID: 25208204. PMCID: PMC4161705.
267. \* Ofrat S, Krueger R, Eaton N, Keyes K, Skodol A, Grant BF, **Hasin DS**. Nonmedical prescription drug use comorbidity: Developing a cohesive risk model. *Journal of Psychopathology and Behavioral Assessment*. 2014 Sep, 36(3):371-379.
268. Pillai A, Nayak MB, Greenfield TK, Bond JC, **Hasin DS**, Patel V. Adolescent Drinking Onset and its Adult Consequences: A Population Based Study From India. *International Journal of Epidemiology*. 2014 Oct; 68(10):922-7. PMID: 25096808. PMCID: PMC4207254.
269. \* Skodol AE, Geier T, Grant BF, **Hasin D**. Personality Disorders and the Persistence of Anxiety Disorders in a Nationally Representative Sample. *Depression and Anxiety*. 2014 Sep; 31(9):721-8. PMID: 24995387.
270. \* Thompson RG, Eaton NR, Hu M– C, Grant BF, **Hasin DS**. Regularly drinking alcohol before sex in the United States: Effects of relationship status and alcohol use disorders. *Drug Alch Dependence*. 2014 Aug 1; 141:167-70. PMID: 24950638. PMCID: PMC4110894.
271. \* Thompson RG, Shmulewitz D, Meyers JL, Stohl M, Aharonovich E, Spivak B, Weizman A, Frisch A, Grant BF, **Hasin D**. Parental psychopathology moderates the influence of parental divorce on lifetime alcohol use disorders among Israeli adults. *Drug Alch Dependence*. 2014 Aug 1; 141:85-91. PMID: 24939440. PMCID: PMC4104554.

272. \* Walsh K, Elliott JC, Shmulewitz D, Aharonovich E, Strous R, Frisch A, Weizman A, Spivak B, Grant BF, **Hasin DS**. Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel. *Comprehensive Psychiatry*. 2014 Apr; 55(3):621-30. PMID: 24387979. PMCID: PMC3965593.
273. \* Waxman R, Fenton M, Skodol A, Grant BF, **Hasin DS**. Childhood maltreatment and personality disorders in the U.S: specificity of effects and the impact of gender. *Personality and Mental Health*. 2014 Feb; 8(1): 30-41. PMID: 24532553. PMCID: PMC3927226.
274. \* Welch AE, Caramanica K, Maslow CB, Cone JE, Farfel MR, Keyes KM, Stellman SD, **Hasin DS**. Frequent binge drinking five to six years after exposure to 9/11: Findings from the World Trade Center Health Registry. *Drug Alch Dependence*. 2014 Jul 1; 140:1-7. PMID: 24831753. PMCID: PMC4154498.
- 2013** 275. \* **Hasin DS**, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM– 5 Criteria for Substance Use Disorders: Recommendations and Rationale. *American Journal of Psychiatry*. 2013 Aug; 170(8):834-51. PMID: 23903334. PMCID: PMC3767415.
276. \* **Hasin DS**, Aharonovich E, O'Leary A, Greenstein E, Pavlicova M, Arunagadai S, Waxman R, Wainberg M, Helzer J, Johnston B. Reducing Heavy Drinking in HIV Primary Care: A Randomized Trial of Brief Intervention, with and without Technological Enhancement. *Addiction*. 2013 Jul; 108(7): 1230-1240. PMID: 23432593. PMCID: PMC3755729
277. Alegria AA, Blanco C, Petry N, Skodol A, Liu S– M, Grant BF, **Hasin DS**. Sex differences in antisocial personality disorder: Results from the National Epidemiological Survey on Alcohol and Related Conditions. *Personality Disorders: Theory, Research, and Treatment*. 2013 Jul; 4(3):214-22. PMID: 23544428. PMCID: PMC3767421
278. Blanco C, Krueger R, **Hasin DS**, Liu SM, Wang S, Kerridge BT, Saha T, Olfson M. Mapping common psychiatric disorders: Structure and predictive validity in the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 2013 Feb; 70(2):199-208. PMID: 23266570. PMCID: PMC3777636
279. \* Carragher N, Krueger RF, Eaton NR, Markon KE, Keyes KM, Blanco C, Saha TD, **Hasin DS**. ADHD and the externalizing spectrum: direct comparison of categorical, continuous, and hybrid models of liability in a nationally representative sample. *Social Psychiatry and Psychiatric Epidemiology*. 2014 Aug; 49(8):1307-17. PMID: 24081325. PMCID: PMC3972373.
280. \* Eaton NR, Keyes KM, Krueger RF, Noordhof A, Skodol AE, Markon KE, Grant BF, **Hasin DS**. Ethnicity and Psychiatric Comorbidity in a National Sample: Evidence for Latent Comorbidity Spectrum Invariance and Connections with Disorder Prevalence. *Social Psychiatry and Psychiatric Epidemiology*. 2013; 48(5):701-710. PMID: 23052426. PMCID: PMC3562755
281. \* Fenton MC, Geier T, Keyes K, Skodol AE, Grant BF, **Hasin DS**. Combined role of childhood maltreatment, family history, and gender in the risk for alcohol dependence. *Psychol Med*. 2013 May; 43(5):1045-57. PMID: 22883538. PMCID: PMC3767412

282. Flórez– Salamanca L, Secades– Villa R, **Hasin DS**, Cottler L, Wang S, Grant BF, Blanco C. Probability and predictors of transition from abuse to dependence on alcohol, cannabis and cocaine: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Am J Drug Alcohol Abuse*. 2013 May; 39(3):168-79 PMID: 23721532. PMCID: PMC3755735
283. Harford TC, Chen CM, Saha TD, Smith SM, **Hasin DS**, Grant BF. An Item Response Theory Analysis of DSM– IV Diagnostic Criteria for Personality Disorders: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. *Personal Disord*. 2013 Jan; 4(1):43-54. PMID: 22449066. PMCID: PMC3760426
284. Khan S, Okuda M, **Hasin DS**, Secades– Villa R, Keyes K, Lin KH, Grant B, Blanco C. Gender Differences in Lifetime Alcohol Dependence: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Alch Clin Exp Research*. 2013 Oct; 37(10):1696-705. PMID: 23763329. PMCID: PMC3796956
285. King A, McNamara P, **Hasin DS**, Cao D. Alcohol Challenge Responses Predict Future Alcohol Use Disorder Symptoms: A Six– Year Prospective Study. *Biological Psychiatry*. 2014 May 15; 75(10):798-80. PMID: 24094754. PMCID: PMC4280017.
286. \* Meyers JL, Shmulewitz D, Aharonovich E, Waxman R, Frisch A, Weizman A, Spivak B, Edenberg HJ, Gelernter J, **Hasin D**. Alcohol metabolizing genes and alcohol phenotypes in an Israeli household sample. *Alcoholism Clinical and Experimental Research*. 2013 Nov; 37(11):1872-81. PMID: 23895337. PMCID: PMC3812252
287. Moreno C, **Hasin DS**, Arango C, Oquendo MA, Vieta E, Liu S, Grant BF, Blanco C. The bipolar– depressive continuum in the National Epidemiologic Survey on Alcohol and Related Conditions. *Bipolar Disord*. 2013 Feb;15(1):112-3. PMID: 23231326. PMCID: PMC3811045
288. Petry NM, Blanco C, Auriacombe M, Borges G, Bucholz K, Crowley TJ, Grant BF, **Hasin DS**, O'Brien C. An overview of and rationale for changes proposed for pathological gambling in DSM– 5. *Journal of Gambling Studies*. 2014 Jun; 30(2):493-502. PMID: 23526033. PMCID: PMC3722301
289. \* Pilowsky D, Wild KM, Geier TJ, Grant BF, **Hasin DS**. Stressful Life Events and Relapse Among Formerly Alcohol Dependent Adults. *Social Work in Mental Health*. 2013, 11:184-7. PMID: 24167441. PMCID: PMC3808003
290. Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, **Hasin D**. Effects of Independent and Substance– induced Major Depressive Disorder on Remission and Relapse of Alcohol, Cocaine and Heroin Dependence. *Addiction*. 2013 Jan; 108(1):115-23. PMID: 22775406. PMCID: PMC3767419
291. \* Shmulewitz D, Wall MM, Aharonovich E, Spivak B, Weizman A, Frisch A, Grant BF, **Hasin D**. Validity of proposed DSM– 5 diagnostic criteria for nicotine use disorder: Results from 734 Israeli lifetime smokers. *Psychol Med*. 2013 Oct; 43(10):2179-90. PMID: 23312475. PMCID: PMC3767315
292. \* Shmulewitz D, Wall MM, Aharonovich E, Spivak B, Weizman A, Frisch A, Grant BF, **Hasin D**. Validity of proposed DSM– 5 diagnostic criteria for nicotine use disorder: Results from 734 Israeli lifetime smokers. *Psychol Med*. 2013 Oct; 43(10):2179-90. PMID: 23312475. PMCID: PMC3767315

293. \* Shoval G, Shmulewitz D, Wall MM, Aharonovich E, Spivak B, Weizman A, **Hasin D**. Alcohol dependence and suicide-related ideation/behaviors in an Israeli household sample, with and without major depression. *Alcoholism, Clinical and Experimental Research*. 2014 Mar; 38(3):820-5 PMID: 24117756. PMCID: PMC395927.
294. Talati A, Wickramaratne PJ, Keyes KM, **Hasin DS**, Levin FR, Weissman MM. Smoking and psychopathology increasingly associated in recent birth cohorts. *Drug Alch Dependence*. 2013 Dec; 133(2):724-32. PMID: 24071570. PMC3818417.
295. \* Thompson R, Lizardi D, Grant BF, **Hasin D**. Parental divorce, maternal– paternal alcohol problems and adult offspring alcohol dependence. *J Soc Work Pract in Addictions*. 2013, 13(3):295-308. PMID: 24678271. PMCID: PMC3963604.
296. \* Thompson, RG, Wall MM, Greenstein E, Grant BF, **Hasin DS**. Substance use disorders and poverty as prospective predictors of first– time homelessness in the United States. *Am Journal of Public Health*. 2013 Dec; 103 Suppl 2:S282-8. PMID: 24148043. PMCID: PMC3865876
- 2012** 297. \* **Hasin DS**, Fenton MC, Beseler C, Park JY, Wall MM. Analyses related to the development of DSM–5 criteria for substance use related disorders: 2. Proposed DSM–5 criteria for alcohol, cannabis, cocaine and heroin disorders in 663 substance abuse patients. *Drug Alch Dependence*. 2012 Apr 1; 122(1–2):28–37 PMID: 21963333. PMCID: PMC3755770
298. \* **Hasin D**, Kilcoyne B. Comorbidity of psychiatric and substance use disorders in the United States: Current issues and findings from the NESARC. *Curr Opin Psychiatry*, 25(3):165-71, 2012. PMID: 22449770. PMCID: PMC3767417
299. \* Aharonovich E, Greenstein E, O’Leary A, Johnston B, Seol SG, **Hasin DS**. HealthCall: Technology– based extension of Motivational Interviewing to reduce non– injection drug use in HIV primary care patients: a pilot study. *AIDS Care*. 2012; 24(12):1461-1469. PMID: 22428809. PMCID: PMC3484210
300. Blanco C, Vesga– López O, Steward JW, Liu SM, Grant BF, **Hasin DS**. Epidemiology of major depression with atypical features: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry*, 2012 Feb;73(2):224–32 PMID: 21939615. PMCID: PMC3475327
301. \* Boschloo L, van den Brink W, Penninx B, Wall MM, **Hasin DS**. Alcohol– use disorder severity predicts first–incidence of depressive disorders. *Psychological Medicine*, 2012 Apr; 42(4):695–703 PMID: 21867593. PMCID: PMC3767409
302. \* Cerdá M, Wall MM, Keyes KM, Galea S, **Hasin D**. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. *Drug Alch Dependence*, 2012 Jan 1; 120(1–3):22–7 PMID: 22099393. PMCID: PMC3251168.
303. \* Eaton NR, Keyes KM, Krueger RF, Balsis S, Skodol AE, Markon KE, Grant BF, **Hasin DS**. An Invariant Dimensional Liability Model of Gender Differences in Mental Disorder Prevalence: Evidence from a National Sample. *J Abnorm Psychol*, 2012 Feb; 121(1):282–8. PMID: 21842958. PMCID: PMC3402021.

304. \* Eaton NR, Krueger RF, Markon KE, Keyes KM, Skodol AE, Wall MM, **Hasin DS**, Grant BF. The Structure and Predictive Validity of the Internalizing Disorders. *J Abnormal Psych*. 2013 Feb; 122(1):86-92. PMID: 22905862. PMCID: PMC3755742
305. \* Fenton MC, Geier T, Greenstein E, Keyes KM, Skodol AE, Krueger R, Grant BF, **Hasin D**. Psychiatric comorbidity and the persistence of drug use disorders in the United States. *Addiction*. 2012 Mar; 107(3):599–609 PMID: 21883607. PMCID: PMC3260401
306. \* Goodwin RD, Zvolensky I, Keyes KM, **Hasin DS**. Mental disorders and cigarette use among adults in the United States. *Am J Addict*. 2012 Sep– Oct; 21(5):416-3. PMID: 22882392. PMCID: PMC3701304
307. \* Keyes KM, Eaton NR, Krueger RF, McLaughlin KA, Wall MM, Grant BF, **Hasin DS**. Child Maltreatment and the Structure of Common Psychiatric Disorders. *Brit J Psychiat*. 2012 Feb; 200(2):107-15. PMID: 22157798. PMCID: PMC3269653.
308. \* Keyes KM, Eaton NR, Krueger RF, Skodol A, Wall MM, Grant BF, Sever LJ, **Hasin DS**. Thought disorder in the meta- structure of psychopathology. *Psychol Med*. 2012 Nov 21:1-11. PMID: 23171498. PMCID: PMC3767418
309. \* Keyes KM, Martins SS, Hatzenbuehler M, Blanco C, Bates L, **Hasin DS**. Mental health service utilization for psychiatric disorders among Latinos living in the United States: the role of ethnic subgroup, ethnic identity, and language/social preferences. *Soc Psychiatry Psychiatr Epidemiol*, 2012 Mar;47(3):383–94 PMID: 21290097. PMCID: PMC3756540
310. \* Keyes KM, Schulenberg JE, O'Mallye PM, Johnston LD, Bachman JG, Li G, **Hasin D**. Birth cohort effects on adolescent alcohol use: The influence of social norms from 1976– 2007. *Arch Gen Psychiatry*, 6:1-10, 2012. PMID: 22868751. PMCID: PMC3597448
311. Lopes M, Olfson M, Rabkin J, **Hasin DS**, Alegria AA, Lin K– H, Grant BF, Blanco C. Gender, HIV status, and psychiatric disorders: Results from the national epidemiologic study on alcohol and related conditions. *J Clin Psychiatry*, 2012 Mar;73(3):384–91. PMID: 22053858. PMCID: PMC3816377
312. Moreno C, **Hasin DS**, Arango C, Oquendo MA, Vieta E, Liu S, Grant BF, Blanco C. Depression in Bipolar versus Major Depressive Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Bipolar Disorders*, 14(3):271-82, 2012. PMID: 22548900. PMCID: PMC3349442
313. \* Saha TD, Harford T, Goldstein RB, Kerridge BT, **Hasin D**. Relationship of substance abuse to dependence in the U.S. general population. *J Stud Alcohol Drugs*, 73(3):368-78, 2012. PMID: 22456242. PMCID: PMC3316712
314. \* Shmulewitz D, Wall MM, Keyes KM, Aharonovich E, Greenstein E, Spivak B, Weizman A, Frisch A, **Hasin D**. Alcohol use disorders and perceived drinking norms: ethnic differences in Israeli adults. *J Stud Alch Drug*, 73(6):981-90, 2012. PMID: 23036217. PMCID: PMC3469051
315. Sugaya L, **Hasin DS**, Olfson M, Lin KH, Grant BF, Blanco C. Child physical abuse and adult mental health: a national study *J Trauma Stress*. 2012 Aug; 25(4):384-92 PMID: 22806701. PMCID: PMC3805363

316. \* Thompson RG, **Hasin D**. Psychiatric disorders and treatment among newly homeless young adults with histories of foster care. *Psychiatric Services*, 63(9):906-12, 2012. PMID: 22706986. PMCID: PMC3812945
317. Tiffany ST, Friedman L, Greenfield SF, **Hasin DS**, Jackson R. Beyond Drug Use: A Systematic Consideration of Other Outcomes in Evaluations of Treatments for Substance Use Disorders. *Addiction*, 2012 Apr; 107(4):709–18 PMID: 21981638. PMCID: PMC3257402
- 2011** 318. \* **Hasin DS**, Fenton M, Skodol A, Krueger B, Keyes KM, Geier, T, Greenstein E, Blanco C, Grant BF. Personality disorders and the 3– year course of alcohol, drug, and nicotine use disorders. *Arch Gen Psychiat*, 68(11):1158– 67, 2011. PMID: 22065531. PMCID: PMC3500879.
319. \* Alonzo D, Thompson RG, Keyes KM, **Hasin D**. Does Past Treatment for Depression Influence the Current Functioning of Individuals with a History of Depression? A National Study. *Soc Work Ment Health*, 9:303–318, 2011. No PMID. No PMCID required.
320. Baca-Garcia E, Perez-Rodriguez MM, Oquendo MA, Keyes KM, **Hasin DS**, Grant BF, Blanco C. Estimating risk for suicide attempt: Are we asking the right questions? Passive suicidal ideation as a marker for suicidal behavior. *J Affect Disord*, 134(1–3):327–32, 2011. PMID: 21784532. PMCID: PMC3172880
321. \* Beseler C, Aharonovich E, **Hasin D**. The Enduring Influence of Drinking Motives on Alcohol Consumption After Fateful Trauma. *Alch Clin Exp Research*, 35(5):1004– 10, 2011. PMID: 21314697. PMCID: PMC3171275
322. Comer JS, Blanco C, **Hasin DS**, Liu SM, Grant BF, Turner BF, Olfson M. Health– related quality of life across the anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 72(1):43–50, 2011. PMID: 20816036. PMCID: PMC3000882
323. Drake RE, Caton CL, Xie H, Hsu E, Gorroochurn P, Samet S, **Hasin DS**. A Prospective 2– Year Study of Emergency Department Patients With Early– Phase Primary Psychosis or Substance– Induced Psychosis. *Am J Psychiatry*, 168(7):742– 8, 2011. PMID: 21454918. PMCID: PMC3768258
324. \* Eaton NR, Krueger RF, Keyes KM, Skodol AE, Markon KE, Grant BF, **Hasin DS**. Borderline personality disorder comorbidity: relationship to the internalizing– externalizing structure of common mental disorders. *Psychol Med*, 41(5):1041–50, 2011. PMID: 20836905. PMCID: PMC3193799.
325. \* Hankerson SH, Fenton MC, Geier TJ, Keyes KM, Weissman MM, **Hasin DS**. Racial Differences in Symptoms, Comorbidity, and Treatment for Major Depressive Disorder among Black and White Adults. *J Natl Med Assoc*, 103(7):576–84, 2011. PMID: 21999032. PMCID: PMC3866690
326. \* Keyes KM, Hatzenbuehler M, **Hasin DS**. Stressful life experiences, alcohol consumption and alcohol use disorders: the epidemiologic evidence for four main types of stressors. *Psychopharmacology*, 218(1):1–17, 2011. PMID: 21373787. PMCID: PMC3755727.

327. \* Keyes KM, Li G, **Hasin DS**. Birth cohort effects and gender differences in alcohol epidemiology: a review and synthesis. *Alch Clin Exp Research*, 35(12):2101–12, 2011. PMID: 21919918. PMCID: PMC3221910.
328. \* Keyes KM, Schulenberg JE, O'Malley PM, Johnston LD, Bachman JG, Li G, **Hasin D**. The social norms of birth cohorts and adolescent marijuana use in the United States, 1976– 2007. *Addiction*, 106(10):1790–800, 2011. PMID: 21545669. PMCID: PMC3174352
329. Lopez– Quintero C, de los Cobos JP, **Hasin D**, Okuda M, Wang S, Grant BF, Blanco C. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the NESARC. *Drug Alch Dependence*, 115(1–2):120–30, 2011. PMID: 21145178. PMCID: PMC3069146.
330. Lopez– Quintero C, **Hasin D**, de los Cobos JP, Pines A, Wang S, Grant BF, Blanco C. Probability and predictors of remission from lifetime nicotine, alcohol, cannabis, or cocaine dependence: Results from the NESARC. *Addiction*, 106(3):657–69, 2011. PMID: 21077975. PMCID: PMC3227547
331. Okuda M, Olfson M, **Hasin D**, Grant BF, Lin KH, Blanco C. Mental health of victims of intimate partner violence: results from a national epidemiologic survey. *Psychiatr Serv*, 62(8):959–62, 2011. PMID: 21807838. PMCID: PMC3204944
332. Pickering RP, Goldstein RB, **Hasin DS**, Blanco C, Smith SM, Huang B, Pulay AJ, Ruan WJ, Saha TD, Stinson FS, Dawson DA, Chou SP, Grant BF. Temporal relationships between overweight and obesity and DSM– IV substance use, mood, and anxiety disorders: results from a prospective study, the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 72(11):1494–1502, 2011. PMID: 21457678. PMCID: PMC3227748
333. \* Shmulewitz D, Keyes K, Wall, MM, Aharonovich E, Aivadyan C, Greenstein, E, Spivak B, Weizman A, Frisch A, Grant BF, **Hasin D**. Nicotine dependence, abuse, craving, and consumption: dimensionality in an Israeli sample. *Addiction*, 106(9):1675–86, 2011. PMID: 21545668. PMCID: PMC3163441
334. \* Skodol AE, Grilo CM, Keyes KM, Geier T, Grant BF, **Hasin DS**. Relationship of personality disorders to the course of major depressive disorder in a national sample. *Am J Psychiatry*, 168(3):257–64, 2011. PMID: 21245088. PMCID: PMC3202962.
335. \* Thompson RG, **Hasin D**. Cigarette, marijuana, alcohol use and prior treatment among newly homeless young adults in New York City: Relationship to a history of foster care. *Drug Alch Dependence*, 117(1):66–9, 2011. PMID: 21288659. PMCID: PMC3100368
336. \* Wall MM, Poh E, Cerda M, Keyes KM, Galea S, **Hasin D**. Adolescent marijuana use from 2002 to 2008: higher in states with medical marijuana laws, cause still unclear. *Ann Epidemiol*, 21(9):714–6, 2011. PMID: 21820632. PMCID: PMC3358137.
337. Xu Y, Okuda M, Hser Y–I, **Hasin D**, Liu S–M, Grant BF, Blanco C. Twelve– month prevalence of psychiatric disorders and treatment–seeking among Asian Americans/Pacific Islanders in the United States: Results from the National Epidemiological Survey on Alcohol and Related Conditions. *J Psychiatr Res*, 45(7):910–8, 2011. PMID: 21238989. PMCID: PMC3155956

- 2010 338. Alegria AA, **Hasin D**, Nunes EV, Liu SM, Davies C, Grant BF, Blanco C: Comorbidity of Generalized Anxiety Disorder and Substance Use Disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 71(9):1187–95, 2010. PMID: 20923623. PMCID: PMC2951633
339. Baca– Garcia E, Perez–Rodriguez M, Keyes KM, Oquendo MA, **Hasin DS**, Grant BF, Blanco C: Suicidal ideation and suicide attempts in the United States: 1991– 1992 and 2001–2002. *Molecular Psychiatry*, 15(3):250–9, 2010. PMID: 18779820. PMCID: PMC2825279
340. \* Beseler C, **Hasin D**. Cannabis dimensionality: Dependence, abuse and consumption. *Addictive Behaviors*, 35(11):961–9, 2010. PMID: 20598807. PMCID: PMC3225022
341. \* Blanco C, Alegria A, Petry N, Grant J, Simpson HB, Liu SM, **Hasin D**. Prevalence and Correlates of Firesetting in the US: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clinical Psychiatry*, 71(9):1218–25, 2010. PMID: 20361899. PMCID: PMC2950908
342. \* Blanco C, Okuda M, Markowitz JC, Liu S–M, Grant BF, **Hasin DS**. The Epidemiology of Chronic Major Depressive Disorder and Dysthymic Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 71(12):1645–56, 2010. PMID: 21190638. PMCID: PMC3202750
343. \* Fenton M, Keyes KM, Martins S, **Hasin DS**. The role of a prescription in anxiety medication use, abuse, and dependence. *American Journal of Psychiatry*, 167(10):1247–53, 2010. PMID 20595413. PMCID: PMC3756550
344. \* Hatzenbuehler ML, McLaughlin KA, Keyes KM, **Hasin DS**. The impact of institutional discrimination on psychiatric disorders in lesbian, gay, and bisexual populations: a prospective study. *American Journal of Public Health*, 100(3):452– 9, 2010. PMID: 20075314. PMCID: PMC2820062.
345. \* Keyes KM, Hatzenbuehler ML, McLaughlin KA, Link B, Olfson M, Grant BF, **Hasin D**. Stigma and treatment for alcohol disorders in the United States. *Am J Epidemiology*, 172(12):1364–72, 2010. PMID: 21044992. PMCID: PMC2998202.
346. \* Keyes KM, Krueger RF, Grant BF, **Hasin DS**. Alcohol craving and the dimensionality of alcohol disorders. *Psychological Medicine*, 12:1–12, 2010. PMID: 20459881. PMCID: PMC2981698
347. \* Keyes KM, Martins SS, Blanco C, **Hasin DS**. Telescoping and gender differences in alcohol dependence: new evidence from two national surveys. *American Journal of Psychiatry*, *Am J Psychiatry*. 167(8):969–76, 2010. PMID: 20439391. PMCID: PMC3767417
348. Listman JB, **Hasin D**, Kranzler H, Malison RT, Mutirangura A, Sughondhabirom A, Aharonovich E, Spivak B, Gelernter J. Identification of population substructure among Jews using STR markers and dependence on reference populations included. *BMC Genetics*, 11(1):48, 2010. PMID: 20546593. PMCID: PMC2896335
349. \* Lizardi D, Thompson R, Keyes KM, **Hasin DS**. The effect of parental remarriage following parental divorce on offspring suicide attempt. *J Families & Society*, 91(2):186–192, 2010. No PMID. No PMCID required.

350. \*Lizardi, D, Thompson, RG, Keyes K, **Hasin D**. The role of depression in the differential effect of childhood parental divorce on male and female adult offspring suicide attempt risk. *J Nerv Ment Dis*, 198(9):687– 90, 2010. PMID: 20823733. PMCID: PMC3755764
351. Okuda M, **Hasin DS**, Olfson M, Khan SS, Nunes EV, Montoya I, Liu SM, Grant BF, Blanco C. Generalizability of clinical trials for cannabis dependence to community samples. *Drug Alch Dependence*, 111(1–2):177–81, 2010. PMID: 20537813. PMCID: PMC2896335
352. Oquendo MA, Currier D, Liu SM, **Hasin DS**, Grant BF, Blanco C. Increased Risk for Suicidal Behavior in comorbid Bipolar Disorder and Alcohol Use Disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clin Psychiatry*, 71(7):902–9, 2010. PMID: 20667292. PMCID: PMC2914308
353. \* Shmulewitz D, Keyes K, Beseler C, Aharonovich E, Aivadyan C, Spivak B, **Hasin D**. The dimensionality of alcohol use disorders: Results from Israel. *Drug Alch Dependence*, 111(1–2):146–54, 2010. PMID: 20537809. PMCID: PMC3884677
354. Schneier FR, Foose TE, **Hasin DS**, Heimberg RG, Liu SM, Grant BF, Blanco C. Social anxiety disorder and alcohol use disorder co–morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychol Med*, 40(6):977–88, 2010. PMID: 20441690. PMCID: PMC2917264
- 2009** 355. \* **Hasin DS**, Beseler CL. Dimensionality of lifetime alcohol abuse, dependence and binge drinking. *Drug Alch Dependence*. 101(1–2):53–61, 2009. PMID: 19095379. PMCID: PMC3767315
356. Alegria AA, Petry NM, **Hasin DS**, Liu SM, Grant BF, Blanco C. Disordered gambling among racial and ethnic groups in the US: results from the national epidemiologic survey on alcohol and related conditions. *CNS Spectr*. 14(3):132– 42, 2009. PMID: 19407710. PMCID: PMC2737691
357. Brown LS, Kritz S, Muhammad A, Bini EJ, Goldsmith RJ, Robinson J, Alderson D, **Hasin DS**, Rotrosen J. Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment Programs. *J Addict Med*. 3(2):95–102, 2009. PMID: 20161081. PMCID: PMC2743506
358. \* Goodwin R, Keyes K, **Hasin D**. Changes in cigarette use and nicotine dependence in the United States: Evidence from the 2001– 2002 wave of the NESARC. *Am J Public Health*, 99(8):1471–7, 2009. PMID: 19008515. PMCID: PMC2707489
359. \* Hatzenbuehler M, Keyes KM, **Hasin D**. State– level policies and psychiatric morbidity in lesbian, gay and bisexual populations. *American Journal of Public Health*, 99(12):2275–81, 2009. PMID: 19833997. PMCID: PMC2775762.
360. \* Hatzenbuehler ML, Keyes KM, **Hasin DS**. Associations between perceived weight discrimination and the prevalence of psychiatric disorders in the general population. *Obesity*, 17(11):2033–9, 2009. PMID: 19390520. PMCID: PMC3767420
361. \* Keyes KM, Geier T, Grant BF, **Hasin DS**. Influence of a drinking quantity and frequency measure on the prevalence and demographic correlates of DSM– IV alcohol dependence. *Alch Clin Exp Research*. 33(5):761–71, 2009. PMID: 19298332. PMCID: PMC3163446

362. \* Lizardi D, Thompson R, Keyes K, **Hasin D**. Parental divorce, parental depression, and gender differences in adult offspring suicide attempt. *Journal of Nervous and Mental Disease*, 197(12):899–904, 2009. PMID: 20010025. PMCID: PMC3767404
363. McBride O, Teesson M, Slade T, **Hasin D**, Degenhardt L, Baillie A: Further evidence of differences in substance use and dependence between Australia and the United States. *Drug Alch Dependence*. 100(3):258–64, 2009. PMID: 19042096. PMCID: PMC3816520
364. \* Pilowsky DJ, Keyes KM, **Hasin DS**. Adverse Childhood Events and Lifetime Alcohol Dependence. *Am J Public Health*. 99(2):258–63, 2009. PMID: 19059847. PMCID: PMC2622772
365. Pulay A, Stinson F, Dawson DA, Goldstein R, Chou P, Huan B, Smith S, Ruan WJ, Pickering R, **Hasin D**, Grant BF. Prevalence, Correlates, Disability, and Comorbidity of DSM– IV Schizotypal Personality Disorder: Results from the Wave 2 NESARC. *J Clin Psychiatry*, 11(2):53–67, 2009. PMID: 19617934. PMCID: PMC2707116
- 2008** 366. \* **Hasin D**, Keyes KM, Alderson D, Wang W, Aharonovich E, Grant BF. Cannabis Withdrawal in the United States: results from the NESARC. *J Clin Psychiatry*. 69(9):1354–63, 2008. PMID: 19012815. PMCID: PMC2777674
367. \* Aharonovich E, Amrhein PC, Bisaga A, Nunes EV, **Hasin DS**. Cognition, commitment language, and behavioral change among cocaine– dependent patients. *Psychol Addict Behav*, 22(4):557–62, 2008. PMID: 19071981. PMCID: PMC2605284
368. \* Aharonovich E, Brooks AC, Nunes EV, **Hasin DS**. Cognitive deficits in marijuana users: effects on MET+CBT treatment outcome. *Drug Alch Dependence*, 95(3):279–83, 2008. PMID: 18329188. PMCID: PMC2429981
369. \* Beseler C, Aharonovich E, Keyes K, **Hasin D**. Adult transition from at– risk drinking to alcohol dependence: The relationship of family history and drinking motives. *Alch Clin Exp Research*, 32(4): 607–616, 2008. PMID: 18341650. (No PMCID required.)
370. \* Blanco C, Grant J, Petry N, Simpson HB, Alegria A, Liu SM, **Hasin D**. Prevalence and Correlates of Shoplifting in the US: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Am Journal Psychiatry*, 165(7):905–13, 2008. PMID: 18381900. (No PMCID required.)
371. \* Blanco C, Ogburn E, Pérez de Los Cobos J, Lujan J, Nunes EV, Grant B, Liu SM, **Hasin DS**. DSM– IV criteria– based clinical subtypes of cannabis use disorders: results from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). *Drug Alch Dependence*, 96(1–2):136–44, 2008. PMID: 18420357. (No PMCID required.)
372. Blanco C, Okuda M, Wright C, **Hasin DS**, Grant BF, Liu SM Olfson M: Mental health of college students and their non–college–attending peers: results from the National Epidemiologic Study on Alcohol and Related Conditions. *Arch Gen Psychiatry*, 65(12):1429–37, 2008. PMID: 19047530. PMCID: PMC2734947.
373. \* Blanco C, Olfson M, Goodwin R, Ogburn E, Liebowitz M, Nunes E, **Hasin D**. Generalizability of Clinical Trials for Major Depression to Community Samples. *J Clin Psychiatry*, 69(8):1276–80, 2008. PMID: 18557666. (No PMCID required.)

374. \* Blanco, C Olfson M, Okuda M, Nunes E, Liu SM, **Hasin D**. Generalizability of Clinical Trials for Alcohol Dependence to Community Samples. *Drug Alch Dependence*, 98(1–2):123– 8, 2008. PMID: 18579319. PMCID: PMC3755733
375. \* Hatzenbuehler ML, Keyes KM, Narrow WE, Grant BF, **Hasin DS**. Racial/ethnic disparities in service utilization for individuals with co-occurring mental health and substance use disorders in the general population. *J Clin Psychiatry*, 69(7):1112– 21, 2008. PMID: 18517286. PMCID: PMC2745048
376. \* Heiman GA, Ogburn E, Gorroochurn P, Keyes K, **Hasin D**. Evidence for a two- stage model of dependence using the NESARC and its implications for genetic association studies. *Drug Alch Dependence*, 92(1–3):258–66, 2008. PMID: 17933473. PMCID: PMC2266584
377. \* Keyes K, Grant B, **Hasin D**. Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. *Drug Alch Dependence*, 93(1–2):21–9, 2008. PMID: 17980512. PMCID: PMC3163892.
378. \* Keyes K, **Hasin D**. Socio-economic status and problem alcohol use: the positive relationship between income and the DSM- IV alcohol abuse diagnosis. *Addiction*, 103(7):1120–30, 2008. PMID: 18494841. (No PMCID required.)
379. \* Keyes K, Hatzenbuehler M, Alberti P, Narrow W, Grant B, **Hasin D**. Service utilization for Axis I psychiatric and substance disorders in white and black adults. *Psychiatric Services*, 59(8):893–901, 2008. PMID: 18678687. PMCID: PMC2729457
380. \* Keyes K, Martins S, **Hasin D**. Past 12- month and lifetime comorbidity and poly- drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug Alch Dependence*, 97(1–2):139–49. 2008. PMID: 18524499. PMCID: PMC3771490
381. Pulay AJ, Dawson DA, **Hasin DS**, Goldstein RB, Ruan WJ, Pickering RP, Huang B, Chou SP, Grant BF. Violent Behavior and DSM- IV Psychiatric Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 69(1): 12–22, 2008. PMID: 18312033. PMCID: PMC2922980
382. \* Thompson RG, Lizardi D, Keyes KM, **Hasin DS**. Childhood or Adolescent Parental Divorce/Separation, Parental History of Alcohol Problems, and Offspring Lifetime Alcohol Dependence. *Drug Alch Dependence*, 98(3):264–9, 2008. PMID: 18757141. PMCID: PMC3818521
383. \* Vesga- Lopez O, Blanco C, Keyes K, Olfson M, Grant BF, **Hasin D**. Psychiatric Disorders in Pregnant and Postpartum Women in the United States. *Arch Gen Psychiatry*, 65(7):805–15, 2008. PMID: 18606953. PMCID: PMC2669282.
384. \* Vesga- López O, Schneier F, Wang S, Heimberg R, Liu S- M, **Hasin DS**, Blanco C. Gender differences in Generalized Anxiety Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *J Clinical Psychiatry*, 69(10):1606–16, 2008. PMID: 19192444. PMCID: PMC3648860

- 2007 385. \* **Hasin D**, Stinson F, Ogburn E, Grant BF: Prevalence, correlates, disability, and comorbidity of DSM– IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*, 64(7):830–842, 2007. PMID: 17606817.
386. \* **Hasin D**, Keyes K, Hatzenbuehler M, Aharonovich E, Alderson D: Alcohol consumption and post– traumatic stress after terrorism exposure: effects of physical proximity, loss, and previously– assessed psychiatric history. *Am J Public Health*, 97(12):2268–2275, 2007. PMID: 17971553. PMCID: PMC2089108
387. \* **Hasin D**, Katz H: Somatoform and substance use disorders. *Psychosomatic Medicine*, 69(9):870–875, 2007. PMID: 18040097
388. \* Blanco C, Alderson D, Ogburn E, Grant BF, Nunes E, Hatzenbuehler M, **Hasin D**. Changes in the Prevalence of Non– Medical Prescription Drug Use and Drug Use Disorders in the United States: 1991– 1992 and 2001–2002. *Drug Alch Dependence*, 90(2– 3):252– 260, 2007. PMID: 17513069.
389. \* Blanco C, Harford T, Grant BF, **Hasin D**. The Latent Structure of Marijuana and Cocaine Use Disorders: Results from the National Longitudinal Alcohol Epidemiologic Survey (NLAES). *Drug Alch Dependence*, 91(1):91–96, 2007. PMID: 17512682. PMCID: PMC2140260
390. Caton CLM, **Hasin DS**, Shrout PE, Drake RE, Dominguez B, First MB, Samet S, Schanzer B: Stability of early–phase primary psychotic disorders with concurrent substance use and substance–induced psychoses. *Brit J Psychiatry*, 190:105–111, 2007. PMID: 17267925
391. Grant BF, Harford TC, Muthen BO, Yi HY, **Hasin DS**, Stinson FS. DSM– IV alcohol dependence and abuse: further evidence of validity in the general population. *Drug Alch Dependence*, 12; 86(2–3):154–166, 2007. PMID: 16814489
392. \* Samet S, Waxman R, Hatzenbuehler M, **Hasin DS**. Assessing addiction: concepts and instruments. *Addict Sci Clin Pract*, 4(1):19–31, 2007. PMID: 18292706. PMCID: PMC2797097
393. \* Schiff M, Benbenishty R, **Hasin D**. Exposure to terrorism and Israeli youth’s cigarettes, alcohol and cannabis use. *Am J Public Health*, 97(10):1852–1858, 2007. PMID: 17761574. PMCID: PMC1994181
394. \* Spivak B, Frisch A, Mamman Z, Aharonovich E, Alderson D, Carr L, Weizman A, **Hasin D**. Effect of ADH1B genotype on alcohol consumption in young Israeli Jews. *Alch Clin Exp Research*, 31(8):1297–1301, 2007. PMID: 17559546
395. \* Wu, LT, Pilowsky D, Schlenger W, **Hasin D**. Alcohol use disorders and use of treatment services among college– aged young adults. *Psychiatric Services*, 58(2):192–200, 2007. PMID: 17287375. PMCID: PMC1831544
- 2006 396. \* **Hasin D**, Hatzenbuehler ML, Keyes K, Ogburn E: Substance use disorders: diagnostic and statistical manual of mental disorders, fourth edition (DSM– IV) and International Classification of Diseases, 10th edition (ICD– 10). *Addiction*, 101 Suppl 1:59–75, 2006. PMID: 16930162.
397. \* **Hasin DS**, Liu X, Alderson D, Grant BF: DSM– IV alcohol dependence: a categorical or dimensional phenotype? *Psychological Medicine*, 6(12):1695–1705, 2006. PMID: 17038207

398. \* **Hasin D**, Samet S, Nunes E, Meydan K, Matsoeane K, Waxman R: Diagnosis of comorbid disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM– IV. *Am J Psychiatry*, 163(4):689–696, 2006. PMID: 16585445.
399. \* Aharonovich E, **Hasin DS**, Brooks AC, Liu X, Bisaga A, Nunes EV: Cognitive deficits predict low treatment retention in cocaine dependent patients. *Drug Alch Dependence*, 81(3):313–322, 2006. PMID: 16171953.
400. \* Aharonovich E, Hatzenbuehler ML, Johnston B, O’Leary A, Morgenstern J, Wainberg ML, Yao P, Helzer JE, **Hasin DS**. A low– cost, sustainable intervention for drinking reduction in the HIV primary care setting. *AIDS Care*, 18(6):561–568, 2006. PMID: 16831783
401. Blanco C, **Hasin D**, Petry N, Stinson F, Grant B. Sex differences in subclinical and DSM– IV pathological gambling: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychological Medicine*, 36(7):943–953, 2006. PMID: 16650342.
402. \* Carpenter KM, Aharonovich E, Liu X, Samet S, **Hasin D**. The Type A– Type B classification in a community sample of problem drinkers: structural and predictive validity. *Addictive Behaviors*, 31:15–30, 2006. PMID: 15908135
403. Caton CL, **Hasin DS**, Shrout PE, Drake RE, Dominguez B, Samet S, Schanzer B. Predictors of psychosis remission in psychotic disorders that co– occur with substance use. *Schizophrenia Bull*, 32(4):618–625, 2006. PMID: 16873441. PMC2632269
404. Grant BF, **Hasin DS**, Stinson FS, Dawson DA, Goldstein RB, Smith SM, Huang B, Saha TD. The epidemiology of DSM– IV panic disorder and agoraphobia in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 67(3):363–374, 2006. PMID: 16649821.
405. Huang B, Dawson DA, Stinson FS, **Hasin DS**, Ruan WJ, Saha TD, Smith SM, Goldstein RB, Grant BF. Prevalence, correlates, and comorbidity of nonmedical prescription drug use and drug use disorders in the United States: results of the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 67(7):1062–1073, 2006. PMID: 16889449.
406. Kranzler H, Mueller T, Cornelius J, Pettinati H, Moak D, Martin PR, Anthenelli R, Brower K, O’Malley S, Mason BJ, **Hasin D**, Keller M. Sertraline treatment of co– occurring alcohol dependence and major depression. *J Clin Psychopharm*, 26:13– 20, 2006. PMID: 16415699
407. Morasco BJ, Pietrzak RH, Blanco C, Grant BF, **Hasin D**, Petry NM. Health problems and medical utilization associated with gambling disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psychosomatic Medicine*, 68(6):976–984, 2006. PMID: 17132843.
408. \* Nunes EV, Liu X, Samet S, Matsoeane K, **Hasin DS**. Independent versus substance– induced major depressive disorder in substance– dependent patients: observational study of course during follow– up. *J Clin Psychiatry*, 67(10):1561– 1567, 2006. PMID: 17107247
409. \* O’Leary A, Broadwell S, Yao P, **Hasin D**. Major depression, alcohol and drug use disorders do not appear to account for the sexually transmitted disease and HIV epidemics in the southern United States. *Sexually Transmitted Diseases*, 33(7 Suppl.): S70–S77, 2006. PMID: 16543865

410. Schanzer BM, First MB, Dominguez B, **Hasin DS**, Caton CL. Diagnosing psychotic disorders in the emergency department in the context of substance use. *Psychiatric Services*, 57(10):1468–1473, 2006. PMID: 17035567
411. \* Schiff M, Benbenishty R, McKay M, DeVoe E, Liu X, **Hasin D**. Exposure to terrorism and Israeli youth's psychological distress and alcohol use: an exploratory study. *Am J Addictions*, 15(3):220–226, 2006. PMID: 16923668
- 2005** 412. \* **Hasin DS**, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Arch Gen Psychiatry*, 62(10):1097–1106, 2005. PMID: 16203955.
413. \* **Hasin DS**, Hatzenbuehler M, Smith S, Grant BF: Co-occurring DSM- IV drug abuse in DSM- IV drug dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug Alch Dependence*, 80:117–123, 2005. PMID: 16157234
414. \*Aharonovich E, Liu X, Samet S, Nunes E, Waxman R, **Hasin D**. Post- discharge cannabis use and its relationship to cocaine, alcohol, and heroin use: a prospective study. *Am J Psychiatry*, 162(8):1507–1514, 2005. PMID: 16055773
415. Caton CL, Dominguez B, Schanzer B, **Hasin DS**, Shrout PE, Felix A, McQuiston H, Opler LA, Hsu E. Risk factors for long- term homelessness: findings from a longitudinal study of first-time homeless single adults. *Am J Public Health*, 95(10):1753–1759, 2005. PMID: 16131638. PMC1449432.
416. Caton CL, Drake RE, **Hasin DS**, Dominguez B, Shrout PE, Samet S, Schanzer WB. Differences between early- phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. *Arch Gen Psychiatry*, 62(2):137– 143, 2005. PMID: 15699290.
417. Grant BF, **Hasin DS**, Blanco C, Stinson F, Chou P, Goldstein R, Smith S, Saha TD, Huang B. The epidemiology of DSM- IV social anxiety in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 66(11):1351–1361, 2005. PMID: 16420070.
418. Grant BF, **Hasin DS**, Stinson FS, Dawson DA, Chou SP, Ruan WJ. Co- occurrence of DSM- IV personality disorders in the US: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Comp Psychiatry*, 46:1– 5, 2005. PMID: 15714187
419. Grant BF, **Hasin DS**, Stinson FS, Dawson DA, Chou SP, Ruan WJ, Huang B. Co- occurrence of 12- month mood and anxiety disorders and personality disorders in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Psychiatric Research*, 39:1–9, 2005. PMID: 15504418.
420. Grant BF, **Hasin DS**, Stinson FS, Dawson DA, Ruan WJ, Goldstein RB, Smith SM, Saha TD, Huang B. Prevalence, correlates, comorbidity and comparative disability of DSM-IV generalized anxiety disorder in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Psych Medicine*, 35(12):1747–1759, 2005. PMID: 16202187.

421. Grant BF, Stinson FS, **Hasin DS**, Dawson DA, Chou SP, Ruan WJ, Huang B. Prevalence, correlates and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 66(10):1205–1215, 2005. PMID: 16259532.
422. \* Lewis M, Lanzara B, Stein J, **Hasin D**. Maternal drinking patterns and drug use increase impact of terrorism among pregnant women attending prenatal care. *J Prenatal Perinatal Psychology Health*, 19:275–288, 2005
423. \* Liu X, Du Y, Teresi J, **Hasin DS**. Concordance correlation in the measurements of time to event. *Statistics in Medicine*, 24:1409–1420, 2005. PMID: 15568183
- 2004** 424. \* **Hasin DS**, Grant BF. The co-occurrence of DSM-IV alcohol abuse in DSM-IV alcohol dependence: NESARC results on heterogeneity that differs by population subgroup. *Arch Gen Psychiatry*, 61:891–896, 2004. PMID: 15351767.
425. Grant BF, **Hasin DS**, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*, 61:1107–1115, 2004. PMID: 15520358.
426. Grant BF, Stinson FS, **Hasin DS**, Dawson DA, Chou SP, Ruan WJ, Pickering RP. Prevalence, correlates, and disability of personality disorders in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *J Clin Psychiatry*, 65:948–958, 2004. PMID: 19617934. PMC2707116.
427. Grant BF, Stinson FS, **Hasin DS**, Dawson DA, Chou SP. Immigration and lifetime prevalence of DSM-IV psychiatric disorders among Mexican Americans and non-Hispanic whites in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions, *Arch Gen Psychiatry*, 61:1226–1233, 2004. PMID: 15583114.
428. \* Henderson C, Liu X, Roux A, Link B, **Hasin D**. The effects of US state income inequality and alcohol policies on symptoms of depression or alcohol dependence. *Soc Science Med*, 58:565–575, 2004. PMID: 14652052
- 2003** 429. \* **Hasin D**, Schuckit M, Martin CS, Grant BG, Bucholz KK, Helzer JE. The validity of DSM-IV alcohol dependence: what do we know and what do we need to know? *Alch Clin Exp Research*, 27:244–252, 2003. PMID: 12605073.
430. \* Aharonovich E, Nunes E, **Hasin D**. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. *Drug Alch Dependence*, 71:207–211, 2003. PMID: 12927659.
- 2002** 431. \* **Hasin D**, Aharonovich E, Liu X, Maman Z, Matseoane K, Carr L, Li T. Alcohol and ADHD in Israel: Ashkenazis, Sephardics and recent Russian Immigrants. *Am J Psychiatry*, 159:1432–1434, 2002. PMID: 12153842
432. \* **Hasin D**, Aharonovich E, Liu X, Maman Z, Matseoane K, Carr L, Li T. Alcohol dependence symptoms and Alcohol Dehydrogenase 2 Polymorphism: Israeli Ashkenazis, Sephardics and recent Russian Immigrants. *Alch Clin Exp Research*, 26:1315–1321, 2002. PMID: 12351924

433. \* **Hasin D**, Grant B. Major depression in 6,050 former drinkers: association with past alcohol dependence. *Arch Gen Psychiatry*, 59:794–800, 2002. PMID: 12215078.
434. \* **Hasin D**, Liu X– H, Nunes E, McCloud S, Samet S, Endicott J. Effects of major depression on remission and relapse of substance dependence. *Arch Gen Psychiatry*, 59:375–380, 2002. PMID: 11926938.
435. \* Aharonovich E, Liu X, Nunes E, **Hasin D**. Suicide attempts in substance abusers: Effects of major depression in relation to substance use disorders. *Am J Psychiatry*, 159:1600–1602, 2002. PMID: 12202286
436. \* Carpenter K, Miele G, **Hasin D**. Does motivation to change mediate the effect of DSM– IV substance use disorders on treatment utilization and substance use? *Addictive Behaviors*, 27:207–225, 2002. PMID: 11817763
437. \* Goodwin RD, **Hasin DS**. Sedative use and misuse in the United States. *Addiction*, 97:555–562, 2002. PMID: 12033656
- 2001** 438. \* **Hasin D**, Liu X– H, Paykin A. DSM– IV alcohol dependence and sustained reduction in drinking: investigation in a community sample. *J Stud Alcohol*, 62:509–517, 2001. PMID: 11513229
439. \* **Hasin D**, Paykin A, Endicott J. Course of DSM– IV alcohol dependence in a community sample: effects of parental history and binge drinking. *Alch Clin Exp Research*, 25: 411–414, 2001. PMID: 11290852
440. \* Aharonovich E, **Hasin D**, Rahav G, Meydan J, Neumark Y. Differences in drinking patterns among Ashkenazi and Sephardic Israelis. *J Stud Alcohol*, 62:301–305, 2001. PMID: 11414339
441. \* Carpenter K, **Hasin D**. Reliability and discriminant validity of type I/II & type A/B alcoholic subtype classifications in untreated problem drinkers: a test of the Apollonian– Dionysian Hypothesis. *Drug Alch Dependence*, 63:51–67, 2001. PMID: 11297831
442. \* Miele G, Carpenter K, Cockerham M, Trautman K, Blaine J, **Hasin D**. Substance Dependence Severity Scale (SDSS): Reliability and validity of ICD– 10 substance use disorders. *Addictive Behaviors*, 26:603–612, 2001. PMID: 11456080
443. \* Neumark Y, Rahav G, **Hasin D**, Teichman M. Jewish– Arab differences in drinking patterns: Israel, 1995. *J Stud Alcohol*, 62:443–447, 2001. PMID: 11513222
- 2000** 444. \* **Hasin D**, Paykin A, Meydan K, Grant B. Withdrawal and tolerance: their prognostic significance in DSM– IV alcohol dependence. *J Stud Alcohol*, 63:431– 438, 2000. PMID: 10807215
445. Carpenter K, **Hasin D**, Allison D, Faith M. The relationship between obesity and DSM– IV major depressive disorder, suicide ideation, suicide attempts: results from a general population survey. *Am J Public Health*, 90:251–257, 2000. PMID: 10667187. PMC1446144.
446. Caton C, **Hasin D**, Shrout P, Opler L, Hirshfield S, Dominguez B, Felix A. Risk factors for homelessness among indigent urban adults with no history of psychotic illness. *Am J Public Health*, 90:258–263, 2000. PMID: 10667188. PMC1446149

447. \* Caton C, Samet S, **Hasin D**. When acute— stage psychosis and substance use co— occur: differentiating substance— induced and primary psychotic disorders. *J Psychiatric Practice*, 6: 256–266, 2000. PMID: 15990489
448. \* Miele G, Carpenter K, Cockerham M, Trautman K, Blaine J, **Hasin D**. Concurrent and predictive validity of the Substance Dependence Severity Scale (SDSS). *Drug Alch Dependence*, 59:77–88, 2000. PMID: 10706977
449. \* Miele G, Carpenter K, Cockerham M, Trautman K, Blaine J, **Hasin D**. Substance Dependence Severity Scale (SDSS): Reliability and validity of a clinician— administered interview for DSM— IV substance use disorders. *Drug Alch Dependence*, 59:63–75, 2000. PMID: 10706976
- 1999** 450. \* **Hasin D**, Carpenter K, Paykin A. At— risk drinkers in the household and short— term course of alcohol dependence. *J Stud Alcohol*, 60:769–775, 1999. PMID: 10606488
451. \* **Hasin D**, Paykin A. DSM— IV Alcohol Abuse: investigation in a sample of at— risk drinkers in the community. *J Stud Alcohol* 60: 181–187, 1999. PMID: 10091956
452. \* **Hasin D**, Paykin A. Alcohol dependence and abuse diagnoses: concurrent validity in a nationally representative sample. *Alch Clin Exp Research*, 23:144– 150, 1999. PMID: 10029216.
453. \* **Hasin D**, Paykin A. Dependence symptoms but no diagnosis: diagnostic “orphans” in a 1992 national sample. *Drug Alch Dependence*, 53:215–222, 1999. PMID: 10080047
454. \* **Hasin D**, Paykin A, Endicott J, Grant B. The validity of DSM— IV alcohol abuse: drunk drivers vs all others. *J Stud Alcohol*, 60:746–755, 1999. PMID: 10606485
455. Canino G, Bravo M, Ramírez R, Febo V, Fernández R, **Hasin D**, Grant B. The Spanish AUDADIS: reliability and concordance with clinical diagnoses in a Hispanic population. *J Stud Alcohol* 60:790–799, 1999. PMID: 10606491.
456. \* Carpenter K, **Hasin D**. Drinking to cope with negative affect and DSM— IV alcohol use disorders: a test of three alternative explanations. *J Stud Alcohol*, 60:694– 704, 1999. PMID: 10487740.
457. Grant B, **Hasin D**. Suicidal ideation among the United States drinking population: results from the NLAES. *Journal of Studies on Alcohol*, 60:422–429, 1999. PMID: 10371272
458. \* Rahav G, **Hasin D**, Paykin A. Drinking patterns of recent Russian immigrants and other Israelis: 1995 national survey results. *Am J Public Health*, 89:1212– 1216, 1999. PMID: 10432908
- 1998** 459. \* **Hasin D**, Carpenter K. Difficulties with questions on usual drinking and the measurement of alcohol consumption. *Alch Clin Exp Research*, 22:580–584, 1998. PMID: 9622435
460. \* **Hasin D**, Paykin A. Dependence symptoms but no diagnosis: diagnostic “orphans” in a community sample. *Drug Alch Dependence*, 50:19–26, 1998. PMID: 9589269
461. \* **Hasin D**, Rahav G, Meydan J, Neumark Y. The drinking of earlier and more recent Russian immigrants to Israel: comparison to other Israelis. *J Substance Abuse*, 10:341–353, 1998. PMID: 10897288

462. \* **Hasin D**, Trautman K, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders: phenomenologically– based diagnosis in patients who abuse alcohol or drugs. *Psychopharm Bull*, 34:3–8, 1998. PMID: 9564191
463. \* Carpenter K, **Hasin D**. A prospective evaluation of the relationship between reasons for drinking and DSM– IV alcohol use disorders. *Addictive Behaviors*, 23: 41–46, 1998. PMID: 9468741
464. \* Carpenter K, **Hasin D**. Reasons for drinking alcohol: relationships with DSM– IV alcohol diagnoses and alcohol consumption in a community sample. *Psych Addictive Beh*, 12:168–184, 1998
- 1997 465. \* **Hasin D**, Carpenter K, McCloud S, Smith M, Grant B. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. *Drug Alch Dependence*, 44:133– 141, 1997. PMID: 9088785.
466. \* **Hasin D**, Grant B, Cottler L, Blaine J, Towle L, Ustun T, Sartorius N. Nosological comparisons of alcohol and drug diagnoses: a multisite, multi– instrument international study. *Drug Alch Dependence*, 47: 217–226, 1997. PMID: 9306047.
467. \* **Hasin D**, Van Rossem R, Endicott J. Differentiating DSM– IV alcohol dependence and abuse by course: community heavy drinkers. *J Substance Abuse*, 9:127–135, 1997. PMID: 9494944.
468. \* **Hasin D**, Van Rossem R, McCloud S, Endicott J. Alcohol dependence and abuse diagnoses: validity in community sample heavy drinkers. *Alch Clin Exp Research*, 21:213–219, 1997. PMID: 9113255.
469. Chatterji S, Saunders J, Vrasti R, Grant B, **Hasin D**, Mager D. Reliability of the alcohol and drug modules of the Alcohol Use Disorders and Associated Disabilities Interview Schedule Alcohol/Drug Revised (AUDADIS– ADR): an international comparison. *Drug Alch Dependence*, 47:171–185, 1997. PMID: 9306043.
470. Cottler L, Grant B, Blaine J, Rubio– Stepic M, Compton W, **Hasin D**, Mager D, Mavreas V, Pull C. Concordance of DSM– IV alcohol and drug use disorder criteria and diagnoses as measured by the AUDADIS– ADR, CIDI and SCAN: results of a cross– national study. *Drug Alch Dependence*, 47:195–206, 1997. PMID: 9306045.
471. Pull C, Saunders J, Mavreas V, Cottler L, Grant B, **Hasin D**, Mager D. Concordance of ICD– 10 alcohol and drug use disorders measured by the AUDADIS, CIDI and SCAN: results of a cross– national study. *Drug Alch Dependence*, 47:207–216, 1997. PMID: 9306046.
472. Üstün B, Compton W, Mager D, Babor T, Baiyewu O, Chatterji S, Cottler L, Gogus A, Mavreas V, Peters L, Pull C, Saunders J, Smeets R, Stipic M– R, Vrasti R, **Hasin D**, Room R, Van Den Brink W, Regier D, Blaine J, Grant B, Sartorius N. WHO study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. *Drug Alch Dependence*, 47:161– 170, 1997. PMID: 9306042.
- 1996 473. \* **Hasin D**, Li Q, McCloud S, Endicott, J. Agreement between DSM– III, DSM– III– R, DSM– IV and ICD– 10 alcohol diagnoses in US community– sample heavy drinkers. *Addiction*, 91:1517–1527, 1996. PMID: 8917919

474. \* **Hasin D**, McCloud S, Li Q, Endicott J. Cross– system agreement among demographic subgroups: DSM– III, DSM– III– R, DSM– IV and ICD– 10 diagnoses of alcohol use disorders. *Drug Alch Dependence*, 41:127–135, 1996. PMID: 8809501
475. \* **Hasin D**, Trautman K, Miele G, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): Reliability for substance abusers. *Am J Psychiatry*, 153:1195–1201, 1996. PMID: 8780425.
476. \* **Hasin D**, Tsai W– Y, Endicott J, Muller T, Coryell W, Keller M. The effects of major depression on alcoholism: five– year course. *Am J Addictions*, 5:144–155, 1996.
477. \* **Hasin D**, Tsai W– Y, Endicott J, Muller T, Coryell W, Keller M. Five– year course of major depression: Effects of comorbid alcoholism. *J Affective Disorders*, 41:63– 70, 1996. PMID: 8938207
478. Grant B, **Hasin D**, Dawson D. The relationship between DSM– IV alcohol use disorders and DSM– IV major depression: examination of the primary– secondary distinction in a general population sample. *J Affective Disorders*, 38:113–128, 1996. PMID: 8791180
479. Langenbucher J, Martin C, **Hasin D**, Helzer J. Alcohol abuse: adding content to category. *Alch Clin Exp Research*, 20:270A–274A, 1996. PMID: 8947279
- 1994** 480. \* **Hasin D**. Treatment/self– help for alcohol– related problems: relationship to social pressure and alcohol dependence. *J Stud Alcohol*, 55:660–666, 1994. PMID: 7861793
481. \* **Hasin D**, Grant B. 1994 Draft DSM– IV criteria for alcohol use disorders: comparison to DSM– III– R. *Alch Clin Exp Research*, 18:1348–1353, 1994. PMID: 7695029
482. \* **Hasin D**, Grant BF. Nosological comparisons of DSM– III– R and DSM– IV alcohol abuse and dependence in a clinical facility: comparison with the 1988 national health interview survey results. *Alch Clin Exp Research*, 18:272–279, 1994. PMID: 8048727
483. \* **Hasin D**, Grant B. AA and other help seeking for alcohol problems: former drinkers in the US general population. *J Substance Abuse*, 7:281–292, 1995. PMID: 8749788
484. \* **Hasin D**, Muthen B, Wisnicki K, Grant B. Validity of the bi– axial dependence concept: a test in the US general population. *Addiction*, 89:573–579, 1994. PMID: 8044123
485. Baron M, Endicott J, Lerer B, Loth J, Alexander JR, Simon R, Sharpe L, Gibbon M, **Hasin D**, Lilliston B, Schacht S, Blumenthal R, Alexander J, Verter A, Tubi N, Fieve R, Gilliam T, Lehner T, Ott J. A pedigree series for mapping disease genes in bipolar affective disorder: sampling, assessment and analytic considerations. *Psychiatric Genetics*, 4:43–55, 1994. PMID: 8049902
486. Mueller T, Lavori P, Keller M, Swartz A, Warshaw M, **Hasin D**, Coryell W, Endicott J, Rice J, Akiskal H. Prognostic effect of the variable course of alcoholism on the 10 year course of depression. *Am J Psychiatry*, 151:701–706, 1994. PMID: 8166311.
- 1993** 487. \* **Hasin D**, Glick H. Depressive symptoms and DSM– III– R alcohol dependence: general population results. *Addiction*, 88:1431–1436, 1993. PMID: 8251881

488. \* Muthen B, Grant B, **Hasin D**. The dimensionality of alcohol abuse and dependence: factor analysis of DSM– III– R and proposed DSM– IV criteria in the 1988 National Health Interview Survey. *Addiction*, 88:1079–1090, 1993. PMID: 8401162.
489. Muthen B, **Hasin D**, Wisnicki K. Factor analysis of ICD– 10 symptom items in the 1988 National Health Interview Survey on alcohol dependence. *Addiction*, 88: 1071–1077, 1993. PMID: 8401161
490. Spitzer R, Yanovski S, Wadden T, Wing R, Marcus M, Stunkard A, Devlin M, Mitchell J, **Hasin D**, Horne R. Binge eating disorder: Its further validation in a multisite study. *Int J Eating Disorders*, 2:137–153, 1993. PMID: 8477283.
- 1992** 491. \* **Hasin D**, Glick H. Severity of alcohol dependence: results from a national survey. *Brit J Addiction*, 87:1725–1730, 1992. PMID: 1490086
492. Devlin M, Walsh B, Spitzer B, **Hasin D**. Is there another binge eating disorder: a review of the literature on overeating in the absence of bulimia nervosa. *Int J Eating Disorders*, 11:330–320, 1992
493. Grant B, Chou P, Pickering R, **Hasin D**. Empirical subtypes of DSM– III– R alcohol dependence: United States, 1988. *Drug Alch Dependence*, 16:1–7, 1992. PMID: 1591982
494. Grant B, Harford T, **Hasin D**, Chou P, Pickering R. DSM– III– R and the proposed DSM– IV alcohol use disorders, US 1988: a nosological comparison. *Alch Clin Exp Research*, 16:1–7, 1992. PMID: 1590542
495. Keller M, Lavori P, Beardslee W, Wunde J, Drs D, **Hasin D**. Clinical course of substance abuse disorders in adolescents. *J Substance Abuse Treatment*, 9:9–14, 1992. PMID: 1593665
496. Romelsjo A, **Hasin D**, Hilton M, Bostrom G, Diderichsen F, Haglund B, Hallqvist J, Karlsson G, Svenstrom L. The relationship between stressful working conditions and high alcohol consumption and severe alcohol problems in an urban general population. *Brit J Addictions*, 87:1173–1183, 1992. PMID: 1511230
497. Spitzer RL, Yanovski S, WaddenT, Wing R, Marcus MD, Stunkard A, Devlin M, Mitchell J, **Hasin D**, Horne RL. Binge eating disorder: A multi-site field trial of the diagnostic criteria. *Int J Eating Disorders* 11(3), 191-203.
- 1991** 498. \* **Hasin D**, Endicott J, Keller MB. Alcohol problems in psychiatric patients: 5– year course. *Comp Psychiatry*, 32:303–316, 1991. PMID: 1935019
499. Martin J, **Hasin D**. Drinking, alcoholism and sexual behavior in a cohort of gay men. *Drugs and Society*, 5: 48–68, 1991
500. Spitzer R, Devlin M, Walsh T, **Hasin D**, Wing R, Marcus M, Stunkard A, Wadden T, Yanovski S, Agras S, Mitchell J, Nonas C. Binge eating disorder: to be or not to be in DSM– IV. *International Journal of Eating Disorders*, 10:627–629, 1991
- 1990** 501. \* **Hasin D**, Grant B, Dufour M, Endicott J. Alcohol problems increase while physician attention declines: 1967– 1984. *Arch Internal Medicine*, 150:397–400, 1990. PMID: 2302015

502. \* **Hasin D**, Grant B, Endicott J. The natural history of alcohol abuse; implications for definitions of alcohol use disorders. *Am J Psychiatry*, 147:1537–1541, 1990. PMID: 2221170.
503. \* **Hasin D**, Grant B, Harford T. Male and female differences in US liver cirrhosis mortality in the United States, 1961– 1985. *J Stud Alcohol*, 51:123–129, 1990. PMID: 2308349
504. \* **Hasin D**, Grant B, Harford T, Hilton M, Endicott J. Multiple alcohol– related problems in the United States: on the rise? *J Stud Alcohol*, 51:485–493, 1990. PMID: 2270056
505. \* **Hasin D**, Grant BF, Weinflash– Konstadt J. The health and social problems of male and female alcoholics. *Medical Times*, 118:57–62, 1990
- 1989** 506. \* **Hasin D**, Endicott J, Keller M. RDC alcoholism in patients with major affective syndromes: 2– year course. *Am J Psychiatry*, 146:318–323, 1989. PMID: 2919688
507. Grant B, **Hasin D**, Harford TC. Screening for major depression among alcoholics: an application of ROC analysis. *Drug Alch Dependence*, 23:123–131, 1989. PMID: 2702922
- 1988** 508. \* **Hasin D**, Grant B, Endicott J, Harford T. Cocaine and heroin dependence compared in poly– drug abusers. *Am J Public Health*, 78:567–569, 1988. PMID: 3354742
509. \* **Hasin D**, Grant B, Endicott J. Lifetime psychiatric comorbidity in hospitalized alcoholics: subject and familial correlates. *International Journal of Addictions*, 23:827–850, 1988. PMID: 3225074
510. \* **Hasin D**, Grant B, Endicott J. Severity of alcohol dependence and social/occupational problems: relationship to clinical and familial history. *Alch Clin Exp Research*, 12:660–664, 1988. PMID: 3067612
511. \* **Hasin D**, Grant B, Harford T, Endicott J. The drug dependence syndrome and related disabilities. *Brit J Addiction*, 83:45–55, 1988. PMID: 3345381
512. \* **Hasin D**, Grant B, Endicott J. Treated and untreated suicide attempts in substance abuse patients. *J Nervous Mental Disorders*, 176:289–294, 1988. PMID: 3367144
513. \* **Hasin D**, Grant B, Weinflash J. Male/female differences in alcohol– related problems: alcohol rehabilitation patients. *Int J Addictions*, 23:437–448, 1988. PMID: 3209286
514. \* **Hasin D**, Link B. Age and recognition of depression: implications for a cohort effect in major depression. *Psychological Med*, 18:683–688, 1988. PMID: 3263662
515. Grant B, **Hasin D**, Harford T. Screening for drug use disorders in alcoholics: an application of ROC analysis. *Drug Alch Dependence*, 21:113–125, 1988. PMID: 3416730
- 1987** 516. \* **Hasin D**, Grant B. Psychiatric diagnosis of patients with substance abuse problems: a comparison of two procedures, the DIS and the SADS-L: alcoholism, drug abuse, anxiety disorders, and antisocial personality disorder. *J Psychiatric Research*, 21:7–22, 1987. PMID: 3560008

517. \* **Hasin D**, Grant B. Diagnosing depressive disorders in patients with alcohol and drug problems: a comparison of the SADS-L and DIS. *J Psychiatric Research*, 21:301–311, 1987. PMID: 3681764
518. \* **Hasin D**, Grant B. Assessment of specific drug disorders in a sample of substance abuse patients: a comparison of the DIS and the SADS-L procedures. *Drug Alch Dependence*, 19:165–176, 1987. PMID: 3582167
519. \* **Hasin D**, Grant B. Neuropsychological functioning in alcoholics: psychiatric comorbidity, drinking, and demographic characteristics. *Comp Psychiatry*, 28:520– 529, 1987. PMID: 3691076
- 1985 520. \* **Hasin D**, Endicott J, Lewis C. Alcohol and drug abuse in patients with affective syndromes. *Compr Psychiatry*, May-Jun; 26(3):283–295, 1985. PMID: 3995939

### **15.3 Reviews, Chapters, Monographs, Editorials**

- 2024 1. **Hasin, DS**, Stohl, M. Higher prevalence estimates of substance use disorders using DSM-5 vs. DSM-IV criteria among US nonelderly adults with substance use: Comments on Compton et al. and the role of DSM-IV diagnostic orphans. *American Journal of Psychiatry*. 2024. In press.
2. **Hasin, DS**, Bujno, JM, Wisell, CG. The Epidemiology of Substance Use and Substance Use Disorder. In Franken, I., Wiers, R. & Witkiewitz, K. (Eds.). *SAGE Handbook of Addiction Psychology*. London, UK: SAGE Publications.
- 2022 3. **Hasin DS**, Samples H. Marijuana Use in the U.S.: Trends, Consequences, Changing Laws. In: Boulton ML, Wallace RB. eds. *Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e*. McGraw Hill; 2022.
- 2021 4. **Hasin D**, Walsh C. Trends over time in adult Cannabis Use: A Review of Recent Findings. *Curr Opin Psychol*. 2021 Apr;38:80-85. PMID: 33873044
5. Kumar N, Janmohamed K, Nyhan K, Martins SS, Cerda M, **Hasin D**, Scott J, Pates R, Ghandour L, Wazaify M, Khoshnood, K. Substance use and substance use disorder, in relation to COVID-19: protocol for a scoping review. *Syst Rev*. 2021 Feb 3;10(1):48. PMID: 33536070
6. Wai J.M., Shulman M., Nunes E.V., **Hasin D.S.**, Weiss R.D. (2021) Co-occurring Mood and Substance Use Disorders. In: el-Guebaly N., Carrà G., Galanter M., Baldacchino A.M. (eds) *Textbook of Addiction Treatment*. Springer, Cham. [https://doi.org/10.1007/978-3-030-36391-8\\_91](https://doi.org/10.1007/978-3-030-36391-8_91)
- 2020 7. **Hasin D**, Walsh C. Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. *J Clin Med*. 2020 Dec 23;10(1):15. PMID: 33374666
8. **Hasin D**, Aharonovich E. Implications of Medical And Recreational Marijuana Laws for Neuroscience Research: A Review. *Curr Behav Neurosci Rep*. 2020 Dec;7(4):258-266. PMID: 34336547

9. Loflin M, Kiluk B, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D'Souza DC; Dworkin RH, Gray KM, **Hasin DS**, Lee DC, LeFoll B, Levin FR, Lile JA, Mason BJ, McRae-Clark AL, I Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R; Weiss RD; Strain EC. The State of Clinical Outcome Assessments for Cannabis Use Disorder Clinical Trials: A Review and Research Agenda. Drug Alcohol Depend. 2020 Jul 1;212:107993. PMID: 32360455
- 2019** 10. McCaul M, Roach D, **Hasin DS**, Weisner C, Chang G, Sinha R. Alcohol and women: a brief overview. Alch Clin Exp Research. 2019 Feb 19. PMID: 30779446
11. Keyes KM, Jager J, Mal-Sarker T, Patrick ME, Rutherford C, Schulenberg J, **Hasin D**. Is there a recent epidemic of women's drinking? A critical review of national studies. Alch Clin Exp Research. 2019 Jul;43(7):1344-1359. PMID: 31034877
12. Knox J, **Hasin DS**, Larson FRR, Kranzler HR. Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry. 2019 Dec 1;205:107590. PMID: 31600616
13. Castillo-Carniglia A, Keyes KM, **Hasin DS**, Cerdá M. Psychiatric comorbidities in alcohol use disorders. The Lancet Psychiatry. 2019 Dec;6(12):1068-1080. PMID: 31630984
- 2018** 14. \* **Hasin DS**. U.S. Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology. 2018 Jan;43(1):195-212. PMID: 28853439
15. \* Sarvet AL, Wall MM, Fink DS, Greene E, Le A, Boustead AE, Pacula RL, Keyes KM, Cerdá M, Galea S, **Hasin DS**. Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. Addiction. 2018 Jun;113(6):1003-1016. PMID: 29468763
- 2017** 16. \* Carliner H, Brown QL, Sarvet AL, **Hasin DS**. Cannabis Use, Attitudes, and Legal Status in the U.S.: A review. Prev Med. 2017 Nov;104:13-23. PMID: 28705601
17. \* Yang L, Wong LY, Grivel M, **Hasin DS**. Stigma and substance use disorders: an international phenomenon. Curr Opin Psychiatry. 2017 Sep;30(5):378-388. PMID: 28700360
- 2016** 18. \* **Hasin D**, Grant BF. NESARC findings on increased prevalence of marijuana use disorders: Consistent with other sources of information. JAMA Psychiatry. 2016 May 1;73(5):532. PMID: 27008098.
19. \* **Hasin D**, Kilcoyne B. Diagnostic assessment of substance abusers. In A. H. Mack, K. T. Brady, S. I. Miller, & R. J. Frances (Eds.): Clinical textbook of addictive disorders. Fourth Edition. Pp. 41-55. New York: Guilford Press. 2016.
20. \* Delker E, Brown Q, **Hasin D**. Alcohol Consumption in Diverse Demographic Populations: An Epidemiological Overview. Alcohol Research and Health. 2016;38(1):7-15. PMID: 27159807
21. \* Sarvet AL, **Hasin DS**. The natural history of substance use disorders. Curr Opin Psychiatry. 2016 Jul;29(4):250-7. PMID: 27153126.
- 2015** 22. \* **Hasin D**. DSM-5 SUD diagnoses: changes, reactions, remaining open questions. Drug Alch Dependence. 2015 Mar 1; 148:226-9. PMID: 25839078.
23. \***Hasin D**, Delker E. "The NESARC – a huge resource for data and research findings". Addiction. 2015 Mar; 110(3):378-80. PMID: 25678283.

24. \* **Hasin D**, Grant B. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. *Soc Psychiatry Psychiatr Epidemiol*. 2015 Nov; 50(11):1609-40. PMID: 26210739. PMCID: PMC4618096.
25. \* Delker E, Brown Q, **Hasin D**. Epidemiological Studies of Substance Dependence and Abuse in Adults. *Current Behavioral Neuroscience Reports*. 2015 Mar; 2(1):15-22. PMID: 26417548. PMCID: PMC4582776.
26. Nunes EV, **Hasin D**, Weiss R. Co-occurring mood and substance use disorders. In: el-Guebaly N, Galanter M, Carra G (Eds.): *Addiction Treatment: International Perspectives*. Volume 1. Pp. 1937-1958. Springer. 2015.
27. \* Shmulewitz D, Greene ER, **Hasin D**. Commonalities and differences across substance use disorders: phenomenological and epidemiological aspects. *Alch Clin Exp Research*. 2015 Oct; 39(10):1878-900. PMID: 26332166.
- 2014** 28. \***Hasin D**, Delker E. DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. In: Levounis P, Herron A (Eds.): *The Addiction Casebook*. American Psychiatric Publishing. Pp. 3-20. 2014.
- 2013** 29. **Hasin D**, Kilcoyne B. Comorbidity of Affective and Substance Use. In, M. Keller, W.H. Coryell, J. Endicott, J. Maser and P.J. Schettler (Eds.): *Clinical Guide to Depression and Bipolar Disorder Findings From the Collaborative Depression Study*. American Psychiatric Association, 107-120. 2013.
30. \* Fenton, MC, Aivadyan C, **Hasin DS**. Epidemiology of Addiction. In: Miller, M (Ed). *Principles of Addiction: comprehensive addictive behaviors and disorders*. 23-40. 2013.
31. \* Fenton, MC, Aivadyan C, **Hasin, DS**. Epidemiology and Diagnosis. In: McCrady, B & Epstein, E (Eds.): *Addictions: a comprehensive guidebook*. Oxford University Press, 73-107. 2013.
- 2012** 32. \* **Hasin D**. Combining Abuse and Dependence in DSM- 5. *Journal of Studies on Alcohol and Drug Disorders*. 73(4):702-4, 2012. PMID: 22630809.
33. Fisher CE, **Hasin D**, Applebaum P, "Promises and Risks for Participants in Studies of Genetic Risk for Alcohol or Drug Dependence," pp. 31-40, Audrey R. Chapman, ed., *Genetic Research on Addiction: Ethics, the Law, and Public Health*, Cambridge University Press, 2012.
34. \* **Hasin DS**. Introduction to DSM- 5 criteria linked papers in drug and alcohol dependence. *Drug Alch Dependence*. 2012 Apr 1; 122(1-2):20-21. PMID: 22137644. No PMCID required
35. \* **Hasin D**, Kilcoyne B. Comorbidity of psychiatric and substance use disorders in the United States: Current issues and findings from the NESARC. *Current Opinion in Psychiatry*, 2012 May;25(3):165-71 PMID: 22449770
36. \* Keyes KM, Hatzenbuehler ML, Grant BF, **Hasin DS**. Stress and Alcohol: Epidemiologic Evidence. *Alcohol Health and Research* 2012;34(4):391-400.

37. Saxena S, Sharan P, Botbol M, **Hasin D**, Herrman H, Hosman C, Jane– Llopis E, Reiss NSDUH, Sturgeon S. Prevention of mental disorders: implications for revision of psychiatric diagnosis and classification. In, Saxena S, Esparza P, Regier DA, Saraceno B, Sartorius N (Eds.) Public health aspects of diagnosis and classification of mental and behavioral disorders: refining the research agenda for DSM– 5 and ICD– 11. Arlington, VA: American Psychiatric Association, 2012, pp. 27– 70.
- 2011** 38. \* **Hasin D**, Fenton M, Weissman MM: Epidemiology of Depressive Disorders. In, Tsuang MT, Tohen M, and Jones P (Eds.): Psychiatric Epidemiology, 3rd edition. John Wiley & Sons, 2011.
39. \* **Hasin DS**, Keyes KM. The Epidemiology of Alcohol and Drug Disorders. In, B.A. Johnson (Ed.), Addiction Medicine: Science and Practice, Volume 1. Springer, 2011.
40. Keyes KM, **Hasin DS**. Epidemiology and Management of Alcohol Misuse Comorbid with Other Disorders. In J. Saunders & J. Rey (Eds.), Young People and Alcohol: Impact, Policy, Prevention, Treatment. Wiley– Blackwell, publishers, 2011.
- 2010** 41. \* **Hasin DS**, Keyes KM. The Epidemiology of Alcohol and Drug Disorders. In B. Johnson (Ed.), Addiction Medicine: Science and Practice. Springer, 2010.
- 2009** 42. **Hasin D**: Epidemiology of alcohol and drug use disorders. In Scheier (Ed.): Handbook of drug use etiology: Theory, methods, and empirical findings. L. M. Washington, DC: American Psychological Association, 2009
- 2008** 43. \* **Hasin, D**. Commentary on Erickson and Wilcox (2006). In defense of gathering evidence on changing “dependence” to “addiction” in DSM– V. Alcoholism Clinical and Experimental Research. 32(1), 6–7, 2008. PMID: 18076746.
44. \* Samet S., **Hasin D**. Clinical Implications of Epidemiologic Data for Diagnosis and Treatment of Psychiatric Comorbidity. Psychiatric Annals. 2008 Nov; 38(11).
- 2007** 45. \* **Hasin D**. Alcohol Use Disorders in the DSM– V: The Task Ahead (commentary) Addiction, 102(10):1535–1537, 2007. PMID: 17854331.
46. Grant BF, Compton WM, Crowley TJ, **Hasin DS**, Helzer JE, Li TK, Rounsaville BJ, Volkow ND, Woody GE. Errors in assessing DSM– IV substance use disorders. Arch Gen Psychiatry. 64(3):379–380, 2007. PMID 17339528.
47. Samet, S., Waxman, R., Hatzenbuehler, M., **Hasin, D**. Assessing addiction: concepts and instruments. Addiction Science and Clinical Practice. 4(1), 19–31, 2007. PMID: 18292706. PMCID: PMC2797097.
- 2006** 48. \* **Hasin D**, Hatzenbuehler ML, Keyes KM, Ogburn E. Vulnerability to alcohol and drug use disorders. In M Tsuang, W Stone, M Lyons (eds): Recognition and Prevention of Major Mental and Substance Use Disorders. Arlington VA: American Psychopathological Association, 2006
49. \* **Hasin D**, Hatzenbuehler M, Waxman R. Genetics of substance use disorders. In WR Miller & KM Carroll (eds): Rethinking substance abuse: what science tells us, and what we should do about it. Guilford Press, New York, 2006

- 2005** 50. \* **Hasin D**, Waxman R. Use of DSM– IV: methods and approaches. In Preedy VR (ed), *The Handbook of Alcohol Related Pathology*, London: Elsevier, 1383–1402, 2005
51. Nunes E, Rubin E, Carpenter K, **Hasin D**. Mood and substance use. In *American Psychiatric Association Textbook of Mood Disorders – Section 8: Additional Perspectives on Mood Disorders*, APA Press, 2005
- 2004** 52. \* **Hasin D**, Nunes E, Meydan J. Epidemiology: comorbidity of substance use and psychiatric disorders. In HR Kranzler and JA Tinsley (eds), *Dual Diagnosis and Treatment: Substance Abuse and Comorbid Disorders*, Marcel Dekker, Inc., 1–34, 2004
53. Nunes E, **Hasin D**, Blanco C. Substance abuse and psychiatric comorbidity – overview of diagnostic methods, diagnostic criteria, structured and semi– structured interviews, and biological markers. In Kranzler HR and Tinsley JA (eds): *Dual Diagnosis and Treatment: Substance Abuse and Comorbid Disorders*, New York: Marcel Dekker, Inc., 61–101, 2004
54. Samet S, **Hasin D**, Nunes E. Diagnosing comorbidity: concepts, criteria, and methods: a review. *Acta Neuropsychiatrica*, 16:9–18, 2004
- 2003** 55. \* **Hasin D**. Classification of alcohol use disorders. *Alch Research Health*, 27:5–17, 2003
- 2001** 56. \* **Hasin D**. The epidemiology of alcohol use in the United States. *Economics of Neuroscience* 9(12) 38–46, 2001
- 1999** 57. \* **Hasin D**. Women and alcohol: use and abuse. *Women’s Health Research*, 1999
- 1998** 58. Compton W, Üstün B, Cottler L, **Hasin D**, Vrasti R: Cross– cultural comparisons of substance abuse: The 12– site WHO study on reliability and validity. In Harris L (ed): *NIDA Research Monograph*, 1998
- 1997** 59. \* **Hasin D**, Muthen B, Grant B. The dimensionality of DSM– IV alcohol abuse and dependence: factor analyses in a clinical sample. In Vrasti R (ed): *Alcoholism – New Research Perspectives*. Hogrefe & Hubner, Germany, 1997
60. \* **Hasin D**, Nunes, E. Comorbidity of alcohol, drug and psychiatric disorders: epidemiology. In Kranzler H, Rounsaville B (eds): *Dual Diagnosis and Treatment*, Marcel Dekker, Inc, New York, 1997
61. Nunes E, **Hasin D**. Overview of diagnostic methods: criteria, structured and semistructured interviews and biological markers. In Kranzler H, Rounsaville B (eds): *Dual Diagnosis and Treatment*, Marcel Dekker, Inc, New York, 1997
- 1996** 62. \* Miele G, Trautman K, **Hasin D**. Assessing comorbid mental and substance use disorders: a guide for practice. *J Practical Psychiatry Beh Health*, 2:272–282, 1996
63. Langenbucher J, Martin C, **Hasin D**, Helzer J: Alcohol abuse: adding content to category. *Alcoholism Clinical and Experimental Research*, 20:270A-274A, 1996.
- 1995** 64. \* **Hasin D**, Babor T, Grant B, Room R, Cottler L: Diagnostic Work Group Report. In Blaine J, Horton A, Towle L (eds): *Diagnosis and Severity of Drug Abuse and Drug Dependence*, NIH Publication No 95–3884, 4–10, 1995

65. \* **Hasin D.** Alcoholism diagnostic issues in a clinical sample. In Blaine J, Horton A, Towle L (eds): *Diagnosis and Severity of Drug Abuse and Drug Dependence*, NIH Publication No 95-3884, 30-36, 1995
- 1993** 66. Spitzer R, Stunkard A, Yanovski S, Marcus M, Wadden T, Wing R, Mitchell J, **Hasin D.** Binge eating disorder should be included in DSM- IV: a reply to Fairburn et al's "The Classification of Recurrent Overeating: The Binge Eating Disorder Proposal". *Int J Eating Disorders*, 2:161-169, 1993
- 1992** 67. Harford TC, Grant B, **Hasin D.** Average daily consumption and frequency of intoxication on occurrence of dependence symptoms and alcohol- related problems. In Clark W, Hilton M (eds): *Alcohol in America: Drinking Practices and Problems*, SUNY Press, 1992
- 1991** 68. \* **Hasin D.** Diagnostic interviews for assessment: background, reliability, and validity. *Alcohol Health Research*, 4: 293-302, 1991
- 1990** 69. \* **Hasin D.** The schedule for affective disorders and schizophrenia: history, uses, and current developments. *Arch Psychiatric Diagnosis Clin Eval*, 1990 Japan
70. Hirschfeld R, **Hasin D**, Keller M, Endicott J, Wunde J: Depression and alcoholism: Comorbidity in a longitudinal study. In Maser J, Cloninger CR (eds): *Comorbidity of Mood and Anxiety Disorders*, American Psychiatric Press, 293-303, 1990
- 1989** 71. \* **Hasin D**, Skodol A: Standardized diagnostic interviews for psychiatric research. In Thompson C (ed): *The Implements of Psychiatric Research*, John Wiley, London, 19-58, 1989

### **15.5 Meetings/Invited oral and poster presentations**

- 2024** 1. Presidential Symposium, Organizer and Presenter, College on Problems of Drug Dependence, June 18, 2024, Montreal, Canada
2. "DSM-5 Substance Use Disorders". Invited presenter, Plenary Panel. May 4, 2024. American Psychiatric Association annual meeting, New York, New York
3. National Geographic article on cannabis use, March 24, 2024  
"Do you smoke weed recreationally? Here's what experts want you to know."
4. "A Comprehensive Look at Cannabis Use Disorder" Presenter, National Academy of Science, Engineering and Medicine, January 12, 2024.
- 2023** 5. "Time Trends in Cannabis Use, Cannabis Use Disorder and Psychiatric Comorbidity: Individual and State-Level Influences" Webinar, Northwest Addiction Technology and Transfer Center, October 18, 2023
6. "State Cannabis Legalization and Increases in Adult Cannabis Use Disorder in Veterans Health Administration Patients, 2005 - 2019", Oral Communication: Cannabis Policy and Regulation, College on Problems of Drug Dependence, Denver, Colorado, June 19, 2023
7. "Epidemiology and U.S. national trends in hallucinogens", invited presenter, Policy Forum, College on Problems of Drug Dependence", Denver, Colorado, June 19, 2023

8. Washington Post article on cannabis use, May 25, 2023.  
[https://www.washingtonpost.com/wellness/interactive/2023/marijuana-cannabis-use-addiction/?itid=ap\\_teddyamenabar](https://www.washingtonpost.com/wellness/interactive/2023/marijuana-cannabis-use-addiction/?itid=ap_teddyamenabar)
9. Co-Chair and discussant, “Changing US trends in alcohol, hallucinogens, cannabis, and in opioid overdoses”. American Psychiatric Association Annual Conference, San Francisco, California, May 24, 2023
10. “Career Development in Addiction Research. Invited presentation for University of Arkansas Addiction Science Training Program, Little Rock, Arkansas, April 19, 2023
11. “Cannabis Laws and Cannabis Epidemiology: a changing landscape”. Invited lecture for New York University Center for Opioid Epidemiology, April 17, 2023
12. “U.S. Cannabis Use and Cannabis Use Disorder” Presentation and chair of international symposium on cannabis, World Psychiatric Association, Paris, France, March 26, 2023
13. “Cannabis Epidemiology: a changing landscape”. Invited lecture for University of Florida Epidemiology seminar. January 12, 2023
- 2019** 14. “Hallucinogens: Epidemiology and Time Trends in the U.S.” Webinar for the American Psychopathological Association in conjunction with Johns Hopkins School of Medicine, November, 2019
15. “Change over time in WHO drinking risk levels”. Presentation, ACTIVE group, Bethesda, MD November, 2019.
16. “Psychedelics: Risks and Opportunities”. American Psychopathological Association Webinar, in conjunction with Johns Hopkins Department of Psychiatry, November, 2019
17. “HealthCall to reduce heavy drinking and improve ART adherence in alcohol-dependent HIV patients”. Invited presentation, NIAAA HIV and alcohol workshop, Rockville, MD, September, 2019
18. “Epidemiology of marijuana use”. Substance Abuse and Mental Health Services Administration (SAMHSA) Technical Expert Panel on the Harms/Risks of Marijuana Use. Rockville, MD, September, 2019
19. “Psychiatric Research Interview for Substance & Mental Disorders – Opioid version (PRISM-5-OP)”. Invited presentation, workshop, College on Problems of Drug Dependence, San Antonio TX, June, 2019
20. “Changing cannabis epidemiology in the US: relationship to pain, self-reported psychosis, and driving under the influence”. Substance Abuse Epidemiology seminar, Columbia University, New York, NY, April 14, 2019
21. “Change in WHO Risk Drinking Levels & Clinical Outcomes: US General Population updates, 2012-2013”. Presentation, ACTIVE group, Bethesda, MD March 20, 2019.

- 2018**
22. Panel presentation on public health aspects of marijuana legalization: New York 1 News, December 17, 2018” <https://www.ny1.com/nyc/all-boroughs/inside-city-hall/2018/12/18/what-would-legalizing-marijuana-mean-for-new-york>
  23. “Measuring addiction to prescription opioids in chronic pain patients”. Webinar presentation to NIDA Clinical Trials Network (CTN) leadership. December 6, 2018.
  24. “Change in WHO Risk Drinking Levels & Clinical Outcomes: Findings from the US General Population”. Presentation, ACTIVE pre-FDA meeting, Bethesda, MD November 8, 2018.
  25. “Changing marijuana laws and US substance use”. Bicknell Lecture and Symposium, Boston University School of Public Health, Boston MA. October 25, 2018
  26. “Measuring addiction to prescription opioids in chronic pain patients”. Webinar presentation to NIDA leadership. October 24, 2018.
  27. “Alcohol and cannabis: changing concepts, changing patterns”. Department of Epidemiology seminar, New York University Department of Population Health, New York, NY, October 18, 2018
  28. “Gender differences in alcohol and drug abuse in the US: trends and changes”. Faculty symposium presenter, American Society on Addiction Medicine, Washington DC, October 12, 2018
  29. “Epidemiology of cannabis use and problems in the US: trends and changes”. Faculty symposium presenter, American Society on Addiction Medicine, Washington DC, October 11, 2018
  30. “Alcohol and cannabis: changing concepts, changing patterns”. Psychiatric epidemiology seminar, Columbia University, New York, NY, September 27, 2018
  31. “Varying time trends in U.S. binge drinking, alcohol use disorders, and other adverse drinking outcomes”. Symposium presentation, Research Society on Alcoholism, San Diego, CA, June 17, 2018.
  32. “Sex/gender differences in the U.S. epidemiology of alcohol and drug use disorders”. Symposium presentation, College on Problems of Drug Dependence. San Diego, CA, June 14, 2018.
  33. “Marijuana laws, use and consequences: The changing picture.” Keynote presentation; Addictions Update; Dept. of Psychiatry, University of Utah, Utah State Division of Substance Use and Mental Health; Salt Lake City, UT. June 6, 2018.
  34. “Change in WHO Risk Drinking Levels & Clinical Outcomes: Findings from the US General Population”. Symposium presentation; American Society of Clinical Psychopharmacology; Miami FL, May 29, 2018
  35. “Marijuana laws, use and consequences: The changing picture.” Symposium presentation; American Psychiatric Association; New York, NY, May 6, 2018.
  36. “Clinical implications of the changing U.S. marijuana landscape”. Division of Behavioral Health Services and Policy Research Seminar, Department of Psychiatry, Columbia University, New York, NY, April 10, 2018

37. Panel presentation on public health aspects of marijuana legalization: New York 1 News, April 19, 2018: <http://www.ny1.com/nyc/all-boroughs/politics/2018/04/19/debate-legalization-marijuana-new-york-state-panel-discusses>
38. "Severity of cannabis use and disorders." Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (AACTTION) meeting; Bethesda, MD, March 23, 2018.
39. "The changing landscape of marijuana laws, use and consequences". Marijuana seminar series; Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University; Baltimore, MD, March 14, 2018;
40. "The changing landscape of marijuana laws, use and consequences." Invited presentation; Yale Department of Sociology; New Haven, CT, February 15, 2018;
41. "Validation of PRISM-5-OP measures of addiction to Prescription Opioids: Results of Study 2B". Presentation to Opioid PMR Consortium Advisory Board. February 1, 2018
42. "Alcohol and opioid use in older Americans". SAMHSA national webinar, January 23, 2018. *Attended by over 900 participants.*
- 2017** 43. "Laws, Norms and Trends in U.S. Cannabis Use". Plenary presentation, American College of Neuropsychopharmacology. Palm Springs, California, December, 2017
44. "Epidemiology Of Alcohol Use And Alcohol Use Disorders, 2001-2002 to 2012-2013". Alcohol, The Brain And Society, Campbell Family Mental Health Research Symposium, Toronto, Canada, November, 2017
45. "WHO Drinking Risk Levels & Alcohol Consequences: NESARC and NESARC-III findings". ACTIVE bi-annual meeting, Washington DC, November, 2017
46. "Trends In Drinking And Alcohol Use Disorders: Gender Differences". Alcohol and Opioid Problems in Women and Girls, Washington DC, October, 2017
47. National Public Radio interview about heavy drinking, August 16, 2017: <https://www.npr.org/sections/thesalt/2017/08/16/543965637/women-who-love-wine-are-you-binge-drinking-without-realizing-it>
48. "The Relationship of WHO Drinking Risk Levels to Alcohol Consequences: Consistency in Population Studies". American Psychological Association, Washington DC, August 2017.
49. "Medical marijuana laws, cannabis use and cannabis use disorders: 1991-1992 to 2012-2013". College on Problems of Drug Dependence. Montreal, Canada, June 2017
50. "Medical marijuana laws and driving under the influence of cannabis or alcohol". Research Society on Alcoholism, Denver, Colorado, June, 2017
51. "Consequences of Marijuana Laws." Dean's Grand Rounds, Mailman School of Public Health. With Silvia Martins, Christine Mauro, Pia Mauro, Arthur Robins Williams. April 26, 2017, New York, NY.

52. "PRISM-5: Diagnostic measure for substance and psychiatric disorders". International Conference on Dual Disorders, March 23, 2017. Madrid, Spain.
53. "Cannabis use, cannabis use disorders and psychiatric comorbidity". International Conference on Dual Disorders, March 23, 2017. Madrid, Spain.
54. "Personality Disorders and the course of Substance and other Psychiatric Disorders". Plenary presentation, American Psychopathological Association, March 3, 2017, New York, NY
55. "DSM-5 Substance Use Disorders". NIDA Phenotyping Workshop, February 28, 2017, Rockville, MD
56. "Cannabis use and cannabis use disorders, U.S." Research seminar presentation, Department of Psychiatry, University of Pennsylvania. January 30, 2017
- 2016** 57. "WHO risk drinking levels, alcohol dependence and impaired functioning". Alcoholism Clinical Trials Initiative (ACTIVE), Bethesda, MD, November 1, 2016.
58. "PRISM-5-Op Validity Study: Measure of Addiction to Prescription Opioids". Post-Marketing Studies of Prescription Opioids Joint Meeting, Jersey City. October 26, 2016.
59. "Frequencies of cocaine use: clinical correlates; change over time" Measures of Outcomes for Stimulant Trials (MOST). FDA at White Oak, October 18, 2016
60. "Marijuana Use, Abuse, Dependence: Implications Of Legalization". Research and Policy conference, Vermont Health and Behavior Center, October 6, 2016
61. "Severity of DSM-5 Cannabis Use Disorder and Clinical Correlates". Clinical Trial Endpoints of Therapeutics for CUDs, NIDA, Bethesda MD, September 12, 2016
62. "World Health Organization (WHO) Drinking Risk Categories and Alcohol Dependence: 3-Year Prospective Study". International Society for Biomedical Research on Alcoholism, Berlin, Germany, September 5, 2016
63. "Changing Times: Marijuana Use and Marijuana Use Disorders in the U.S." President's Symposium Presentation, College on Problems of Drug Dependence, Palm Springs CA, June 11-16, 2016.
64. "Marijuana Use and Cannabis Use Disorders in the U.S.: Changing Times". Departmental Seminar, Epidemiology, Mailman School of Public Health, February 19, 2016, New York, New York
- 2015** 65. "PRISM-5-Op – a diagnostic measure of addiction to prescription opioids". Organizational meeting for "A prospective investigation of the risks of opioid misuse, abuse, and addiction among patients treated with extended-release/long acting (ER/LA) opioids for the treatment of chronic pain", FDA-mandated PMR study. November 8-19, 2015, Seattle WA.
66. "Marijuana use and marijuana use disorders in the United States". Columbia University Psychiatric Epidemiology Training Program seminar, October 2015, New York, NY

67. "Change in WHO risk drinking levels and DSM-IV alcohol dependence". Alcohol Clinical Trials Initiative (ACTIVE) group. Bethesda, MD, October, 2015
68. "Medical marijuana laws and U.S. adolescent marijuana use: results over 20 years". Expert Advisory Group on Cannabis, Canadian Center on Substance Abuse, Ottawa Canada, September 2015
69. National Public Radio panel discussion of marijuana use in adolescents, July 3, 2015  
<https://www.sciencefriday.com/segments/can-marijuana-help-or-hurt-adolescent-health/>
70. "Change in drinking level and drinking consequences: NESARC findings". Research Society on Alcoholism, San Antonio TX, June 2015
71. "Medical marijuana laws and U.S. adolescent marijuana use: results over 20 years". College on Problems of Drug Dependence, Workshop organizer, Phoenix AZ, June 2015
72. DSM-5 and the Comorbidity of Psychiatric and Substance Use Disorders. International Congress on Dual Diagnosis, Barcelona, Spain, April, 2015
73. Reducing Unsafe Drinking and Other Risk Behaviors in Those with HIV: Behavioral, Pharmacologic and Technology Approaches. CDC HIV branch, Atlanta GA January 2015
- 2014** 74. Alcohol consumption and consequences. Alcohol Clinical Trials Initiative (ACTIVE) group. Bethesda, MD, October, 2014
75. Reducing Unsafe Drinking and Other Risk Behaviors in Those with HIV: Behavioral, Pharmacologic and Technology– Enhanced Approaches. Research Society on Alcoholism, June, 2014, Seattle, WA (session organizer, chair and presenter)
76. DSM-5 Substance Use Disorders. College on Problems of Drug Dependence, June, 2014, San Diego, CA (Session organizer, chair and presenter)
77. Measuring Addiction with DSM-5 Criteria. Food and Drug Administration (FDA), May 20, 2014. Public meeting on prescription opioids and addiction (Invited speaker). Gaithersburg, MD
78. Youth and marijuana. American Psychiatric Association, May 1, 2014, New York, NY (Invited presenter)
79. DSM-5 Substance Use Disorders. American Psychiatric Association, May 5, 2014, New York, NY (Invited presenter)
80. DSM-5 Substance Use Disorders. Albert Einstein Medical Center, Jacobi Hospital, Department of Psychiatry Grand Rounds, April 30, 2014, New York, NY
81. DSM-5 Substance Use Disorders. University of Arkansas for Medical Sciences Department of Psychiatry Grand Rounds. March, 2014
- 2013** 82. DSM-5 Substance Use Disorders. American Society on Addiction Medicine, October, 2013, State of the Art Course in Addiction Medicine, Arlington VA (Invited presenter)

83. DSM-5 Substance Use Disorders. Coalition of Behavioral Health Services, October, 2013, Houston, TX (Invited presenter)
84. DSM-5 Substance Use Disorders. Beth Israel Hospital, Department of Psychiatry Grand Rounds, August, 2013, New York, NY
85. Early trauma and adult substance use disorders. College on Problems of Drug Dependence, June, 2013, San Diego, CA (Session organizer, chair and presenter)
86. DSM-5 Substance Use Disorders. American Psychiatric Association, May, 2013, San Francisco, CA (Invited presenter)
87. Alcohol and depression in the NIMH Collaborative Depression Study. American Psychiatric Association, May, 2013, San Francisco, CA (Invited presenter)
- 2012** 88. Meta-structure of common psychiatric disorders. World Psychiatric Association, October, 2012, Prague, Czech Republic (Session organizer and chair)
89. Meta-structure of common psychiatric disorders. Research Society on Alcoholism, June, 2012, San Francisco, CA (Session organizer and chair)
90. Technological innovation in interventions for substance use disorders. College on Problems of Drug Dependence, June, 2012, Palm Springs, CA (Co– chair and presenter)
- 2011** 91. DSM-5 substance use disorders: the evidence base. American Academy of Addiction Psychiatry, December, 2011, Scottsdale AZ (Invited presenter)
92. DSM-5 substance use disorders: craving, legal consequences, nicotine use disorders. American Public Health Association, October, 2011, Washington DC (Invited presenter)
93. Substance– induced disorders in DSM– 5. International Congress on Dual Disorders, October, 2011, Barcelona, Spain (Invited speaker)
94. Epidemiology of comorbidity in the NESARC. International Congress on Dual Disorders, October, 2011, Barcelona, Spain (Invited speaker)
95. Some Key Changes Proposed for DSM-V. International Society of Addiction Medicine, September, 2011, Oslo, Norway (Invited presenter)
96. DSM-V: Implications for research and treatment. International Society of Addiction Medicine, September, 2011, Oslo, Norway (Plenary speaker)
97. DSM-5 substance use disorders: craving, legal consequences, nicotine use disorders. American Psychological Association, August, 2011, Washington DC (invited presenter)
98. HealthCall: Technologically enhanced brief intervention for health behaviors in HIV primary care patients. 6<sup>th</sup> International Conference on HIV Treatment, Prevention, Adherence, May, 2011, Miami, FL (Invited presenter)
99. DSM-5 substance use disorders: combining abuse and dependence across substances. American Society of Addiction Medicine, April, 2011, Washington DC (Invited presenter)

100. DSM-5 substance use disorders. NIDA Clinical Trials Network Steering Committee, March, 2011, Bethesda, MD (Invited presenter)
101. DSM-5 substance use disorders. University of Connecticut Department of Psychiatry Grand Rounds, February, 2011, Farmington, Connecticut. MD (Invited presenter)
102. Technologically enhanced brief intervention for risky drinking in HIV primary care. University of Connecticut Alcohol Research Center, February, 2011, Farmington, Connecticut (Invited presenter)
103. Technologically enhanced brief intervention for risky drinking in HIV primary care. HIV Research Center Grand Rounds, Columbia University. New York, NY, January, 2011 (Invited presenter)
- 2010** 104. DSM-5 substance use disorders. NIDA Genetics Consortium, November, 2010, Bethesda, MD (Invited presenter)
105. Drinking, drug use, HIV and ethnicity: general population and clinical epidemiologic findings. National Hispanic Science Network, September, 2010, New Orleans, LA (Invited presenter)
106. DSM-5 substance use disorders. American Psychological Association, August, 2010, San Diego, CA (Invited Leader, Conversation hour)
107. Epidemiology and public health research: A journal editor's perspective. College on Problems of Drug Dependence, June, 2010, Phoenix, AZ (Invited presentation)
108. Dependence, abuse, consumption, craving: DSM-5 substance use disorders. College on Problems of Drug Dependence, June, 2010, Phoenix, AZ (Workshop co– chair and presenter)
109. Research Society on Alcoholism. June, 2010, Ft. Lauderdale, FL (Symposium presenter): abuse, dependence and craving: U.S. and Israel results for alcohol and nicotine
110. Dependence, abuse, consumption, craving: DSM-5 substance use disorders. American Psychiatric Association, May, 2010, New Orleans, LA (Symposium co– chair and presenter)
111. Marijuana abuse and dependence in the general population. American Psychiatric Association, May, 2010, New Orleans, LA (Symposium Presenter)
112. Epidemiology, DSM-5 and implications for genetic research. Henri Begleiter Memorial Grand Rounds, March, 2010, SUNY Downstate, Brooklyn, NY
113. Personality disorders and persistence of DSM-IV and DSM-5 alcohol, drug and nicotine disorders. NIDA Extramural Research Division, March, 2010, Rockville, MD (Invited presenter)
- 2009** 114. Personality disorders and persistence of alcohol, drug and nicotine disorders. American Association of Addiction Psychiatry, December, 2009, Los Angeles, CA (Symposium presenter)
115. Abuse and dependence: combine or keep separate? American Psychological Association, August, 2009, Toronto, Canada (Symposium presenter)
116. Gene x Environment Interaction in Alcohol Phenotypes. Invited presentation to NIAAA staff, June, 2009

117. Substance use disorders: DSM-5 update. Research Society on Alcoholism, June, 2009, San Diego, CA (Symposium Chair and presenter)
118. Personality Disorders in the United States: Relationship to Early Experiences and Axis I Disorders. American Psychiatric Association, May, 2009, San Francisco, CA (Symposium Chair and presenter)
119. Speaker and day– long guest: Alcohol use disorders: comorbidity, course and DSM– 5 considerations. Alcohol Research Group (NIAAA-funded research center), March, 2009, Berkeley, CA
120. Alcohol use disorders: comorbidity, course and DSM-5 considerations. Grand Rounds, Yale Department of Psychiatry, February, 2009, New Haven, CT
121. Alcohol use disorders: comorbidity, course and DSM-5 considerations. Grand Rounds, Columbia University Department of Psychiatry, January, 2009, New York, NY
- 2008** 122. Exposure to terrorism and substance abuse. European Conference on Neuropsychiatry, September, 2008, Barcelona, Spain (Symposium presenter)
123. The epidemiology of alcohol use, abuse and dependence. Research Society on Alcoholism, June, 2008, Washington DC (Lecture Series)
124. New findings on alcohol use disorders in the U.S. general population. Research Society on Alcoholism, June, 2008, Washington DC (Symposium Chair and presenter)
- 2007** 125. Dimensional substance phenotypes: Dependence and abuse. College on Problems of Drug Dependence, June, 2007, Quebec, Canada, (Workshop presenter)
126. Alcohol and cannabis dependence and abuse criteria as dimensional phenotypes. NIDA Genetics Consortium, Bethesda, MD, June, 2007, (Presentation)
127. The epidemiology of comorbidity: substance and psychiatric disorders. Grand Rounds, SUNY Downstate, February, 2007, Brooklyn, NY
- 2006** 128. Alcohol and drug dependence as a dimensional phenotype. ISBRA– WHO, June, 2006, Sydney, Australia, (Symposium presenter)
129. Alcohol and somatoform disorders. DSM-5 preliminary conference, June, 2006, Beijing, China (Presenter)
130. Alcohol use disorders in the U.S.: Prevalence, correlates, comorbidity and treatment. College on Problems of Drug Dependence, June, 2006, San Juan, Puerto Rico (Workshop presenter)
131. The diagnosis and assessment of alcohol use disorders. Research Society on Alcoholism, June, 2006, Baltimore, MD (Lecture Series)
132. Alcohol use disorders in the U.S. Prevalence, correlates, comorbidity and treatment. Research Society on Alcoholism, June, 2006, Baltimore, MD (Symposium presenter)

133. Cannabis withdrawal syndrome: evidence from 1,119 frequent cannabis users in a national survey. American Psychiatric Association, May, 2006, New York, NY (Symposium presenter)
134. Alcohol, drug and psychiatric disorders in the United States. American Psychiatric Association, May, 2006, New York, NY (Symposium Chair and Presenter)
135. Genetic research on alcohol and drugs: from abstinence to dependence. Ethics in Genetics Conference, Columbia University, May, 2006, New York, NY (Invited presenter)
136. The epidemiology of comorbidity: substance and psychiatric disorders. Grand Rounds, Massachusetts General Hospital, February, 2006, Boston, MA
137. Selecting the populations. NIAAA/NIDA/NIMH Workshop on methodology of comorbidity clinical trials, February, 2006 (Presentation)
- 2005**
138. Gene– environment interactions in substance use disorders. American Association of Addiction Psychiatry, December, 2005, Scottsdale, AZ (Symposium presenter)
139. Genetics and substance use disorders. CACTUS conference, October, 2005, Santa Fe, New Mexico (Presenter)
140. Predictors of primary and substance– induced psychosis remission. American Psychiatric Association, May, 2005, Atlanta, GA (Symposium Presenter)
141. PRISM for comorbidity diagnosis. Comorbidity research conference, April, 2005, Barcelona, Spain (Plenary Speaker)
142. Gene– environment interaction in substance use disorders. American Psychopathological Association, March, 2005, New York, NY (Plenary presenter)
- 2004**
143. Genetics of substance abuse. Clinical Trials Network Blending Conference, September, 2004, Detroit, MI (Workshop presenter)
144. The course of alcohol and drug disorders in clinical and community settings. American Psychiatric Association, May, 2004, New York NY (Symposium Organizer and Presenter)
145. High– risk drinkers 10 years later: predicting the onset of alcohol dependence. American Psychiatric Association, May, 2004, New York NY (Symposium Presenter)
- 2003**
146. ADH1B, alcohol and nicotine in an Israeli sample. College on Problems of Drug Dependence, June, 2003, Bal Harbor, FL (Symposium presenter)
147. High– risk community drinkers: a 10– year follow– up. Research Society on Alcoholism, May, 2003, Ft. Lauderdale, FL (Symposium presenter)
148. Using the PRISM to diagnose psychotic disorders in substance abusers. American Psychiatric Association, May, 2003, San Francisco, CA (Symposium Presenter)
- 2002**
149. Assessment of addiction. Clinical Trials Network Blending Conference, March, 2002, New York, NY (Workshop presenter)

150. Primary and substance– induced depression: effects on the course of alcohol, cocaine and heroin dependence. College on Problems of Drug Dependence, June, 2002, Quebec, Canada (Symposium presenter)
151. Alcohol dependence: what do we know, what do we need to know? Research Society on Alcoholism, June, 2002, San Francisco, CA (Symposium Chair and presenter)
152. Phenotypes for studies on gene x environment interaction. NIAAA External Advisory Board, April, 2002 (Presentation)
- 2001** 153. Alcohol in Israel: Gene-environment Interaction. International Society on Addiction Medicine, September, 2001, Tel Aviv, Israel (Plenary session)
154. Alcohol abuse and dependence in the general population. Grand Rounds, SUNY Stony Brook Department of Psychiatry, August, 2001, Stony Brook, NY.
- 2000** 155. Alcohol Abuse and Dependence: course in the general population. Grand Rounds, Columbia University Department of Psychiatry, November, 2000, New York, NY.

### **15.7 Letters to the Editor**

- 2022** 1. **Hasin D.** Long-term cannabis use and preparedness for ageing. *Lancet Healthy Longev.* 2022 Oct;3(10):e645-e646. doi: 10.1016/S2666-7568(22)00221-5. PMID: 36202122.
- 2020** 2. **Hasin D.** Alcohol Use Disorder and Suicide Risk: A Fresh and Closer Look. *Am J Psychiatry.* 2020 July 1;177(7):572-573. PMID: 32605449
- 2019** 3. Anton R, Witkiewitz K, Falk D, Litten R, **Hasin D**, Mann K, O'Malley, S. Response to Dr. Mark Litt's Commentary. *Alch Clin Exp Research.* 2019 Aug 5. PMID: 31381170
4. Brown Q, **Hasin D.** "Possible unintended consequences for pregnant women of legalizing cannabis use". *Addiction*, 2019 PMID:31746493
- 2017** 5. Martins SS, Santaella-Tenorio J, **Hasin DS.** Factors to consider for reducing U.S. opioid-related deaths: looking beyond access-reply. *JAMA Psychiatry.* 2017 Nov 1;74(11):1171-1172. PMID: 28903133
- 2014** 6. \* **Hasin D.** Truth (validity) and use despite consequences: the DSM– 5 SUD unidimensional syndrome. *Addiction.* 2014 Nov; 109(11):1781-2. PMID: 25297956.
- 2012** 7. Wall MM, Poh E, Cerda M, Keyes KM, Galea S, **Hasin D.** Commentary on Harper S, Strumpf EC, and Kaufman JS, "Do Medical Marijuana Laws Increase Marijuana Use? Replication study and extension". *Annals of Epidemiology.* 2012 Jul; 22(7):536– 7. PMID: 22534177. PMCID: PMC3547124
- 2011** 8. \* **Hasin D.** Opioid Use Disorder as a condition of graded severity, similar to other substance use disorders. *Addiction.* 106(3):599–600, 2011. PMID: 21299672
- 2010** 9. \* **Hasin D.** Commentary on Borges et al. (2010): cross–national dimensionality of alcohol use disorders. *Addiction.* 2010 Feb; 105(2):255–6. PMID: 20078483.

- 2005** 10. \* **Hasin D.** Still difficult to know what alcohol dependent individuals can return to controlled drinking: comments on Dawson et al (2005). *Addiction*, 100(3):295–296; discussion 296–298, 2005. PMID: 15733241.
11. Meydan J, Liu X, **Hasin D.** Alcohol and drug use in schizophrenia as predictors of functional impairment (letter). *Schizophrenia Research*, 77(1):105–106, 2005 Sep 1. PMID: 16005390.
- 1992** 12. \***Hasin D.** Commentary. *Annual Review Addiction Research Treatment*, 57–59, 1992
- 1990** 13. \***Hasin DS**, Grant BF, Endicott J. Letter *American Journal of Psychiatry* 148:1096, 1991. Response to letters on Hasin & Grant, *American Journal of Psychiatry*, 1990
14. **Hasin DS**, Grant BF, Endicott J. Letter *American Journal of Psychiatry* 148:1410–1411, 1991. Response to letters on Hasin & Grant, *American Journal of Psychiatry*, 1990